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Abstract of thesis 
 
Introduction: It is proposed that squamous cell carcinoma of the bronchus develops from 
carcinogen-exposed epithelium through a series of pre-invasive lesions of increasing 
histological and cytological abnormality. This has not been reliably demonstrated, and it is 
not known whether pre-invasive lesion development follows a predictable time-course and 
pattern or whether all pre-invasive lesions are committed to the development of malignancy. 
Pre-invasive lesions manifest genetic changes similar in pattern to that of squamous cell 
carcinoma. The accumulation of genetic damage, as a consequence of prolonged 
carcinogen exposure, may drive the progression of an individual pre-invasive lesion to 
malignancy, and the ultimate pattern of genetic changes may determine the outcome of that 
lesion.  
Methods: In the present work patients with pre-invasive lesions underwent serial 
bronchoscopy and biopsy to determine the natural history of pre-invasive lesions. Serial 
biopsies from lesions under follow-up were studied histologically and using loss of 
heterozygosity analysis at chromosomal loci thought to be involved in the pathogenesis of 
squamous cell carcinoma.  
Results: The natural history of pre-invasive lesions is variable. Some lesions progress, 
some regress and some remain unchanged histologically. Different lesions in a single patient 
may have different natural histories and different outcomes. Short-term follow-up may 
misrepresent the long-term evolution of an individual lesion or bronchoscopic location. 
Molecular studies showed that different lesions in individual patients appeared to have 
originated from a single progenitor cell, but acquired significant genetic differences during 
lesion development. Progression of pre-invasive lesions to carcinoma was associated with 
loss of heterozygosity along the majority of 3p with loss at 9p and the acquisition of 4p16 
loss at the transition from carcinoma-in-situ to invasive disease. Regression to normal 
epithelium was associated with the failure to acquire these changes at the same time.  
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Lung cancer is the commonest cause of death due to malignant disease in the United 
Kingdom but despite advances in imaging and treatment the prognosis of lung cancer 
sufferers has not changed significantly in the past 40 years1. The cure rate remains at 7-
13%, due in part to the late stage at which the disease presents in the majority of patients2. 
Evidence that the treatment of early stage and radiologically occult lung cancer improves 
long-term survival has stimulated research efforts into methods of early detection and 
screening3,4. Studies using spiral computed tomography and sputum analysis have shown 
some promise5,6. However, only established invasive carcinomas are detected using these 
modalities, a stage at which metastatic spread may already have occurred, and currently 
their effect on long-term survival is not known. Interest has therefore turned to even earlier 
stages of lung cancer development, when the disease has not yet become frankly invasive. 
 
Pre-invasive lesions of the bronchus 
Pre-invasive lesions are defined as “a precursor lesion of squamous cell carcinoma arising in 
the bronchial epithelium. Squamous dysplasia and carcinoma-in-situ are a continuum of 
recognisable histologic changes in the large airways. They can occur as single or multifocal 
lesions throughout the tracheobronchial tree. Dysplasia or carcinoma-in-situ may exist as an 
isolated finding or as a bronchial surface lesion accompanying invasive carcinoma”7 (figure 
1.1). The basement membrane is intact in pre-invasive lesions8, and there is no possibility of 
metastatic spread, which is in contrast to squamous cell carcinoma where there is the 
potential for metastasis as soon as invasion occurs. There is some evidence that a 90% 5-
year survival might be achieved by treating lesions at the pre-invasive stage3,9. 
Consequently, pre-invasive lesions are thought good candidates for therapy, with the 
aspiration that their treatment will improve long-term survival from carcinoma of the 
bronchus. Large studies have shown that only 10% of heavy smokers develop carcinoma of 
the bronchus10,11. The studies of Auerbach showed that up to 75% of heavy smokers and 
patients with previous lung cancers may harbour pre-invasive lesions of the bronchus12, 
which suggests that although pre-invasive lesions are prevalent within the bronchial tree of 
smokers, not all pre-invasive lesions are committed to progress to carcinoma. This raises 
questions regarding their treatment, as lesions that are not at risk of malignancy should not 
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require intervention. To identify which lesions are at risk and target treatment appropriately, 
and to interpret the results of studies of treatment of pre-invasive lesions, a detailed 
understanding of the natural history of pre-invasive lesions is necessary. 
 
The prevalence of pre-invasive lesions 
The seminal study by Auerbach and colleagues12 in the 1950s examined 208 serial sections 
from post-mortem specimens of the bronchial tree of a cohort of smokers, non-smokers and 
lung cancer sufferers. Pre-invasive lesions were a frequent finding in the bronchial 
epithelium of smokers and patients with lung cancer and their prevalence and histological 
grade were related to the intensity and duration of smoking (figure 1.2)12. Carcinoma-in-situ 
was detected in 75% of the heavy (>40 cigarettes per day) smokers and 11% of the sections 
from these subjects. There was no “dysplasia” category in their classification of lesions, and 
carcinoma-in-situ was defined as “all bronchial epithelial lesions composed entirely of 
atypical cells and lacking cilia”. The authors accepted that there were differences between 
the lesions categorised as “carcinoma-in-situ” but could not differentiate the lesions further 
due to a lack of sensitivity in their techniques. Nevertheless, the findings suggest that pre-
invasive lesion development may be a consequence of cigarette smoke exposure and could 
be related to the risk of lung cancer, in particular squamous cell carcinoma. 
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The prevalence of pre-invasive lesions was addressed in a more recent study by Paris et 
al13. In 241 patients at high risk for lung cancer (as defined by the IASLC criteria) the 
prevalence of high-grade pre-invasive lesions was 9%. The prevalence was higher in current 
(12%) than former smokers (4%). The histological grade of dysplasia observed within the 
bronchial tree was related to the extent of tobacco exposure. There was a clear association 
between the presence of high-grade pre-invasive lesions and previous carcinoma of the 
bronchus, a history of head and neck carcinoma (odds ratio 4.0 based on 15 patients) and 
occupational exposure to asbestos or other carcinogens. The risk of having a high-grade 
pre-invasive lesion ranged from 0.2% to 90.4% and was related to the number of risk factors 
for carcinoma within the individual patient. A multi-centre randomised study by Häußinger14 
and colleagues using a different autofluorescence system stratified 1173 patients by their 
risk factors. The highest prevalence of pre-invasive lesions was in patients with abnormal 
sputum cytology but normal chest radiology (11.1%). Patients with previously resected 
carcinomas had a prevalence of 6.7% and those with radiological or clinical suspicion of lung 
cancer 4.6%. There were no pre-invasive lesions found in those with Chronic Obstructive 
Pulmonary Disease or occupational exposure to carcinogen alone.  
 
Further data are available from the chemoprevention studies of Lam and colleagues where 
volunteer smokers underwent autofluorescence bronchoscopy15. The prevalence of 
carcinoma-in-situ was 1.8%, severe dysplasia 6.5%, moderate dysplasia 14% and mild 
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Figure 1.2 The prevalence of pre-invasive lesions in the study by 
Auerbach and colleagues. 
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dysplasia 40%. Males appeared to have a higher prevalence of pre-invasive lesions, high-
grade lesions occurring in 31% of males but only 14% of females. The overall prevalence 
and number of lesions per patient were lower in females even after adjustment for smoking. 
The reasons for this are not clear but may be related to sex-related differences in the 
susceptibility of the epithelium to the toxic effects of cigarette smoke. 
 
The natural history of pre-invasive lesions 
Sputum studies 
The hypothesis that squamous cell carcinoma of the bronchus develops through a series 
pre-invasive lesions was originally inferred from the sputum studies of Saccomanno and 
colleagues16. Uranium miners, at high risk of developing lung cancers were followed using 
cytological analysis of serial sputum specimens for up to 10 years. The morphology of 
abnormal cells in sputum was considered indicative of the histology of the underlying lesion. 
In some patients, sputum cytology became increasingly abnormal until squamous carcinoma 
cells were seen. In others, the abnormalities returned to normal and carcinoma was not 
detected during long-term follow-up. This study has been presented as proof that squamous 
carcinoma of the bronchus develops from pre-invasive lesions. Although sputum is 
representative of the entire respiratory tract and easy to collect, the studies of Auerbach et 
al.12 suggest that smokers usually carry multiple pre-invasive lesions, and therefore the fate 
of any individual lesion cannot be inferred from the sputum findings alone. Unfortunately, 
correlation with the pathology of individual lesions was not performed and so the study 
cannot be regarded as conclusive evidence of the pathway by which squamous cell 
carcinoma of the bronchus develops from pre-invasive lesions. 
 
Animal studies 
Animal studies using dogs, hamsters and rats have investigated pre-invasive lesions17-19. 
Concentrated carcinogen was applied to the tissue and the development of abnormal lesions 
determined either by serial biopsy or sacrifice of animals. Either the animals own bronchial 
tree, or transplanted human bronchial epithelium was used. On exposure to carcinogen, 
usually derivatives from cigarette smoke such as benzo-α-pyrene, the sequence of lesion 
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progression from normal epithelium through metaplasia, dysplasia and carcinoma-in-situ to 
invasive carcinoma was observed19. When the carcinogen was withdrawn, or after only a 
single short exposure to carcinogen, regression to normal epithelium was observed in some 
studies18. Animal studies, although useful as a model, are of limited applicability to human 
pathophysiology. The carcinogen levels used were higher, more concentrated and applied 
for a shorter time than the more chronic cigarette smoke exposure in humans. Nevertheless 
the results are of value as they provide experimental evidence of the pathway by which 
squamous cell carcinoma of the bronchus develops. 
 
Human studies 
Studies involving the follow-up of patients 
The presence of pre-invasive lesions of the bronchus signifies an increased likelihood of 
development of carcinoma of the bronchus. Loewen et al20 recently described a group of 169 
patients from the USA undergoing surveillance using CT scanning and autofluorescence 
bronchoscopy. Of the patient group, 66% had pre-invasive lesions of squamous metaplasia 
or worse and 7% developed a lung cancer in the 3-16 month follow-up period, over half of 
which were adenocarcinomas. A similar group of 46 patients, reported by Pasic et al21, were 
followed up using autofluorescence bronchoscopy 4-6 monthly for a median of 50 months. 
The number of pre-invasive lesions found within the airways was related to the patient’s 
probability of carcinoma development. In contrast to the USA study above, 24% of this Dutch 
group of patients developed squamous cell carcinoma; no adenocarcinomas were found. 
The relationship between the individual lesions followed and the development of carcinoma 
was not discussed.  A Japanese study followed 124 patients with serial bronchoscopies 
every 4-6 months. New endobronchial lesions developed in 7 patients (1 CIS, 5 squamous 
cell carcinomas and 1 small cell carcinoma). In 10 patients, new peripheral lesions were 
found (6 squamous cell carcinomas, 2 adenocarcinomas, 1 small cell and 1 large cell 
carcinoma). Only 3 severe dysplasia lesions developed into carcinoma-in-situ. The median 
time to progression was 24 months, and 80% of the lesions were stage 0 or 1. Risk factors 
for progression were Chronic Obstructive Pulmonary Disease, number of pack years 
smoked and lesion grade (i.e. high-grade lesion)22. 
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A 4 year study in Italy23 showed that 10 of 22 patients with dysplasia developed a carcinoma, 
7 of which were squamous cell, during follow-up. The grade of dysplasia at baseline was 
related to the probability that a carcinoma would occur. There was no bronchoscopic follow-
up, and so once again the relationship between individual lesions and the development of 
carcinoma could not be determined. Additional information is provided by the study by Sin et 
al.24 from Canada, where a raised serum C-reactive protein was associated with the 
histologic progression of dysplasia or the development of new lesions in 50% of the study 
patients. These data suggest that in patients at high-risk for lung cancer, pre-invasive lesions 
of high grade are prevalent. The risk of development of carcinoma of the bronchus, 
particularly squamous cell, is related to their number and severity.  
 
Studies involving the bronchoscopic follow-up of lesions 
The literature on the natural history of pre-invasive lesions has accumulated over 50 years 
and is difficult to interpret. The criteria for the diagnosis and classification of pre-invasive 
lesions has changed twice7,8,12,25  which makes the analysis of older studies problematic. The 
possibility that an individual lesion may progress to an invasive carcinoma has prompted 
some groups to take the view that all carcinoma-in-situ should be treated26. Thus in many 
studies carcinoma-in-situ and invasive carcinoma were joint end-points, which compromises 
evaluation of the natural history of high-grade lesions27,28. In most studies, higher grade 
lesions have been followed up for only very short periods of time, typically less than 6 
months, and usually not as far as the development of invasive malignancy26. The lesions 
were then treated, which invalidates the follow-up data.  
 
Despite the 2004 WHO guidelines7, the differentiation between severe dysplasia and 
carcinoma-in-situ, particularly in biopsy specimens, can be difficult. It is interesting to note 
that the agreement between the two observers for the reporting of the histopathology has not 
been stated in any of the studies, nor was the quality of the biopsies assessed. This is 
despite known difficulties with the subdivision between mild and moderate dysplasia, 
between severe dysplasia and carcinoma-in-situ, and also the effect of the quality and 
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structural integrity of the biopsy on the interpretability of the histological features29. 
Bronchoscopic biopsy and specimen processing is known to compromise the histological 
appearance of some specimens. The interpretation of studies of the natural history of pre-
invasive lesions is critically dependent on accurate histology, particularly if differentiation is 
to be made between carcinoma-in-situ and severe dysplasia.  
 
The studies in which follow-up data on pre-invasive lesions can be found are listed in table 
1.1. Given the difficulty in detecting pre-invasive lesions30, and their relatively low frequency 
in the at-risk population14, it is not surprising that the majority of studies have included 
patients in whom pre-invasive lesions have already been identified. Most have followed 
individual lesions, but some have followed the whole patient, reporting outcome in terms of 
the observed carcinoma, regardless of it’s location or cell type. There is heterogeneity 
between the groups of patients included, the specific types of lesion followed, the end-points 
of the studies and the criteria for intervention for pre-invasive lesions.  
 
The largest study, that of Bota et al26, followed carcinoma-in-situ for only 3 months prior to 
endobronchial therapy. No further post-treatment data are given, and the efficacy of the 
treatments applied are not evaluated. Severe dysplasia was followed up, and found to 
regress in a significant proportion of patients. Only the ultimate outcome of an individual 
lesion was reported, limited by the length of the study, and not the specific histological or 
bronchoscopic features as they evolved over time. Jeanmart et al.28 reported the outcome of 
individual lesions over time. As both carcinoma-in-situ and invasive carcinoma were end-
points the outcome of severe dysplasia and carcinoma-in-situ are difficult to evaluate with 
certainty. The study by Breuer et al.27 had similar issues, with the definition of “progression” 
of a high-grade lesion including lesions that had remained stable for 3 months, or 
progression from severe dysplasia to carcinoma-in-situ. Only 11 lesions of high-grade were 
identified in the study by Hoshino et al.31 and no lesions of carcinoma-in-situ, while studies 
by Moro-Sibilot et al.32, Sozzi et al.33 and Lamy et al.34 contribute very few high-grade lesions 
to the literature. The placebo arms of the chemoprevention studies of Lam et al. provide 
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valuable information, although follow-up was for only 6 months and there were very few 
high-grade lesions35,36.  
 
It is difficult to interpret the studies of Satoh et al.37, Thiberville et al.38 and Venmans et al.39 
alongside the more recent studies as the lesions were classified using the 1981 WHO 
criteria25. In the study by Venmans et al.39 in particular, all the carcinoma-in-situ was treated, 
which compromised the results. Satoh et al.37 followed 4 lesions in 3 patients, all of which 
developed into invasive carcinoma in up to 6 years. It is conspicuous that the high grade 
lesions progressed more rapidly than the low-grade lesion. The study by Thiberville and 
colleagues38 followed the histological and molecular progression of a series of pre-invasive 
lesions, some of which were treated and some of which were not. Four lesions are shown 
with their detailed histological follow-up data in the study by Breuer et al.27, but without 
timescales.  
 
Tables 1.2 and 1.3 show the outcome of pre-invasive lesions from the literature. When the 
data from all the studies are combined it is noted that pre-invasive lesions may progress to 
invasive squamous cell carcinoma, and the risk is much higher for high-grade lesions than 
low-grade lesions. The probability of progression appears higher for carcinoma-in-situ than 
severe dysplasia, but this is based on the analysis of 49 carcinoma-in-situ lesions. It is not 
clear whether carcinoma-in-situ had indeed progressed to invasive carcinoma or persisted 
as carcinoma-in-situ in many of these lesions which makes interpretation of the data difficult. 
A significant proportion of carcinoma-in-situ and severe dysplasia lesions regress towards 
normal epithelium. It has been suggested that severe dysplasia is more likely to regress than 
carcinoma-in-situ, but the protocol of the study in question treated carcinoma-in-situ if it 
persisted at 3 months which invalidates the conclusions drawn26. It is observed that as many 
carcinoma-in-situ lesions remain stable as they progress to invasive carcinoma or regress 
towards normal, suggesting that the length of follow-up has been inadequate for many of 
these lesions. Combining carcinoma-in-situ and severe dysplasia together into a “high-
grade” lesion category shows an equal rate of progression and regression. Low-grade 
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lesions have a comparatively low risk of progression and are most likely to regress to normal 
or remain stable.  
 
These data are based on 165 high-grade lesions in the literature. It is questionable, given 
the low numbers of lesions followed-up and the heterogeneity of inclusion criteria and 
reporting of outcomes, whether any firm conclusions regarding the clinical management of 
high-grade pre-invasive lesions can be drawn. There are no clinical features that predict the 
outcome of a manifest lesion.  
 
From these studies several important questions remain unanswered: 
1. Does squamous cell carcinoma of the bronchus develop through a series of pre-
invasive lesions of increasing histological and cytological abnormality? The length of 
follow-up for virtually all of the lesions in the literature is insufficient to adequately 
answer this question. 
2. Are all pre-invasive lesions committed to the development of malignancy? There is 
no convincing evidence that the entire sequence of histopathological changes from 
normal epithelium to squamous cell carcinoma occurs in every lesion. 
3. Does pre-invasive lesion development follow a predictable time-course and pattern? 
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Table 1.1: Studies of follow-up of pre-invasive lesions. Abbreviations: MiD Mild dysplasia, MoD Moderate dysplasia, SD Severe dysplasia, CIS Carcinoma-in-
situ, ASD Angiogenic squamous dysplasia, LGL Low-grade lesion, PDT Photodynamic therapy, CRP C-reactive protein, High-risk is as defined by the IASLC criteria. 
 
Study Selection 
criteria 
Patients 
(no.) 
Male 
(%) 
Lesions 
(no.) 
Follow-up  
(months) 
Lesion types included Lesions types excluded Comments 
Lam 200140 High-risk  101 61 248 6 months Up to severe dysplasia CIS & carcinoma Chemoprevention study 
Bota 200126 High-risk  104 96 416 3-24  Up to SD CIS treated  
Jeanmart 200328 Ex-smokers 48 94 80 18-36  Up to SD CIS & carcinoma end-points  
Breuer 200527 Smokers 52 85 134 11-21  Up to SD CIS & carcinoma end-points  
Hoshino 200431 Detected lesions 50 98 99 6-17 Up to SD None  
Moro-Sibilot 200432 Detected lesions 27 89 31 25 CIS & SD LGL and carcinoma  
Lamy 200234 Detected lesions 37 NA 29 19-28 All No SD / CIS reported Methylation status & outcome 
Sozzi 200233 Detected lesions 2 100 20 48 All CIS treated Case study 2 patients 
Keith 200041 ASD only 11 NA 20 12 ASD All others Part of larger histology study 
George 200742 High risk 22 86 36 12-85 All None 9 patients previous cancers 
Lam 200435 High risk 112 73 403 6 All None Chemoprevention study 
 
Studies performed using pre-1999 WHO criteria for pre-invasive lesions 
Study Selection 
criteria 
Patients 
(no.) 
Male 
(%) 
Lesions 
(no.) 
Follow-up  
(months) 
Lesion types included Lesions types excluded Comments 
Satoh 199737 SD & MiD only 3 100 4 7-72 3 SD and 1 MiD None Lesion follow-up case study 
Venmans 200039 CIS only 9 78 13 6 months CIS + detected in follow-up All others  PDT treatment study 
Thiberville 199538 High-risk 6 92 11 48 All  Some CIS treated Molecular changes study 
 
Studies in which lesions were treated 
Study Selection 
criteria 
Patients 
(no.) 
Male 
(%) 
Lesions 
(no.) 
Follow-up  
(months) 
Lesion types included Lesions types excluded Comments 
Deygas 200143 CIS only 35 97 41 1-12 CIS All others Study of cryotherapy 
 
Studies of resection margin CIS 
Study Selection 
criteria 
Patients 
(no.) 
Male 
(%) 
Lesions 
(no.) 
Follow-up  
(months) 
Lesion types included Lesions types excluded Comments 
Pasic 200544 CIS only 11 82 11 11-89 CIS resection margin All others Resection margin lesions only 
 
Studies in which patient outcome determined (no individual lesion data) 
Study Selection criteria Patients 
(no.) 
Male 
(%) 
Follow-up 
(months) 
Outcome Purpose of study 
Sin 200624 “Dysplasia” 65 75 6 50% progression at 6 months Relationship outcome to CRP 
Ponticiello 200023 High-risk with dysplasia 22 69 48 10/22 carcinoma Relationship outcome to grade of dysplasia & p53 
Pasic 200321 High-risk 46 85 12-80 11/46 carcinoma Retrospective. Relationship number of lesions to outcome 
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Table 1.2: Studies of follow-up of untreated pre-invasive lesions. The numbers of lesions with the given outcome are shown for each study. A range is given for 
studies where differentiation between outcomes cannot be determined from the data, e.g. carcinoma-in-situ stable at 3 months or progression to invasive carcinoma. 
The outcomes of the lesions are therefore calculated as a range.  Abbreviations: MPA metaplasia, LGL low-grade lesion, HGL high-grade lesion, SD severe 
dysplasia, CIS carcinoma-in-situ. 
 Bota 200126 
George 
200742 
Jeanmart 
200328 
Breuer 
200527 
Hoshino 
200431 
Moro-S 
200432 
Lamy 
200234 
Satoh 
199737 
Thiberville 
199538 
Lam 
200435 
Lam 
200336 
Total 
(numbers) 
Total  
(%) 
CIS progression 0-25/32 X 5/8 X X 2/7 X X 1/2 X X 8-33/49 16-67 
CIS regression 7/32 X 0/8 X X 3/7 X X 0/2 X X 10/49 20 
CIS stable 0-25/32 X 3/8 X X 2/7 X X 1/2 X X 6-31/49 12-63 
SD progression 0-8/27 X 2/9 SQC 4/9 CIS 
8/25  
incl CIS 
2/11 
SQC 1/1 X 3/3 X 0/2 0/2 20-28/80 25-35 
SD regression 19/27 X 3/9 13/25 5/11 0/1 X 0/3 X 2/2 2/2 44/80 55 
SD stable 0-8/27 X 0/9 4/25 4/11 0/1 X 0/3 X 0/2 0/2 8-16/80 10-20 
HGL progression 0-33/59 6/36 7/17 8/25 incl 
some stable 2/11 3/8 X 3/3 1/2 0/2 0/2 30-63/165 19-38 
HGL regression 26/59 7/36 3/17 13/25  
excl CIS 5/11 3/8 X 0/3 0/2 2/2 2/2 61/165 37 
HGL stable 0-33/59 23/36 7/17 4/25  
excl CIS 4/11 2/8 X 0/3 1/2 0/2 0/2 41-74/165 25-45 
LGL progression 6/169 0/17 11/18 9/64 1/88 X 6/29 
HGL/SQC 1/1 0/9 0/145 3/105 37/645 6 
LGL regression 100/169 14/17 7/18 41/64 50/88 X 0/29 0/1 3/9 102/145 61/105 378/645 59 
LGL stable 63/169 3/17 0/18 14/64 37/88 X 23/29 0/1 6/9 43/145 41/105 230/645 36 
MPA progression 48/152 X 5/26 13/45 X X X X X 12/68 16/29 94/320 29 
MPA regression 56/152 X 0-21/26 19/45 X X X X X 0/68 8/29 83-104 /320 26-32 
MPA stable 48/152 X 0-21/26 13/45 X X X X X 56/68 5/29 122-143 /320 38-45 
Distant Carcinoma 
(number)  5 3/8    6       
Duration of follow-
up (months) 3-24 12-85 18-36 11-21 6-17 25 19-28 7-72 48 6 6   
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Table 1.3: Studies of follow-up of treated pre-invasive lesions. The numbers of lesions with the given outcome are shown for each study. Abbreviations: MPA 
metaplasia, LGL low-grade lesion, HGL high-grade lesion, SD severe dysplasia, CIS carcinoma-in-situ, PDT photodynamic therapy, CP Chemoprevention. 
 
 Venmans 200039 
Lam 
200240 
Deygas 
200143 
Moro-Sibilot  
200432 
Sozzi 
200233 
Lam 
200336 
Lam 
200435 
Total  
(no. patients) 
Total 
(%) 
Distant SQC   8/35       
CIS progression 2/6 X 7/35 11/21 2/2 X  22/64 34 
CIS regression 3/6 X 25/35 9/21 0/2 X  37/64 58 
CIS stable 1/6 X 3/35 1/21 0/2 X  5/64 8 
SD progression 3/3 X X 1/2 0/1 0/2 0/2 4/10 40 
SD regression 0/3 X X 1/2 1/1 2/2 2/2 6/10 60 
SD stable 0/3 X X 0/2 0/1 0/2 0/2 0/10 0 
HGL progression 5/9 X 7/35 3/8 2/3 0/2 0/2 17/59 29 
HGL regression 3/9 X 25/35 3/8 1/3 2/2 2/2 36/59 61 
HGL stable 1/9 X 3/35 2/8 0/3 0/2 0/2 6/59 10 
LGL progression 1/4 1/94 X X 1/2 3/108 3/114 9/322 3 
LGL regression 3/4 55/94 X X 1/2 74/108 73/114 206/322 64 
LGL stable 0/4 38/94 X X 0/2 31/108 38/114 107/322 33 
MPA progression X 8/20 X X X 5/23 15/56 28/99 28 
MPA regression X 10/20 X X X 10/23 34/56 54/99 54 
MPA stable X 2/20 X X X 8/23 7/56 17/99 17 
Treatments PDT CP Cryotherapy Various endobronchial 
Specific  
chosen CP CP   
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Autofluorescence bronchoscopy 
Autofluorescence bronchoscopy has been developed specifically to detect pre-invasive 
lesions45-47. The ability to detect lesions, particularly those of higher-grade, has enabled the 
study of pre-invasive lesions as a means of early identification and treatment of squamous 
cell carcinoma of the bronchus.  
 
Pre-invasive lesions are small, and difficult to detect using conventional bronchoscopy30. In 
an attempt to address this problem, bronchoscopic devices have been developed which 
exploit differences in the fluorescence properties of normal and abnormal bronchial mucosa. 
They can be used to inspect the central airways and identify subtle endobronchial lesions 
previously not visible using conventional white light bronchoscopy. This technique cannot 
identify lesions beyond the range of the bronchoscope, in locations such as the distal 
airways and pulmonary parenchyma.  
 
Fluorescence and tumour detection 
It has been known since the early part of the last century that tissues fluoresce when 
exposed to light of a suitable wavelength. Tumours, both benign and malignant, alter the 
fluorescence properties of the tissue, facilitating their detection using this technique48,49. The 
difficulty was that within the bronchus, the intensity of fluorescence was often too low to be 
detected with the naked eye or was swamped by reflected light from the excitation beam. 
Exogenous photosensitizing fluorescent compounds, such as hematoporphyrin derivatives 
were used to enhance the intensity of the fluorescence pattern50,51. Unfortunately the 
photosensitizer caused transient but severe photosensitivity of the skin and consequently 
there was limited uptake of the technology in clinical and research practice. 
 
Interest in fluorescence-based detection returned because subsequent technological 
advances in image acquisition and processing facilitated the detection of subtle differences 
in fluorescence characteristics without the requirement for a fluoropher. Observations in the 
lung have shown that dysplasia, carcinoma in situ, and microinvasive carcinoma exhibit 
slightly weaker red fluorescence but much weaker green fluorescence than normal tissues 
Part 1: Introduction 
Page 15 of 178 
when illuminated by 380-440nm wavelength (blue spectrum) light (figure 1.2)52. The reasons 
for this difference are not fully understood. In tissues, the endogenous fluorophores include 
collagen, nicotinamide, adenine dinucleotide, flavins and porphyrins. Cell nuclei generate 
relatively little fluorescence signal compared to the cell cytoplasm. In both pre-invasive 
lesions and carcinoma, there is an increased cell nuclear:cytoplasmic ratio, which reduces 
the fluorescence signal from the cytoplasm. Lesions cause thickening of the epithelium, 
which reduces the fluorescence from the underlying stromal collagen. Neovascularisation 
due to neoangiogenesis induced by the lesion cells increases the local haemoglobin 
concentration and thereby alters the fluorescence signal53,54. It is thought that the differences 
in autofluorescence observed in pre-invasive and malignant lesions compared to normal 
tissue are due to a combination of these factors, although our understanding is 
incomplete52,53. 
 
Autofluorescence bronchoscopy systems 
The first bronchoscopy system to become commercially available was the light-induced 
fluorescence endoscopy (LIFE) device (Xillix Technologies Corporation, Vancouver, 
Canada)55,56. The bronchial tree was illuminated by blue (442 nm) light from a helium-
cadmium laser, and the fluorescence images were collected by the imaging bundles of the 
bronchoscope. The red and green wavelengths were filtered and amplified with separate 
image-intensifying cameras. Their relative intensities were then measured and used to 
create a computer-enhanced image, which delineated the abnormal areas of fluorescence 
when displayed on a monitor. Fluorescence bronchoscopy was performed during the same 
session as conventional white light bronchoscopy, but separate light sources were required. 
Most of the work in this field was performed using this device, including validation of 
autofluorescence for the detection of pre-invasive lesions and microinvasive carcinoma. 
 
Karl Storz Gmbh (Tuttlingen, Germany), subsequently developed a system using a 
conventional xenon light source, together with an optical filter fitted to the eyepiece of the 
bronchoscope57. The light source can illuminate the bronchial tree with either white light 
(conventional white light mode) or two bands of blue light (380 to 460 nm and 380 to 440nm, 
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autofluorescence mode), the mode of illumination being controlled by a switch incorporated 
into the bronchoscope. An optical filter transmits the red and green wavelengths together 
with a small part of the excitation wavelength, allowing visualization in areas of low 
fluorescence. The images can be viewed directly through the eyepiece of the bronchoscope 
or displayed on a monitor using a CCD-camera. Although the Storz system was designed to 
detect both autofluorescence and induced-fluorescence (using the pro-drug 5 
aminolaevulinic acid) [30,31],  the most commonly employed technique is autofluorescence, 
as it is easy to perform and avoids light sensitization.  
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Adapted from Hung J et al.52 
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Clinical studies using autofluorescence bronchoscopy 
Most of the published clinical studies on autofluorescence bronchoscopy have been 
conducted with the LIFE device. In the majority, white light bronchoscopy was performed 
before autofluorescence bronchoscopy in the same session, and the abnormal areas 
observed with each modality were carefully documented. The ability to detect preinvasive 
lesions and invasive carcinoma was assessed by histological examination of biopsies taken 
from the bronchoscopically abnormal areas and comparison with control biopsies from 
bronchoscopically normal areas. 
 
The five largest studies involving the LIFE device have reported a 1.5 to 6.3-fold increase in 
the detection of dysplasia and carcinoma in situ46,55,56,58-60 (see table 1.4). Although invasive 
carcinomas are considered relatively easy to detect with white light bronchoscopy, some of 
these studies have also reported improved detection of these lesions with fluorescence 
bronchoscopy46,59. In a recent multi-centre study of patients investigated for possible 
carcinoma, the sensitivity of detection of high-grade pre-invasive lesions was improved by 
4.25, although the false positive rate was increased by 3.56 in the same group, when 
compared to white light detection using the same device59. This suggests that despite 
extensive training and experience, and with the newest imaging technology, 
autofluorescence detection still provides benefits over white light detection for high-grade 
pre-invasive lesions. This benefit decreased to 1.50 when the detection of lesions from 
moderate dysplasia to invasive carcinoma were considered, reflecting the ability of white 
light bronchoscopy to detect lesions at the fully invasive carcinoma stage. In a meta-analysis 
of 14 studies with 15 datasets, 3612 samples from 1358 patients were analysed for lesions 
of moderate dysplasia or higher grade. The sensitivity of autofluorescence was 90% (range 
84-93%) with a specificity of 56% (45-66%), while the sensitivity of white light bronchoscopy 
was 66% (58%-73%) with a specificity of 69% (57%-79%)61. 
 
The design of these studies has been criticized because performing a preliminary white light 
bronchoscopy may lead to bias in sensitivity of the subsequent fluorescence 
bronchoscopy62,63. In one large randomized study, the order in which the procedures were 
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performed (white light first or autofluorescence first) or the bronchoscopist performing the 
procedures did not influence the relative sensitivities of either modality for lesion detection64. 
In none of the studies have the abnormalities been autofluorescence negative but white light 
positive. The specific appearances on autofluorescence bronchoscopy do not correlate with 
the histopathological appearances. Although several groups have attempted to classify the 
abnormalities seen with the autofluorescence bronchoscope, their utility in terms of the 
diagnosis is not well established46,59.  
 
The study that showed the largest advantage for fluorescence bronchoscopy reported 
results that were based upon the number of biopsies that revealed abnormal histology, 
rather than upon the number of discrete lesions detected46,62. The ability to ascertain an 
abnormality may therefore have been exaggerated if more than one biopsy was taken from 
some lesions. Although these criticisms should be taken into account when interpreting the 
data, the broad agreement that exists among these large studies suggests that fluorescence 
bronchoscopy with the LIFE device genuinely facilitates the detection of moderate to severe 
dysplasia and carcinoma in situ.  
 
Data in favor of fluorescence bronchoscopy have not been universal. As an example, a 1998 
study from the MD Anderson Cancer Center found a lower sensitivity associated with the 
LIFE device65. The authors of this study had hoped that the LIFE device would facilitate the 
detection of metaplasia and dysplasia, which were endpoints in their lung cancer 
chemoprevention trials. However, the detection of these abnormalities was not significantly 
increased in 39 individuals undergoing combined white light and fluorescence bronchoscopy 
when compared with the results obtained in a matched group of 53 controls undergoing 
white light bronchoscopy alone. Biopsies from areas judged to be normal by the LIFE device 
yielded a similar number of metaplastic and dysplastic lesions as did those from areas 
judged to be abnormal. The data obtained with the LIFE device were stratified according to 
smoking status and history of previous smoking-related cancer, in order to establish whether 
abnormalities of fluorescence might reflect lung cancer risk factors other than histological 
abnormalities, but no correlations were found. 
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The apparent discrepancy between the findings of the MD Anderson study and other studies 
involving the LIFE device has been attributed to the lower prevalence of severe dysplasia 
and absence of carcinoma in situ in participants recruited into the MD Anderson study66. It 
has therefore been suggested that the LIFE device has sufficient sensitivity to detect severe 
dysplasia and carcinoma in situ but is neither sensitive nor specific for detecting milder 
degrees of dysplasia and metaplasia66. 
 
Clinical experience with the Storz fluorescence bronchoscope is not as extensive as with the 
LIFE device, but evidence suggests that both systems improve the detection of airway 
abnormalities to a similar degree14,62,67,68. One potential advantage of the Storz fluorescence 
bronchoscope is the shorter procedure time required for use. This was best demonstrated in 
a multicenter study comparing autofluorescence using both LIFE and Storz systems, in 
conjunction with white light bronchoscopy, in over 300 patients67. The diagnostic 
performance of each system was similar, but the time required for examination was 
significantly shorter with the Storz system (7.4 versus 11.7 minutes for the LIFE system). 
Similar reductions in examination time have been seen with the SAFE-1000 device69. 
 
Limitations of autofluorescence bronchoscopy 
In a study of 11 healthy volunteers average age 59 years, there was a 30% inter-patient 
variation in the red and green intensities and a 26% variation in the red and green ratios 
during autofluorescence70. Within individuals there was also variability in the red and green 
autofluorescence signals due to the nature of tissues within the bronchial wall. Some 
variability in autofluorescence signals could be attributed to the instrument used. The 
variability is usually compensated by automatic colour balance within the autofluorescence 
system but the clinical effect of this variability is not known. The authors suggest that these 
factor should be taken into account when designing autofluorescence systems, but the 
clinical impact has never been assessed. 
 
Part 1: Introduction 
Page 21 of 178 
An important limitation of autofluorescence bronchoscopy is the high rate of false positive 
findings. In a large multicenter study, only 95 of 285 biopsies obtained from areas with 
abnormal autofluorescence detected by the LIFE device actually contained abnormal 
histology, yielding a positive predictive value of only 33 percent46. However, one study has 
shown that 50% of lesions with abnormal autofluorescence but normal histology carried 
molecular changes similar to pre-invasive lesions and invasive carcinoma71. 
 
In contrast, in a study from Japan autofluorescence bronchoscopy was performed 
immediately prior to lung resection for carcinoma72. The resected specimen was then 
subjected to detailed analysis looking for pre-invasive lesions. Autofluorescence failed to 
identify 8/16 (50%) of the prevalent lesions found within the resected specimen. The 
relationship between the autofluorescence properties of an individual lesion, the 
histopathology and subsequent histological outcome is not known. It is possible that 
autofluorescence changes in an area of bronchial mucosa reflect subtle ultrastructural 
changes not present in autofluorescence negative lesions. Autofluorescence changes may 
indicate an increased risk of developing lesions or malignancy but may just as easily signify 
that a lesion is indolent and unlikely to progress to malignancy. No studies have addressed 
this question, which will be difficult to answer until technology advances sufficiently to map 
lesions within the entire bronchial epithelium without the need for biopsy, as this disrupts the 
mucosa and may influence the long-term outcome of the lesion. Narrow band imaging has 
shown some promise, with a relative sensitivity for the detection of pre-invasive lesions from 
moderate dysplasia to carcinoma-in-situ of 3.0 compared to 3.7 for autofluorescence (no 
significant difference)73. It is not known how the vessel abnormalities seen with narrow band 
imaging correlate with the histologies of high-grade lesions, and therefore much work 
remains before the technique can be widely applied in the research context. 
 
Clinical indications for autofluorescence bronchoscopy 
The clinical applications of autofluorescence are still being evaluated but include the 
investigation of patients with high-grade sputum atypia with normal radiological imaging 
(grade of recommendation 1b), where its diagnostic yield for lung cancer may be up to 
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6.3%74. In a large multicentre study of patients using the Storz device, the sensitivity of 
autofluorescence for the detection of high-grade pre-invasive lesions was greatest in 
patients with a radiological suspicion of lung cancer, or abnormal sputum cytology but 
normal chest radiology14. Improvement in the sensitivity of lesion detection over white light of 
2.5 and 2.8 respectively was obtained. Other clinical applications include longitudinal 
surveillance of patients with dysplasia and CIS (grade 2c), and the assessment of early 
central lung cancer being considered for curative endobronchial treatment (grade 2c).   
 
It has been suggested that fluorescence bronchoscopy may be of value in identifying 
patients at risk of developing lung cancer.  In a study of 46 patients with sputum atypia or a 
previous history of an aerodigestive cancer, the number of areas of abnormal 
autofluorescence was related to the risk of squamous cell carcinoma development over the 
next four years21.  Similarly, in a separate study of 22 patients with different grades of pre-
invasive lesion, combined surveillance with fluorescence bronchoscopy and annual chest CT 
disclosed an exceptionally high lung cancer risk in patients with severe dysplasia and CIS 
(54% at 2 years)42. 
 
In summary 
Autofluorescence bronchoscopy is an effective technique for the detection of pre-invasive 
lesions of the bronchus. It is limited by a high false positive rate and by the inability to view 
the entire tracheobronchial tree. Of concern is the suggestion that not all pre-invasive lesions 
are visible using autofluorescence.  
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Table 1.4: Studies of autofluorescence. 
    HGL HGL HGL MoD+ MoD+ MoD+ 
Author Year Patients # Lesions # Sens WLB (%) Sens AFL + WLB (%)  Relative sens Sens WLB (%) Sens AFL + WLB (%) Relative sens 
LIFE           
Lee69 2007 48 28 - 86 - - - - 
Moro-Sibilot75 2002 244 81 35 86 2.4 - - - 
Sato76 2001 50 67 85 94 - - - - 
Shibuya77 2001 64 45 69 91 1.3 - - - 
Van Rens78 2001 69 15 20 100 5 - - - 
Venmans79 2000 114 101 57 84 1.5 - - - 
Venmans47 1999 95 40 70 85 1.2 - - - 
Vermylen80 1999 34 16 25 93 3.8 - - - 
Kurie65 1998 39 60 43 - - - - - 
Venmans63 1998 33 13 78 100 1.4 - - - 
Lam56 1994 100 113 16 94 5.3 - - - 
Lam55 1993 94 77 48 73 1.5 - - - 
Edell59 2009  170 76 10 44 4.3 47 71 1.5 
Chajjed58 2005 151 63 61 92 1.5 71 94 1.2 
Chiyo81 2005 32 30 58 100 1.7 67 100 1.6 
Ikeda60 1999 158 72 51 90 1.6 64 73 - 
Kakihana82 1999 72 89 51 88 1.7 66 92 1.4 
Lam46 1998 173 102 9 56 6.3 25 67 2.7 
Ueno83 2007 31 29 - - - 54 77 - 
Hirsch64 2001 5 75 - - - 22 81 3.7 
Kusunoki84 2000 65 137 - - - 61 90 - 
Yokomise85 1997 30 14 - - - 65 90 1.4 
Ikeda86 1997 30 41 - - - 93 100 - 
Total  1901 1384 46 86 2.7 58 85 1.9 
          
SAFE1000          
Horvath87 1999 10 15 21 79 3.8 - - - 
SAFE3000          
Ikeda60 2006 154 48 65 90 1.4 78 94 1.21 
          
Storz          
Haussinger62 1999 60 7 33 83 2.8 - - - 
Haussinger14 2005 53 53 58 82 1.4 - - - 
HGL: High grade lesions, Moderate dysplasia, severe dysplasia and carcinoma-in-situ. MoD+: lesions of moderate dysplasia or worse including invasive squamous cell 
carcinoma. WLB: White light bronchoscopy. AFL: autofluorescence bronchoscopy. Sens: sensitivity. 
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The molecular biology of pre-invasive lesions of the bronchus 
Introduction 
The bronchial epithelium of smokers is exposed to the carcinogens in cigarette smoke. The 
entire tracheobronchial epithelium is exposed to carcinogen and at risk of DNA damage, a 
phenomenon known as “field cancerisation”88,89. This renders the entire tracheobronchial 
tree susceptible to malignant transformation and the development of carcinoma. Some 
carcinogens, including the benzo-α-pyrene derivatives, are known to bind to DNA and 
induce damage90. When the damaged DNA replicates and separates during mitosis gain or 
loss of chromosomal DNA within the daughter cells may occur. Genetic loss may inactivate 
tumour suppressor genes91. Tumour suppressor genes regulate cell growth, replication and 
differentiation and so prevent the uncontrolled growth of clones of cells and inhibit the 
development of features of malignancy such as invasion and angiogenesis. Inactivation of a 
tumour suppressor gene is believed to occur through a “two-hit” process, in which one allele 
is deleted (detectable by loss of heterozygosity) and the other is deactivated (for instance, by 
mutation or methylation)92. This frees the affected cell and subsequent clone of cells from 
growth and invasion control and renders it susceptible to malignant transformation. 
 
Genetic loss has been identified at multiple chromosomal loci in lung cancers using loss of 
heterozygosity analysis93-96. Specific patterns of genetic loss are associated with each of the 
major histological types of lung cancer although there is considerable overlap; for instance 
chromosome 3p genetic loss is common in both small cell and squamous cell carcinomas97. 
It is the overall pattern of the loci of genetic loss that is more typical of specific histologies98-
100. In squamous cell carcinoma of the bronchus genetic loss at multiple different 
chromosomal loci has been found, although consistent patterns have emerged93-101.  
 
Genetic loss in pre-invasive lesions 
Genetic loss using LOH analysis has also been discovered in histologically normal 
epithelium from both current and former smokers but not in those who have never 
smoked102,103. There is no difference in the pattern of genetic loss between current and 
former smokers. The extent of this loss may vary from 1-2 loci to a pattern similar to that of 
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established squamous cell carcinoma. Pre-invasive lesions of both low-grade and high-
grade show genetic loss. The extent of the genetic loss and the number of chromosomal 
regions affected is greater than in histologically normal epithelium but less than squamous 
cell carcinoma104,105. It has been proposed that the accumulation of genetic changes in 
histologically normal epithelium drives the progression through pre-invasive lesions of 
increasing abnormality to squamous cell carcinoma106,107. Between 10 and 20 mutations are 
thought to be required to generate a malignant phenotype, but it has been suggested that 
some genetic changes may be associated with cigarette smoke exposure, rather than 
malignant change93. This has prompted the study of genetic loss in pre-invasive lesions to 
determine which changes drive the progression to malignancy and the point in the 
pathogenesis of carcinoma at which they occur.  
 
Pattern of genetic loss in pre-invasive lesions 
Genetic loss in pre-invasive lesions has been studied using specimens resected for lung 
cancer93-101. Pre-invasive lesions of different grades were microdissected using various 
techniques and DNA extracted for analysis. Loss of heterozygosity was assessed using 
blood lymphocytes as a source of constitutional DNA. The LOH patterns of histologically 
normal epithelium, pre-invasive lesions and squamous cell carcinomas found within the 
resection specimens were compared.  
 
It has been shown that in specimens resected for lung cancer, multiple areas of histologically 
normal bronchial epithelium remote from the carcinoma show genetic loss in a pattern 
suggesting a clonal relationship to the carcinoma108. In such circumstances, not only is the 
pattern of genetic loci showing LOH similar, but the same parental allele is lost at each 
locus, a phenomenon termed “Allele-specific loss”109. This is not universal among pre-
invasive lesions, and in one study, 2 out of 8 patients were found to have different patterns 
of genetic or allele loss, suggesting that they are not clonally related to the carcinoma110.  
 
Genetic loss at 3p has been found in normal epithelium, 50-90% of dysplasia and 100% of 
carcinoma-in-situ and squamous cell carcinomas109. The loci with genetic loss were 
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“discontinuous”, with areas of genetic loss interspersed with areas where heterozygosity was 
retained105,109-111. The extent of 3p genetic loss appears to increase in parallel with the 
histological grade of the lesion such that a larger number of loci show genetic loss in higher-
grade lesions and carcinomas than lower-grade lesions. This suggests that LOH at 3p may 
progress as pre-invasive lesions progresses to invasive squamous cell carcinoma. It is 
concluded therefore that chromosome 3p loss is an early and frequent event in the 
pathogenesis of squamous cell carcinoma. 
 
LOH at 9p has also been found in histologically normal epithelium, pre-invasive lesions of all 
grades and squamous cell carcinoma104,105,112. The frequency of lesions demonstrating 
genetic loss and the number of markers in which loss of heterozygosity was found was 
greater in higher-grade than lower-grade lesions, and was greatest in squamous cell 
carcinoma. LOH at 9p21 was found in 63% of dysplasia lesions and 54% of early squamous 
cell carcinomas with a reduced expression of p73, a molecule with similar actions to p53113. 
The extent of 9p21 LOH in dysplasia and early squamous cell carcinoma was similar to later 
more invasive squamous cell carcinoma. This suggests that 9p21 LOH, with consequent 
loss of p73 and p16 expression is an early event in the pathogenesis of squamous cell 
carcinoma. A greater proportion of histologically normal epithelium and squamous 
metaplasia lesions harbour 3p LOH than 9p LOH. It has therefore been proposed that 3p 
LOH occurs earlier in the pathogenesis of pre-invasive lesions than 9p LOH, but both occur 
as early events.  
 
A similar pattern is seen in chromosome 8p114, where genetic loss was found in normal 
epithelium, low-grade and high-grade pre-invasive lesions and squamous cell carcinoma. 
The proportion of lesions at each histological grade showing LOH at 8p rose with increasing 
histological grade. The frequency of LOH at 8p in normal epithelium and low-grade dysplasia 
was lower than the frequency of 3p and 9p LOH which suggests that 8p LOH is a later event 
than 3p and 9p LOH. 
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Not all genetic changes are believed to occur early in the putative scheme of the 
development of squamous cell carcinoma. Damage to the p53 locus on chromosome 17p 
detected either by sequence analysis or loss of heterozygosity has been found at much 
greater frequency in squamous cell carcinomas than pre-invasive lesions found in the same 
patient at the same time104. Loss of heterozygosity at 17p13 and 5q21 are found in moderate 
and severe dysplasia but are rare findings in normal epithelium or mild dysplasia104 which 
suggests that p53 damage occurs relatively late in the development of squamous cell 
carcinoma. 
 
Theoretical timescale for the natural history of pre-invasive lesions 
The results of these studies have been used to construct a theoretical timescale of the 
molecular changes associated with pre-invasive lesion development106. In this scheme, 3p 
and 9p LOH are shown to occur in carcinogen-exposed histologically normal epithelium105. 
LOH at 8p occurs in normal epithelium and low-grade lesions, but later than LOH at 3p and 
9p. LOH at 5q21 and 17p13 and the accumulation of further 3p LOH are seen as later 
events38,93. The studies from which this scheme is derived are limited as the specimens were 
taken at a single time-point from patients with established carcinoma. There was no follow-
up of individual lesions and therefore the behaviour and outcome of the lesions under study 
is not known. The timescale is derived by inference from the data from these studies, and 
consequently is dependent on two assumptions.  
 
The first assumption is that all pre-invasive lesions are programmed to progress to 
squamous cell carcinoma and that the identifiable changes drive this progression, which has 
not yet been conclusively proved. It is assumed that lesions at different histological grades 
represent points along the continuum from normal epithelium through dysplasia, carcinoma-
in-situ to invasive squamous cell carcinoma. LOH identified within each lesion is considered 
to drive progression to the next histological grade. The second assumption is that all pre-
invasive lesions progress through the putative sequence of pre-invasive lesions to 
squamous cell carcinoma in a predictable and consistent manner. There have been no 
previous longitudinal studies of pre-invasive lesion histology and behaviour, and the validity 
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of these assumptions is not known. The studies described above, although providing 
valuable insights, cannot determine whether the accumulation of genetic changes drives the 
behaviour of an individual lesion or identify the changes or combination of changes that 
drives the progression to invasion of any given lesion. Longitudinal studies of pre-invasive 
lesions in which serial biopsies from lesions are taken are required to obtain specimens 
which allow detectable genetic changes to be related directly to lesion histology, behaviour 
and outcome. 
 
Only one study has attempted to identify the genetic changes associated with the natural 
history of pre-invasive lesions sampled by serial bronchoscopy and biopsy38. The results 
were compromised by the treatment of all high-grade lesions within the study using systemic 
retinoids or photodynamic therapy. None of the lesions studied progressed to malignancy. A 
small number of patients were studied, and data was missing for many of the lesions. The 
regression of pre-invasive lesions to a lower histological grade was associated with an 
inability to detect LOH at chromosomes 3p, 5q and 9p. This suggests that there may be a 
relationship between the pattern of genetic loss (LOH) within a lesion and the outcome of 
pre-invasive lesions. 
 
Summary 
The available data suggest that pre-invasive lesions of the bronchus, the precursors of 
squamous cell carcinoma, manifest genetic changes similar in pattern to that of squamous 
cell carcinoma. The accumulation of genetic loss, as a consequence of prolonged 
carcinogen exposure, may drive the progression of an individual pre-invasive lesion to 
malignancy, and the ultimate pattern of genetic changes may determine the outcome of that 
lesion. Analysis of individual lesions with close correlation of LOH analysis with clinical and 
outcome data may identify a pattern that drives the progression to malignancy or identify a 
pattern associated with the indolence or regression of lesions. The results may offer insights 
into the processes underlying the behaviour of pre-invasive lesions of the bronchus, and 
identify targets that would facilitate the identification of lesions at the highest risk of 
progression to malignancy. Targeted intervention can be offered to such lesions. 
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Hypothesis 
Autofluorescence bronchoscopy is more sensitive than conventional white light 
bronchoscopy for the detection of pre-invasive lesions and invasive carcinomas of the 
bronchus in patients at high risk for lung cancer. 
 
Objectives 
• Determine the sensitivity and specificity of combined autofluorescence and white 
light bronchoscopy for the detection of pre-invasive lesions of the bronchus. 
• Determine whether autofluorescence bronchoscopy in conjunction with white light 
bronchoscopy is more sensitive than white light bronchoscopy alone for the 
detection of pre-invasive lesions and carcinoma of the bronchus. 
 
Methods 
The study protocol was approved by the University College London / University College 
London Hospitals committees on the ethics of research on human subjects study no 
01/0147. Written informed consent to enter the study was obtained from each participant 
prior to study entry.  
 
Patient selection 
Patients were recruited into the study from 2 main sources: 
From University College London Hospitals. 
Patients at high risk for lung cancer with suspicious clinical or radiological findings were 
considered for the study. 
Risk factors for lung cancer were defined as any of: 
• a smoking history of greater than 20 pack years. 
• occupational exposure to carcinogen e.g. asbestos. 
• chronic airflow obstruction due to smoking. 
• previous lung cancer treated with curative intent. 
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Suspicious clinical findings were defined as clinical symptoms or signs suggestive of lung 
cancer. The symptoms included cough, haemoptysis, chest pain, increasing dyspnoea, 
weight loss, anorexia, hoarse voice, and wheeze. Clinical signs included lobar collapse, 
localised monophonic wheeze, pleural or pericardial effusion and paraneoplastic 
neurological syndromes. 
 
Suspicious radiological findings included mass lesion, lobar or whole lung collapse, pleural 
effusion and hilar or mediastinal lymphadenopathy in the context of a high risk for lung 
cancer. Patients with lesions considered outside the range of the bronchoscope were not 
considered for the study. 
 
From other referring hospitals  
Patients were referred specifically for assessment using autofluorescence bronchoscopy and 
were at high risk of lung cancer with suspicious clinical or radiological findings. The patients 
had undergone conventional white light bronchoscopy at the referring hospital.  
The patients were referred for the following indications: 
• Patients with clinical or radiological features suspicious for lung cancer but no 
abnormality at conventional bronchoscopy. 
• Patients with abnormal sputum or bronchial cytology but no abnormality at conventional 
bronchoscopy.  
• Patients referred for further assessment and management of pre-invasive bronchial 
lesions detected by conventional bronchoscopy. 
• Patients referred for assessment and treatment of localised endobronchial carcinoma 
considered not suitable for surgical resection. 
• Patients with pre-invasive lesions identified at the resection margins after resection with 
curative intent for lung cancer. 
 
Exclusion criteria 
• Advanced carcinoma of the lung with a poor short-term prognosis. 
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• Medically unfit to undergo bronchoscopy and biopsy. 
• Coagulation or other disorder precluding biopsy. 
• Recent pneumonia or excessive secretions that would compromise autofluorescence 
images. 
• Failure to give informed consent. 
 
Bronchoscopic investigation 
This was performed under topical anaesthesia using lignocaine 1-4% and intravenous 
sedation with midazolam or propofol in accordance with the British Thoracic Society 
Guidelines (2001)115. The D-light autofluorescence bronchoscope (Karl Storz GmbH & Co. 
KG, Tuttlingen, Germany) was used.  
 
Order of Procedures 
1. The visible bronchial tree was inspected using white light and the images interpreted 
by two experienced bronchoscopists. 
2. The visible bronchial tree was inspected using autofluorescence and the images 
interpreted by two experienced bronchoscopists and the findings noted. The 
bronchoscopic size and location of each abnormal lesion was estimated relative to 
local endobronchial landmarks such as carinae and carefully recorded. The extent, 
colour and surface appearance of each abnormal area of autofluorescence was 
recorded. 
3. The bronchoscopic findings were recorded on video for later review. 
4. Biopsy of bronchoscopically normal and abnormal areas. 
• Patients where no bronchoscopic abnormality was found: random biopsies were 
taken from all lobes of the lung and also from the main carina.  
• Patients where bronchoscopic abnormalities were found: biopsies were taken from 
all bronchoscopically normal lobes of the lung as controls and then from all areas 
identified as bronchoscopically abnormal under white light or autofluorescence. 
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Sampling and histopathology 
Disposable “cup” forceps were used (OlympusTM Endojaw 2.0mm), a fresh pair of forceps for 
each bronchoscopic location biopsied to prevent cross contamination of specimens. At least 
3 biopsies of 1mm diameter or greater were taken from each location to minimize bias due to 
sampling error. The biopsies were placed into 10% neutral buffered formalin, a fresh 
container for each biopsy. The biopsies were processed into paraffin wax blocks using a 
Leica TP1050 processing machine. This uses a 3 hour cycle involving formalin fixation, 
dehydration in 70%, 90% and 100% ethanol, clearing in xylene and then embedding of the 
biopsy in a wax block and was performed by the University College London Hospitals 
accredited diagnostic pathology service. The blocks were cut into 5µm sections using a 
microtome and stained with Gill’s haematoxylin and 1% eosin Y using an automated staining 
machine and the standard departmental protocol.  
 
A Histopathologist with an interest in pulmonary pathology reported the diagnostic slides 
using the WHO criteria 19998 in a blinded fashion, without any knowledge of the 
bronchoscopic findings. Pre-invasive lesions were subdivided into high-grade (CIS and SD) 
and low-grade lesions (mild and moderate dysplasia) to reflect the difficulty of making 
definitive histological diagnoses in biopsies that were often crushed during sampling or 
incomplete due to sloughing of surface layers. The slides were reviewed by a second 
reference pathologist with an interest in pulmonary pathology using the same criteria. In the 
case of disagreement over the diagnosis, a third reference pathologist from another centre 
reviewed the slides and a final definitive diagnosis was determined.  
 
Subsequent management of patients 
Patients with invasive carcinoma were treated according to national guidelines after 
discussion at the local multidisciplinary meeting. Those with pre-invasive lesions but without 
clinical, pathological or radiological evidence of invasive carcinoma were invited to enter a 
longitudinal study of the natural history of pre-invasive lesions. Patients entering this study 
underwent further combined white light and autofluorescence bronchoscopies at intervals. 
The results of these bronchoscopies are included in the present study results, although 
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control biopsies were not always taken.  
 
Analysis and statistics 
An initial assessment of the learning curve of the autofluorescence bronchoscope was made 
to ensure that the results were not confounded by the period spent learning to interpret the 
images. Consequently the results from the first half of the study were compared with the 
second half of the study. Comparison of the bronchoscopic and histological findings was 
made to assess the efficacy of autofluorescence bronchoscopy. Histological analysis of the 
entire bronchial tree is the only method by which all the pre-invasive lesions and invasive 
carcinomas present within the airways can be identified. This cannot be performed in a living 
individual, and so it is not possible to measure the true sensitivity of lesion detection for 
either white light or autofluorescence bronchoscopy75. 
 
The ability of white light and autofluorescence bronchoscopy to detect abnormal lesions was 
assessed by comparing the histology of biopsies obtained from sites that appeared 
abnormal with those from sites that appeared normal using the chi-squared test. The number 
of lesions identified bronchoscopically was expressed as a percentage of the total number of 
lesions found by biopsy of both bronchoscopically normal and abnormal areas. The change 
in lesion detection was used to calculate the relative sensitivity of autofluorescence and 
white light bronchoscopy. A two-sample test of proportions was used to separately assess 
the difference in autofluorescence detection of invasive carcinoma, high-grade and low-
grade lesions from sites identified as having abnormal autofluorescence compared to control 
sites. The positive predictive values for both white light and autofluorescence were 
calculated. These comparisons assume that all lesions occur independently of each other 
and so individual lesions were required to be separated by normal mucosa. The level of 
significance was set at 5% and the confidence intervals were calculated using Greenwood’s 
method.  
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Results 
84 patients entered the study with a mean age of 63.9 years (range 35-86 years) of whom 
66 were male, 18 female, and their characteristics are shown in table 2.1. All patients gave 
significant smoking histories and 3 had additionally been exposed to asbestos. Thirty-two 
patients had been diagnosed with Chronic Obstructive Pulmonary Disease. Twenty patients 
had previously undergone curative treatment for lung cancer.  
 
Areas biopsied with no bronchoscopic abnormality 
207 locations with normal white light and autofluorescence bronchoscopic appearances 
were biopsied. The results are shown in table 2.2A. Histology of 87% of the locations (180 
sites) sampled showed normal bronchial epithelium or squamous metaplasia. Low-grade 
pre-invasive lesions were found in 10.6% (22 sites), and 2.4% (5 sites) contained high-grade 
pre-invasive lesions. Squamous cell carcinoma was not found in any of these locations. The 
negative predictive value for autofluorescence was therefore 87%. 
 
Areas biopsied for bronchoscopic abnormality 
205 areas identified as bronchoscopically abnormal either under white light, 
autofluorescence or both bronchoscopic modes have been biopsied. The results are shown 
in table 2.2B and figure 2.1. Within these sites, 30 squamous cell carcinomas, 79 high-grade 
lesions and 18 low-grade lesions were found. Pre-invasive lesions or invasive carcinomas 
were detected within 78/109 sites with white light and 127/205 sites with autofluorescence, 
giving positive predictive values of 72% and 62% respectively. Overall autofluorescence 
detected 59% (95% CI: 44-73%) more lesions (pre-invasive lesions and carcinomas) than 
white light, giving a relative sensitivity of 1.59. 
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Table 2.1: The clinical characteristics of study patients  
Patient characteristics  
Median age (years) 63.9  
Age range (years) 35-86  
Standard deviation 9.74  
  
Males (number) 66 
Females (number) 18 
  
Co-morbidity  
Documented COPD 32 
Asbestos exposure 3 
Previous carcinoma 20 
Head and neck carcinoma 0 
  
Cigarette consumption  
Current smokers (number of patients) 39 
Former smokers (number of patients) 45 
Mean no. cigarettes smoked 24.2 per day 
Standard deviation 13.5 per day 
  
Median no of years smoked 44 years 
Mean no of years since stopped 10.5 years 
  
Referral source No. of patients 
Middlesex Hospital 35  
Other UK Hospitals 49  
  
Indication for bronchoscopy No. of patients 
Pre-invasive lesion diagnosed at previous conventional bronchoscopy 26 
Abnormal cytology found at previous bronchoscopy 17 
Mass identified radiologically 15 
Haemoptysis without radiological abnormality 11 
Known carcinoma: assessment for treatment 7 
Paraneoplastic neurological syndrome 5 
Other (cough, previous carcinoma, hoarse voice) 3 
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Table 2.2: The bronchoscopic and histological findings.  
 
Table 2.2A: Locations sampled with no bronchoscopic abnormality 
 WLB negative AFL negative % 
NAD 180 87 
LGL 22 10.6 
HGL 5 2.4 
SQC 0 0 
Total 207 100 
 
Table 2.2B: Locations sampled for bronchoscopic abnormality 
 WLB positive (All AFL positive) 
WLB negative 
(All AFL positive) Total AFL positive 
NAD 31 47 78 
LGL 11 7 18 
HGL 45 34 79 
SQC 22 8 30 
Total 109 96 205 
 
The number of patients are shown. AFL autofluorescence, WLB white light. NAD No 
abnormality or inflammation only. LGL Low-grade lesion, HGL High-grade lesion, SQC 
squamous cell carcinoma.  
 
 
Figure 2.1: Histological diagnosis of areas biopsied with bronchoscopic abnormality. 
The number of lesions with abnormal bronchoscopic appearances and their histological 
diagnosis are shown.  
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Squamous cell carcinoma 
Squamous cell carcinoma of the bronchus was diagnosed in 30 patients. Conventional white 
light bronchoscopy identified 22 squamous cell carcinomas, while fluorescence 
bronchoscopy additionally identified a further 8 carcinomas that were not apparent under 
white light bronchoscopy (table 2.3). The detection of invasive carcinoma by 
autofluorescence relative to white light bronchoscopy was enhanced by 36% (99% CI: 13% 
to 65%), relative sensitivity 1.36.  
 
In 4 patients, surgery was performed with no evidence of recurrence or metastasis at 1-4 
years of follow-up. Review of the autofluorescence bronchoscopy video was necessary in 2 
patients immediately prior to surgery to determine the resection margin as the carcinoma 
could not be identified using rigid bronchoscopy. One patient was treated with radical 
external beam radiotherapy and remains well at 6 months. One patient has recently been 
treated with photodynamic therapy and remains under follow-up. In two patients who were 
investigated for a radiological mass, autofluorescence identified a carcinoma not visible 
under white light in a remote part of the bronchial tree. The patients have both undergone 
palliative therapy only. 
 
Table 2.3: Patients with autofluorescence detected but white light invisible carcinoma  
 Indication for bronchoscopy Location Histology Stage Treatment Outcome 
1 Pre-invasive lesion LLL apical SQC 1a Surgery Well 1 year 
2 Radiological lesion LLL SQC 1a Radical radiotherapy 
Well 
6 months 
3 Abnormal cytology RML SQC 1a Surgery Well 2 years 
4 Abnormal cytology RLL SQC 1a Surgery Well 4 years 
5 Abnormal cytology RLL apical SQC 1a Surgery Well  4 years 
6 Previous carcinoma RUL SQC 1a PDT Awaited 
7 Radiological lesion LLL SQC 4 Palliative Palliative 
8 Radiological lesion L main SQC 4 Palliative Palliative 
Part 2: Studies of autofluorescence bronchoscopy 
Page 39 of 178 
Pre-invasive lesions 
High-grade lesions 
Of 205 locations biopsied, 79 have shown HGLs all of which were positive to 
autofluorescence, but only 45 were visible using white light. There were 5 HGLs identified in 
biopsies from bronchoscopically normal mucosa. Autofluorescence enhanced the detection 
by of high-grade pre-invasive lesions by 76% (99% CI: 56% to 90%), relative sensitivity 1.76 
. 
Low-grade lesions 
LGLs were identified in 18 sites under autofluorescence, while 11 appeared abnormal under 
white light. Autofluorescence enhanced the detection of low-grade lesions by 64% (99% CI: 
23% to 93%), relative sensitivity 1.64, in lesions visible bronchoscopically. There were 22 
LGLs identified in biopsies from bronchoscopically normal mucosa. This shows that 55% of 
the detected LGLs were not visible bronchoscopically to either white light or 
autofluorescence. When the detection of LGLs by autofluorescence or random mucosal 
biopsy are compared, there was a decrease in the number of lesions identified by 
autofluorescence by 1.9% (99%CI: -9.4% to 5.7%), relative sensitivity 0.98.  
 
Effect of the learning curve 
In order to assess whether the results could be affected by a potential learning curve of the 
instrument, the results of bronchoscopies performed during the period 1999-2000 were 
compared to the period 2001-2003 (figure 2.2). 42 patients were bronchoscoped in the 
period 1999-2000 and 42 patients were bronchoscoped in the period 2001-2003. There was 
no statistical difference in the sensitivity of detection of squamous cell carcinoma, high-grade 
lesions or low-grade lesions between the two time periods (p=0.38 using Chi-squared test 
with continuity correction).  
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Figure 2.2: Comparison of lesion detection rates 1999-2000 vs. 2001-2003 
The detection rates of lesions using combined modality autofluorescence and conventional 
white light bronchoscopy are compared. WLB white light bronchoscopy, AFL 
autofluorescence, LGL low-grade lesion, HGL high-grade lesion, SQC squamous cell 
carcinoma. The time period 1999-2000 is shown in grey, and 2001-2003 in black.  
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Discussion 
84 patients with risk factors and clinical features suspicious for lung cancer underwent 
bronchoscopy with conventional white light followed by autofluorescence. In the study 
patients, 84 HGLs and 40 LGLs were found. Autofluorescence improved the sensitivity of 
detection of high-grade lesions by 76% (relative sensitivity 1.76). The sensitivity of detection 
of bronchoscopically visible LGLs was improved by 64% (relative sensitivity 1.64) but there 
was little overall impact on the detection of LGLs as 55% of the LGLs identified were found 
in random biopsies of bronchoscopically normal mucosa. The addition of autofluorescence to 
white light bronchoscopy enabled the detection of 8 squamous cell carcinomas that were not 
identifiable under white light alone.  
 
1. Validity of the results 
a. The learning curve 
The present study shows that there was no significant learning curve with the 
autofluorescence bronchoscope used and excludes the possibility of bias due to this effect. 
This is primarily due to the quality of the images produced and the clear differentiation 
between normal and abnormal provided by the autofluorescence equipment. The 
bronchoscopies were performed by a physician with a special interest in early bronchial 
mucosal lesions in a research setting with sufficient time for careful inspection of the 
bronchial mucosa. The images were interpreted by 2 experienced bronchoscopists. Although 
this provides the best possible analysis and interpretation of the findings, this may have 
introduced bias through over diagnosis of minor abnormalities, or the identification of subtle 
abnormalities that would not be visible in usual clinical practice with such a device. The high 
observed false positive rate lends support to this idea. 
 
b. False positive results 
In the present study combined white light and autofluorescence bronchoscopy produces a 
false positive rate of 38%. This is comparable with previous studies using autofluorescence, 
although most were performed using the LIFE device, which suggests that there was no 
significant over-diagnosis bias46,55,64,86. The high false positive rate observed in the present, 
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and in previous studies, may be due to a number of different confounding factors. Excessive 
mucus or secretions within the bronchial tree, or mucosal damage due to trauma from the 
bronchoscope may produce false positive autofluorescence appearances. The presence of 
blood, from trauma to the bronchus from the bronchoscope, endobronchial bleeding or 
epistaxis from per-nasal bronchoscopy may contribute to the false positive rate. Squamous 
metaplasia and mucosal inflammation, common in both smokers and patients with chronic 
obstructive pulmonary disease, may result in sufficient mucosal disease to generate 
abnormal autofluorescence. Although traumatic mucosal damage and mucus can usually be 
identified under white light bronchoscopy, inflammation and squamous metaplasia can be 
difficult to identify, closely resembling abnormal mucosa. Consequently using current 
technology a significant false positive rate is considered inevitable when using 
autofluorescence detection systems.  
 
Molecular changes similar to HGLs have been found in 21/26 patients exhibiting abnormal 
autofluorescence patterns but no evidence of histopathological HGL, but none of 21 patients 
with normal bronchoscopic and histopathological appearances71. The areas of abnormal 
autofluorescence were histopathologically metaplasia, inflammation and LGL, and showed 
fewer chromosomal changes than HGLs, but more changes than normal epithelium. It is 
uncertain whether abnormal autofluorescence represents an area of mucosa at higher risk of 
lesion or malignant disease development, or is a marker of damaged or inflamed epithelium. 
There are no follow-up studies of autofluorescence positive, histopathologically normal 
epithelium. Molecular studies would compare the allelotypes and expression patterns of 
bronchoscopically normal and abnormal mucosa with normal histology. Bronchoscopic 
follow-up of these false positive areas would allow the determination of their malignant 
potential. 
 
The results of the present study suggest that all bronchoscopic areas appearing abnormal 
under autofluorescence require histological confirmation. Some histologically normal 
bronchial mucosa has abnormal autofluorescence, and some histologically abnormal 
mucosa has normal autofluorescence. The relationship between autofluorescence 
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appearances, histopathology and outcome of an individual area of bronchial mucosa is not 
known. Studies are required to further define the meaning of an autofluorescence 
abnormality.  
 
It is not clear whether histology is the best standard against which autofluorescence should 
be evaluated, and further studies are required. The act of biopsy disrupts the mucosa and 
alters the biology of the epithelium. This is reflected in the persistent of autofluorescence 
abnormality for up to a year in any area of traumatised or biopsied bronchial mucosa. 
Sampling methods that avoid disruption of the mucosa, including optical or light-based 
sampling techniques, would mitigate this problem, but are as yet not ready for research or 
clinical practice. 
 
c. Order of the procedures 
White light bronchoscopy was performed immediately before autofluorescence in all the 
study patients and so the bronchoscopists were aware of the white light findings during the 
autofluorescence bronchoscopy. There is a potential source of bias from this approach. 
Previous studies of autofluorescence have shown that there is no difference in the detection 
rates of pre-invasive lesions due to the order of the procedures, although these studies were 
performed using the LIFE bronchoscope63. The method used avoids the potential over 
diagnosis bias as white light bronchoscopy was expected to be less sensitive and was 
performed before the more sensitive autofluorescence. This prevented the autofluorescence 
images affecting the interpretation of the white light appearances. Ideally a separate pair of 
bronchoscopists would have interpreted the white light and then the autofluorescence 
appearances, but limitations on the personnel available within the study precluded this 
approach.  
 
2. The detection of pre-invasive lesions 
a. Squamous cell carcinoma 
Autofluorescence facilitated the detection of 8 squamous cell carcinomas that were not 
identified using conventional white light bronchoscopy. This allowed a curative resection to 
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be performed for the micro-invasive carcinoma in 4 of the patients. One patient was 
successfully treated with radical radiotherapy and another with Photodynamic Therapy with 
curative intent. In the studies presented here, autofluorescence will be used as the major 
detection modality for HGLs, with the development of micro-invasive carcinoma as an 
important study endpoint. The results suggest that autofluorescence is effective as a 
diagnostic tool for the detection of micro-invasive carcinoma, significantly improving the 
detection rate over conventional white light bronchoscopy by 36%.  
 
b. High-grade lesions 
The detection of HGLs was improved using combined modality white light and 
autofluorescence bronchoscopy over conventional white light bronchoscopy by 76% (relative 
sensitivity 1.76). This suggests that autofluorescence is of value in the detection of HGLs. 
The improvement in lesion detection is lower than in previous studies that used the LIFE 
device, but comparable to the smaller initial studies using the Storz device (table 1.4). The 
improvement in sensitivity may have been compromised by the study protocol, in which 
careful inspection of the bronchial mucosa may have enhanced white light detection rates. 
This is supported by the finding that 58% of the HGLs detected were also visible using the 
conventional white light mode and is higher than the 13-29% detection rate in older 
studies116.  
 
The false negative rate of 2.4% using random biopsies as the control suggests that some 
lesions were missed during combined modality white light and autofluorescence 
bronchoscopy. The exact size of this error cannot be measured, as the true prevalence of 
both carcinoma and HGLs cannot be determined without detailed histological analysis of the 
entire bronchial tree. This can only be achieved by lung resection immediately after 
bronchoscopy or at post-mortem examination. In a study using the LIFE device in which 
autofluorescence was performed immediately prior to lung resection for carcinoma, 
autofluorescence detected only 50% of high-grade lesions and squamous cell carcinomas in 
the bronchial tree72. In the present study, the comparison with control biopsies provides an 
estimate of the positive and negative predictive value of autofluorescence. Together, the 
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findings suggest that the combination of white light and autofluorescence using the study 
protocol is an effective and sensitive method for the detection of high-grade pre-invasive 
lesions of the bronchus, and can be applied to surveillance studies of bronchial pre-invasive 
lesions. 
 
The prevalence of pre-invasive lesions found in random biopsies from bronchoscopically 
normal areas of the bronchial tree, at 10.6% for LGL and 2.4% for HGL, shows that the 
overall prevalence for pre-invasive lesions is higher than was detected using 
autofluorescence in this selected group of patients. This finding is in keeping with the “field 
cancerization” hypothesis89, and suggests that there may be two distinct populations of pre-
invasive lesions, autofluorescence positive and autofluorescence negative. As the 
autofluorescence negative lesions are impossible to detect other than fortuitously using 
biopsy, they are impossible to study at this time. However, they may influence the outcome 
of the patients under study and so techniques to allow their detection are needed. This 
finding may explain the incidence of carcinoma development in locations remote from the 
lesions under observation in the previous studies of pre-invasive lesion outcome (see part 1: 
Pre-invasive lesions of the bronchus, and table 1.2).  
 
c. Low-grade lesions 
In 84 patients at high-risk for lung cancer with suspicious clinical features, from whom 205 
bronchoscopically abnormal locations were sampled, only 18 LGLs were found. This 
represents a significantly lower prevalence than would be expected based on previous 
studies. The sensitivity of LGL detection appeared to be improved using combined modality 
white light and autofluorescence compared to conventional bronchoscopy, but 22 LGLs were 
found in 207 sites with no bronchoscopic abnormality under white light or autofluorescence. 
Combined modality white light and autofluorescence bronchoscopy identified 18/40 LGLs 
and random biopsies 22/40 LGLs. This suggests that the targeting of autofluorescence 
abnormalities does not improve the detection of low grade lesions when compared to 
random biopsies. The one previous study of autofluorescence in patients with LGLs only is in 
agreement, as lesion detection was unaffected by the addition of autofluorescence using the 
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LIFE device to conventional white light bronchoscopy65. These data suggest that 
autofluorescence is a successful tool for the identification of HGLs and squamous cell 
carcinoma of the bronchus, but less effective for the detection of LGLs.  
 
The differentiation of HGLs, LGLs, false positive findings and invasive carcinomas is not 
currently possible using current autofluorescence technology. This means that all abnormal 
bronchoscopic appearances require histological confirmation. The significance and outcome 
of pre-invasive lesions, both those visible bronchoscopically and those not detected by 
autofluorescence is not established, and require a longitudinal study of bronchoscopic and 
histological changes throughout the bronchial tree. Ideally, the bronchoscopic findings would 
be correlated with detailed analysis of the histology of the visible bronchial mucosa, but such 
a study is currently not technically feasible in vivo.  
 
In summary, combined modality white light and autofluorescence bronchoscopy significantly 
improves the sensitivity of HGL and invasive carcinoma detection, but has at best a limited 
impact on LGL detection. This technology is currently the most sensitive method of HGL and 
invasive carcinoma detection, and is suitable for use in longitudinal studies of pre-invasive 
bronchial lesions.  
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Hypothesis 
Squamous cell carcinoma of the bronchus develops from carcinogen-exposed bronchial 
epithelium through a series of pre-invasive lesions of increasing histological and cytological 
abnormality. 
 
Objective 
The objective of this study was to 
• Confirm that squamous cell carcinoma of the bronchus develops from carcinogen-
exposed bronchial epithelium through a series of pre-invasive lesions of increasing 
histological and cytological abnormality. 
• Determine the time-course of pre-invasive lesion development 
• Determine whether pre-invasive lesions are committed to the development of 
malignancy 
 
Methods 
The study protocol was approved by the University College London / University College 
London Hospitals committees on the ethics of research on human subjects study no 
01/0148. Written informed consent to enter the study was obtained from each participant 
prior to study entry and confirmed at each bronchoscopy. 
 
Patient selection 
Patients were identified from “The detection of bronchial lesions using autofluorescence 
bronchoscopy” study discussed in part 2 who had pre-invasive lesions of the bronchus but 
no clinical or radiological evidence of invasive carcinoma. At the follow-up out-patient 
appointment after autofluorescence bronchoscopy the study was offered to all eligible 
patients. No patient declined participation, although some patients withdrew from the study 
during the follow-up period (see results). 
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Exclusion criteria 
• A diagnosis of invasive carcinoma of the lung at presentation. However, patients who 
have previously undergone curative treatment for invasive carcinoma of the lung and 
who have no clinical or radiological evidence of disease persistence or recurrence were 
eligible for the study.  
• General medical conditions precluding bronchoscopy or affecting short-term prognosis. 
• Specific respiratory disease affecting ability to tolerate bronchoscopy. 
• Recent pneumonia or excessive secretions that would compromise autofluorescence 
images. 
• Abnormalities of coagulation precluding safe bronchial biopsy. 
• Refusal or inability to give informed consent. 
 
Investigation 
The overall protocol of the study is shown in figure 3.1. The significance and implications of 
pre-invasive lesions and the options for management were discussed with each patient in an 
outpatient setting.  
 
Clinical assessment 
i. History and Examination 
At first presentation to the study a full clinical history was taken and a clinical examination 
performed. A past medical history of malignant disease (including specifically lung cancer 
and head and neck carcinoma), smoking related disease, chronic airflow disease including 
asthma and disorders that would affect the suitability for bronchoscopy were obtained. 
Symptoms and signs compatible with lung cancer, paraneoplastic syndromes or  chronic 
airflow obstruction were specifically noted. A detailed smoking history was taken, including 
the number of cigarettes smoked per day, the age at which smoking started and the date of 
smoking cessation if applicable. An occupational history focusing on occupational exposure 
to carcinogen was obtained. 
 
Part 3: The natural history of pre-invasive lesions 
Page 50 of 178 
ii. Investigations 
Blood tests Full blood count, urea, creatinine and electrolytes and coagulation studies were 
performed to ensure the patient was safe to undergo bronchoscopy  
Spirometry was obtained to assess for chronic airflow obstruction as a risk factor for lung 
cancer and to assess suitability and safety of bronchoscopy. 
CT scan of the thorax. To exclude a mass lesion or other evidence of carcinoma including 
metastases or lymphadenopathy. 
Positron Emission Tomogram To identify pulmonary masses, hilar and mediastinal 
lymphadenopathy, and metastases not identified by CT scan of the thorax. 
 
Bronchoscopic procedures 
An initial study bronchoscopy was performed to confirm the presence of pre-invasive lesions 
of the bronchus and exclude carcinoma of the bronchus with the greatest possible 
confidence. This occurred within 4 months of “The detection of bronchial lesions using 
autofluorescence bronchoscopy” study bronchoscopy discussed in part 2 and was 
performed under a general anaesthetic. A rigid bronchoscope was inserted through which 
the fibreoptic bronchoscope was passed. This approach was adopted to facilitate thorough 
inspection of the entire visible tracheobronchial tree and provide conditions under which the 
most accurate and best quality biopsies could be obtained. Those patients with pre-invasive 
lesions but without evidence of carcinoma underwent continued follow-up of the lesions. 
 
Follow-up bronchoscopies were performed under sedation with topical anaesthesia to the 
bronchial tree in accordance with the British Thoracic Society Guidelines (2001)115. In some 
patients, a general anaesthetic was used due to previous difficulties with sedation or due to 
patient preference. The frequency of follow-up bronchoscopies was determined by the 
histological grade of the most abnormal lesion found at the previous bronchoscopy: 
Low-grade pre-invasive lesion (Mild-moderate dysplasia)  6-12 monthly 
High-grade lesion (carcinoma-in-situ or severe dysplasia) 4 monthly 
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Figure 3.1: The programme of the study of pre-invasive lesions of the bronchus 
 
 
At each follow-up bronchoscopy, the results of previous biopsies were reviewed, and the 
locations to be biopsied determined. All pre-determined areas of the bronchial tree were re-
biopsied, as well as any areas of new white light or autofluorescence abnormality. The 
procedure was performed using the same protocol as the initial bronchoscopy, except that 
control biopsies were not taken. The histopathology results returned from the laboratory 2 
weeks later. At that time the results were discussed within the research team, and the date 
of the next bronchoscopy booked. 
 
During follow-up of pre-invasive lesions, to ensure that distant or co-incident carcinomas had 
not developed, a CT scan of the thorax was performed annually, and a PET scan was 
obtained every 18 months. In circumstances where the development of carcinoma was 
suspected, for instance a change or worsening of symptoms, worsening chest radiological 
appearances such as a new mass or lobar collapse, new abnormalities on study PET or CT 
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scan or increasing suspicion of invasion in the biopsies from high-grade lesions, the patient 
underwent further detailed CT scans of the thorax, a PET scan and a full clinical assessment 
for carcinoma and staging.  
 
Bronchoscopy protocol 
White light bronchoscopy 
All visible areas of the bronchial tree were inspected. The location, size and appearance of 
areas abnormal bronchoscopically were noted and recorded on video for later review.  
 
Autofluorescence bronchoscopy 
Performed after white light bronchoscopy. The location, size and appearance of areas 
abnormal bronchoscopically under autofluorescence were noted and recorded on video for 
later review.  
 
The bronchoscopic appearances were reviewed by 2 bronchoscopists experienced in both 
conventional and autofluorescence bronchoscopy and a consensus was reached regarding 
the findings. An example of the bronchoscopic appearances is shown in figure 3.2. The 
abnormalities were carefully mapped onto a bronchial tree diagram (figure 3.3) for later 
reference during surveillance bronchoscopies. Sites identified as bronchoscopically 
abnormal either under white light or autofluorescence were selected for sampling.  
 
Follow-up of patients began in 1999 and the bronchoscopic appearances were recorded in 
clinical records by Dr Jeremy George. This author established the study protocols, the 
Ethical Committee approvals and Research and Development approvals in 2001. Formal 
systematic data collection was commenced at this time. The data collection was performed 
by this author from 2001-2004. After the end of this author’s fellowship in 2004 data was 
collected by Dr Jeremy George and Sister Bernadette Carroll using protocols and recording 
mechanisms established by this author in 2001. Analysis of all the data was performed by 
this author.  
Part 3: The natural history of pre-invasive lesions 
Page 53 of 178 
Figure 3.2: Example bronchoscopic appearances from a patient with carcinoma-in-situ 
of the bronchus. The white light (A) and autofluorescence appearances (B) are shown. 
 
 
 
 
 
 
 
 
 
Figure 3.3: A example of a study bronchoscopy report  
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 Sample acquisition 
i. Bronchoscopy samples 
• Control biopsies were obtained systematically from sites appearing normal under 
both white light and autofluorescence at the initial bronchoscopy only. Each lobe of 
the lungs that did not show an abnormality was sampled. 
• Biopsies of bronchoscopically abnormal areas. Distal locations with bronchoscopic 
abnormalities were biopsied prior to more proximal areas to reduce cross-
contamination of biopsy material. 
• Bronchial wash cytology of bronchoscopically the most abnormal area. The site was 
washed with 30ml of 0.9% saline solution and the aspirate divided in half. Half of the 
sample was stored in a plain Universal container. The other half was transferred to a 
bottle containing PreservCyt™ (Cytyc Corp™, Boxborough, USA). 
• Bronchial brush cytology of bronchoscopically the most abnormal area. The site was 
brushed with a standard protected cytology brush under direct vision through the 
bronchoscope. Smears were prepared onto 4 slides, three of which were plain glass 
and the other a ChemMate™ Capillary gap immunohistochemistry slide (Dako™, Ely, 
UK). Two plain glass slides were sprayed with Cytofixx™ cytological fixative (Cellpath 
PLC™, Hemel Hempstead, UK) and allowed to air dry. The other two slides (one 
plain glass slide and the ChemMate slide) were allowed to air dry briefly and then 
rapidly frozen to -80°C.  
• Biopsy of the most abnormal area bronchoscopically. This was judged subjectively 
on a combination of the extent of the bronchoscopic abnormality and the severity of 
the mucosal abnormality assessed by the visual appearances including mucosal 
nodularity, irregularity, dark autofluorescence images, contact bleeding.  
 
A minimum of 3 biopsies per location of at least 1mm diameter each judged visually were 
obtained to minimize bias from sampling error. The first 2 biopsies were placed into 10% 
neutral buffered formalin, a fresh container for each biopsy. The third was immediately 
placed into Tissue-Tek OCT gel (Raymond Lamb Ltd™, Eastbourne, UK) and frozen on 
dry ice to -80°C. For each bronchoscopic location biopsied, the sequence of 2 biopsies to 
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formalin and 1 to frozen was repeated until sufficient material for analysis (judged 
subjectively) had been collected or the lesion was completely obscured by blood and 
debris from biopsy. Disposable “cup” forceps were used (OlympusTM Endojaw 2.0mm), a 
fresh pair of forceps for each location for biopsy to prevent cross contamination of 
specimens. Cup forceps minimise trauma to the biopsy, and maintain the integrity of the 
epithelium better than toothed forceps. 
 
ii. Sputum  
This was collected by the patient into a plain Universal container over the 24 hours prior to 
attendance for bronchoscopy. This was sent to the Cytology department, University College 
London Hospitals, processed onto slides and stained with the Papanicolau technique. The 
cytology was reviewed by a Consultant Cytopathologist. The remainder of the sample was 
stored frozen for future studies.  
 
iii. Blood 
12ml of fresh whole blood was collected into tubes coated with EDTA (Becton-Dickinson 
Vacutainer™, USA) as an anticoagulant and stored at -80°C to be used later as a source of 
reference DNA for molecular studies. A further 8ml of blood was collected into Serum 
Separation Tubes (Becton-Dickinson Vacutainer™, USA), spun down and the serum 
supernatant removed and stored at -80°C for use in later studies.  
 
Sample Processing 
Each biopsy was placed on an acetate strip for identification and immediately fixed in 10% 
neutral buffered formalin for 4 hours. The biopsies were then processed into paraffin wax 
blocks using a Leica TP1050 processing machine. This uses a 3 hour cycle involving 
formalin fixation, dehydration in 70%, 90% and 100% ethanol, clearing in xylene and then 
embedding of the biopsy in a wax block and was performed by the University College 
London Hospitals accredited diagnostic pathology service. The blocks were cut into 5µm 
sections using a microtome and stained with Gill’s Haematoxylin and 1% Eosin Y using an 
automated staining machine and the standard departmental protocol. A Histopathologist with 
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an interest in pulmonary pathology reported the diagnostic slides using the WHO criteria 
1999 (figure 3.4), and the slides were reviewed by a second reference pathologist with an 
interest in pulmonary pathology using the same criteria. In the case of disagreement over the 
diagnosis, a third reference pathologist from another centre reviewed the slides and a final 
definitive diagnosis was determined. 
 
The biopsies frozen in OCT were stored in plastic boxes in a -80°C freezer. Care was taken 
to ensure that the biopsies did not thaw at any point during specimen transport from the 
bronchoscopy suite to the freezer. The bronchial brushing slides that had been frozen during 
the bronchoscopy were stored along with the biopsies in the freezer. The bronchial washings 
that had been collected into PreservCyt™ were processed onto plain glass slides using a 
Thinprep™ cytology preparation machine using the standard manufacturer’s protocols. 
 
Management of the outcomes of pre-invasive lesions 
Invasive carcinoma: On detection of invasive carcinoma the patient was offered treatment 
with curative intent. For those patients treated with curative intent, any remaining pre-
invasive lesions continued under follow-up. In those patients in whom cure was not 
achieved, further appropriate management was offered outside the study. 
 
Regression to normal epithelium: was defined as the finding of normal histology from an 
area of a previous pre-invasive lesion during 2 successive bronchoscopies. Despite 
regression, lesions were maintained under surveillance in the present study. 
 
Recording of study data 
Central to this project, and to the co-ordination between the clinical findings and the results 
from the scientific projects is the recording of the bronchoscopic appearances, the location of 
lesions in the bronchial tree, the number of biopsies obtained from each lesion and the 
histopathological results. This was achieved in 3 ways. 
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Figure 3.4: The WHO Criteria for the diagnosis of pre-invasive lesions of the bronchus 
19998 
 
 
 
 
 
i. A paper record was created for each patient. The case history was recorded along with 
the patients demographic data. Bronchoscopy and fluorescence study reports, 
histopathology, radiology and PET scan reports and all clinical correspondence was filed. 
This record was used to co-ordinate the clinical data and histological data. Figure 3.5 
shows the correlation chart of the histology and bronchoscopic findings from a sample 
patient record which was used to determine the bronchoscopic locations under 
surveillance at each bronchoscopy 
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ii. A computer database  was written using Filemaker pro 5.5™ for Macintosh™ and 
Windows™. This mirrored the paper record and contained each patients demographic 
data, and the bronchoscopic results listed by bronchoscopy. The site from which each 
individual biopsy was taken, the histology result and the physical location in which the 
biopsy was stored was recorded for use in the scientific projects. The form of the biopsy 
(fresh frozen or formalin fixed to block) was listed, and the history of the biopsy (e.g. 
defrosted from frozen to block) was recorded. 
 
 
iii. From the records a timeline was generated for each patient showing each lesion, its 
bronchoscopic location of origin and the histology of that lesion over time. This was used 
to generate the cumulative results and charts.  
 
Project Management 
In addition to the above, each patient’s past history was obtained form the referring hospitals 
where available. Samples from biopsies taken at these hospitals were obtained and 
processed so that they were available for the scientific studies. Figure 3.6 shows the process 
of the management for the surveillance study. 
 
Figure 3.5: A correlation chart of biopsies and bronchoscopic findings 
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Figure 3.6: The management structure of the project 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analysis 
The behaviour of each pre-invasive lesion under follow-up was observed over a period of 
time. Statistical methods of analysis could not be applied to this study design and this was 
discussed with the Department of Medical Statistics, University College London Hospitals. 
For the purposes of evaluation the WHO classification (figure 3.4) was subdivided into high-
grade lesions (carcinoma-in-situ and severe dysplasia) and low-grade lesions (mild and 
moderate dysplasia). This was due to the difficulties in differentiating carcinoma-in-situ from 
severe dysplasia and moderate dysplasia from mild dysplasia in bronchial biopsies using the 
WHO criteria8. The bronchial biopsies were often traumatised during the biopsy procedure 
and processing, such that epithelial lesions were often difficult to orientate, and therefore 
sub-classify.  
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Results 
There were 26 patients (23 male) median age 66.5 years (range 49-75 years) studied for a 
median of 31 months (range 14 to 110 months). The histological diagnoses of the 60 pre-
invasive lesions studied are shown in figure 3.7. The lesions occurred in the same lung in 10 
of 16 patients with HGLs and both lungs in the remainder. The lesions were distributed in all 
lobes of the lungs, with no specific predilection for any lobe or bronchoscopic location 
including carinae or bronchial walls. 
 
Observations from the follow-up of pre-invasive lesions 
Pre-invasive lesions evolve into squamous cell carcinoma 
There was progression to invasive squamous cell carcinoma in eight lesions in seven 
patients (lesion L1, L2, L3, L11, L20, L24, L28, L44). The progression occurred between 4 
and 34 months after the first detection of a lesion. In all except lesion L24 the first detected 
abnormality was HGL, and no lesions progressed directly to carcinoma from LGL. Lesion 
L24 was first noted at LGL, followed by normal epithelium, with subsequently HGL until the 
development of squamous cell carcinoma. None of the lesions progressing to invasive 
squamous cell carcinoma showed any evidence of histological regression during their time-
course.  
 
Pre-invasive lesions progress to high-grade histology 
Progression from a LGL to a HGL was observed in one lesion (L14) over 8 months. This 
lesion later regressed to normal epithelium.  
 
Pre-invasive lesions show apparent regression to normal epithelium 
Histological regression to normal epithelium was observed in 17 lesions. The highest grade 
of abnormality attained was HGL in eight of the lesions (L6, L14, L16 possibly treatment 
related, L22, L23, L31, L33, L37) and LGL in nine lesions (L15, L34, L35, L39, L40, L48, 
L58, L59, L60). The 12 LGL with no evidence of HGL development remained at LGL for less 
than 18 months and 9 out of 12 regressed to normal epithelium. One lesion remained at low-
grade for 38 months and then regressed to normal.  
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In 4 lesions, LGL was detected between 12 and 50 months after the regression of a previous 
pre-invasive lesion (L22, L33, L52, L56).  HGL was found in 3 lesions (L54, L55, L57) 28 
months after the regression of LGLs. The remaining ten lesions that regressed showed no 
evidence of a pre-invasive lesion. No specific features predicted regression in an individual 
lesion. 
 
Pre-invasive lesions with unchanged histology 
There was no change in the histological diagnosis of 21 HGLs (L4, L5, L7, L8, L9, L10, L12, 
L13, L17, L25, L26, L27, L30, L32, L36, L41, L42, L43, L45, L46, L47) followed for between 
6 and 58 months (median 14 months). Some of the lesions were affected by treatment to a 
nearby carcinoma thus invalidating further follow-up data (e.g. L12 and L17). Lesion L30 was 
observed for 58 months without evidence of carcinoma development or of regression.  
 
New pre-invasive lesions develop at any location 
As part of the study protocol, randomly selected bronchoscopically normal areas were 
biopsied as “controls”. In 10 of these areas that had been normal histologically (L6, L13, L25, 
L26, L31, L48, L49, L50 L53, L56), pre-invasive lesions were identified at later 
bronchoscopies. None progressed to invasive carcinoma, although 3 of the lesions (L6, L31, 
L48) apparently regressed to normal epithelium while the remainder did not change 
histology.  
 
During the course of the study 24 new lesions were identified using autofluorescence 
bronchoscopy (19 HGL L2, L3, L4, L5, L6, L8, L10, L13, L17, L18, L20, L23, L26, L27, L29, 
L31, L32, L41, L47, and 5 LGL L49, L50, L53, L56, L57) in locations that had been 
bronchoscopically normal and not previously biopsied. Their natural history was not different 
to those lesions that were detected during earlier bronchoscopies. 
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Pre-invasive lesions may not show consistent histological appearances in serial biopsies 
In  lesions L2, L19, L22, L29 and L30 during serial biopsy, high-grade histology appeared to 
be interspersed with normal histology. Similarly, lesions L21 and L43 showed high-grade 
histology with episodic low-grade histology. Bronchoscopically (judged by their 
autofluorescence appearances) all the lesions were too large to be completely removed by 
bronchoscopic biopsy, although multiple biopsies were taken from each lesion at each 
bronchoscopy. 
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Figure 3.7: The histopathological natural history of pre-invasive lesions of the bronchus 
This shows the evolution of lesions during the serial bronchoscopies of 26 patients with the UCL patient number shown on the right hand side. Biographical data 
regarding the patients are given and the results of all the bronchoscopies in all the patients are shown. Each bronchoscopic location with an abnormality is shown by 
a horizontal bar with the bronchoscopic location given on the left hand side. The colour of the bar represents the histopathological diagnosis at the bronchoscopic 
location at the time-point on the x-axis. The timing of each bronchoscopy in the timeline of the patient is shown by a black vertical bar. Treatments, interventions and 
disseminated carcinoma are shown as text. A gap within the horizontal bar shows that no biopsy was taken at that time-point. A step in the horizontal bar indicates 
that the following lesion whose histology is described was not in the exact bronchoscopic location as the preceding lesion, but within the same lobe. The P number 
refers to the UCL study number and the L number is the lesion number referred to in the text. Abbreviations: PDT photodynamic therapy, RT radiotherapy, LLL left 
lower lobe, ChT chemotherapy, LUL left upper lobe, RUL right upper lobe, RML right middle lobe, RLL right lower lobe, R main right main bronchus, L main left main 
bronchus, apical the apical segment of lobe in question, SCLC small cell lung cancer, cpd cigarettes per day, COPD chronic obstructive pulmonary disease. 
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Figure 3.8: The patterns of pre-invasive lesions within individual patients 
The bronchoscopic extent and histopathology of lesions are plotted onto a line diagram of the bronchial tree to highlight the temporal and spatial relationships of 
lesions within an individual patient. The colour of a lesion indicates the histopathology and the key shown on the legend. The length of an abnormality within the 
bronchial tree indicates the bronchoscopic extent judged by autofluorescence. Lobectomies are shown by erasing the part of the lung that was resected. The L 
refers to the lesion number used in the text, and the P number refers to the patient number in the UCL study. 
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Observations from the follow-up of patients 
Patients develop carcinomas during follow-up 
In patients P2 and P3 multiple HGLs were found. New lesions arose during the period of 
follow-up all of which were high-grade. Only one lesion in each patient progressed to 
carcinoma, at 25 months in patient P2 and 10 months in patient P3, while the remaining 
lesions either regressed towards normal epithelium or remained with an unchanged 
histological diagnosis.  
 
Bronchoscopically some of the lesions increased in size (figure 3.8), while others remained 
the same size but this was not related to the ultimate outcome of the lesion. Patient P26 had 
two lesions, L44 and L45, one of which (L44) progressed to carcinoma at 10 months but the 
other remained histologically and bronchoscopically unchanged. In patient P9 there was an 
HGL in the left upper lobe which remained stable for 12 months until squamous cell 
carcinoma developed. In patients P3, P11 and P26, HGLs remained histologically indolent 
while one lesion within each patient progressed to squamous cell carcinoma. 
 
Two patients developed 2 carcinomas each. In patient P11, the carcinomas were discovered 
at the same time, one having originated in a HGL that had been unchanged for 30 months, 
and the other in a remote location in the contra-lateral lung. Patient P1 had two carcinomas, 
one in the trachea and the other in the right upper lobe. Both appeared to develop directly 
from HGLs, and both within a short time (6 months) after initial detection. 
 
In 5 patients, carcinoma developed in a location remote from the HGLs under follow-up. In 
patient P7, lesion L21 remained histologically unchanged while a carcinoma was found 
distally within the same lobe 12 months after presentation. There was a similar occurrence in 
patient P6 where a carcinoma was found at month 22 distally within the same segment as 
the lesion under follow-up. In patient P5 the carcinoma at month 10 was peripherally located 
in the right mid-zone, unrelated to the 3 HGLs being studied. In patient P10 who had 
undergone a right pneumonectomy, 3 HGLs were detected at 3 sites (L25, L26 and L27) that 
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had developed from histologically normal epithelium. None of the HGLs evolved into the 
invasive carcinoma which was found at month 36 (figure 3.8).  
 
The first detected lesion in patient P4 was LGL in the left upper lobe (L14). At three 
subsequent bronchoscopies over an 18 month period, HGL was found at the site of the LGL. 
Following this, LGL and then normal epithelium was identified at that site. A new LGL was 
detected at month 22 (L15) which appeared to spontaneously regress to normal epithelium. 
At month 64, some 30 months after the apparent regression of the original lesions, a 
squamous cell carcinoma was found, but not at the same bronchoscopic location as either of 
the previous lesions. 
 
Patients with lesions that regressed to normal epithelium 
A HGL was the first identified abnormality in patient P8 (L22), who subsequently developed 
a second HGL in month 14 (L23). Both lesions regressed to normal epithelium, although at 
the site of lesion L22 there was LGL followed by normal epithelium. At month 32 at the site 
of lesion L22 there was again LGL, 14 months after the apparent regression of the original 
lesion. 
 
Lesion regression was seen in patient P13, who had a right middle lobe carcinoma. This was 
resected by lobectomy, but the resection margin showed a HGL (L33). Two further lesions, 
both LGL (L34 and L35), were found elsewhere in the bronchial tree at the same time as the 
carcinoma. All three lesions regressed to normal epithelium, although subsequently at month 
18 the site of lesion L33 showed LGL followed by normal histology at the next biopsy. In 
patient P15, after resection of a left upper lobe carcinoma, there appeared to be regression 
of a left lower lobe HGL.  
 
HGLs regressed to normal in patients without evidence of other progressive or indolent 
HGLs, and independent of the risk factor profile of the individual patient e.g. L14 in P4, L22 
in P7, L23 in P8, L33 in P13, L37 in P15, L39 in P16 and L52 in P19.  
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Patients in whom carcinoma was treated with curative intent 
Treatment to HGLs applied at the same time as treatment to a nearby carcinoma was not 
always successful. Lesions L10, L12, L24 and L43 in patients P3, P9 and P60 remained 
HGL after treatment with photodynamic therapy to invasive carcinomas and the nearby 
HGLs.  
 
Patients with lesions that remained histologically unchanged 
In patient P12, lesions L30 and L32 remained indolent for 58 months and 28 months 
respectively, whilst regression of lesion L31 was observed. Lesion L30 increased in size 
significantly over time, eventually involving the left upper lobe stump and the left main 
bronchus to the orifice of the left lower lobe (figure 3.8). Both of the lesions detected during 
follow-up in patient P61 remained unchanged histologically. Unfortunately, the patient 
declined long-term participation in the study. 
 
Patients with multiple lesions 
Multiple lesions were found in 18 patients (P1, P2, P3, P4, P5, P6, P8, P10, P11, P12, P13, 
P16, P17, P18, P20, P21, P26, P61). In 6 patients, progression and regression of lesions 
was seen within the same patient (P2, P3, P4, P12, P13, P20). There were no specific 
bronchoscopic or histological features that differentiated lesions that progressed from those 
that regressed. New HGLs developed in locations bronchoscopically remote from the HGLs 
under follow-up in patients including P2, P3, P5, P6, P8, P10, P11, P12, P17, P26 and P61. 
Again, no specific feature in these patients predicted the outcome of individual lesions in 
terms of regression or progression. The time taken for lesions to evolve varied between 
patients and between lesions within the individual patient.  
 
The bronchoscopic extent of autofluorescence abnormalities 
Information regarding the extent of an individual lesion is limited, as bronchoscopy and 
biopsy do not permit detailed sampling of the entirety of the lesions under investigation. 
Therefore the dimensions of an individual lesion were inferred from the autofluorescence 
bronchoscopic appearances rather than from direct evidence by mapping biopsies. This was 
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collated with the histopathological findings. The results from patients in whom the 
dimensions of the abnormal autofluorescence (and by inference the pre-invasive lesions) 
changed significantly are shown in figure 3.8.  
 
The bronchoscopic extent of some HGLs increased (e.g. L3 in P2, L30 in P12) but remained 
unchanged in others (e.g. L19 in P6, L28 in P11), although histopathologically the lesions 
remained at high-grade. The bronchoscopic abnormality in one lesion returned to normal 
with the regression of the lesion to normal epithelium (L14). There was no association 
between the bronchoscopic extent of an individual pre-invasive lesion, either at the point of 
first detection or at any time during follow-up, and the histopathological evolution of the 
lesion. The rate of change of lesion extent, whether the lesion increased in size or became 
bronchoscopically smaller did not predict the histological behaviour or outcome of the pre-
invasive lesion. The bronchoscopic appearance in terms of colour and nodularity of the 
lesion (results not shown), either under white light or autofluorescence was not predictive of 
the histological diagnosis or the natural history of any lesion. The bronchoscopic 
appearances returned to normal in those lesions that regressed to histologically normal 
epithelium. 
 
New HGLs arose directly from apparently histologically and bronchoscopically normal 
epithelium or in the location of a previous LGL e.g. P9. There was no difference in terms of 
natural history or outcome between newly developed HGLs and those identified at the first 
bronchoscopy. There was no clear relationship between cigarette smoking and the 
behaviour or outcome of HGLs. 
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Discussion  
There was bronchoscopic and histological follow-up of 26 patients with 60 pre-invasive 
lesions of the bronchus for 14-110 months. Pre-invasive lesions progressed to carcinoma, 
regressed to normal epithelium or remained unchanged for substantial periods of time. 
Lesions that had appeared to regress to normal epithelium showed pre-invasive lesions at 
the same bronchoscopic location later in the time-course. Carcinoma developed only in 
lesions that were high-grade and did not develop from lower-grade lesions and none of the 
lesions that progressed to carcinoma had regressed at any point in their observed time-
course. New lesions were seen to evolve directly from normal epithelium, and developed at 
any bronchoscopic location at any time, with any natural history and outcome. The 
autofluorescence findings, both in terms of lesion extent and bronchoscopic appearance, did 
not predict the underlying histological diagnosis or the histological progress of an individual 
lesion whether the lesion was of high- or low-grade.  
 
Limitations of the methodology 
High-grade pre-invasive lesions are known to have abnormal gap junctions between the 
cells making sloughing of the mucosa a common occurrence. Biopsy forceps tend to crush 
bronchial biopsies, and the orientation of the mucosa is often lost due to folding of the 
sample in the biopsy forceps (figure 4.3). Although internationally accepted guidelines for the 
diagnosis of pre-invasive lesions are available8, the classification was based on lesions 
found in specimens of lung resected for carcinoma. Disruption of the epithelium during 
bronchoscopic biopsy can cause difficulty in the precise classification of the abnormalities 
found, particularly between severe dysplasia and carcinoma-in-situ. Within the present 
study, the biopsies were taken with “cup” forceps using minimal trauma to extract and 
process the samples. Despite these efforts, biopsies were found to be difficult to interpret 
due to crush trauma from the biopsy procedure, and epithelial loss in the processing of the 
biopsy. 
 
To minimise error through possible misclassification of the histological diagnosis of 
bronchoscopic biopsies, severe dysplasia and carcinoma-in-situ were combined into a single 
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“high-grade” histology category. Mild and moderate dysplasia were combined into a single 
“low-grade” histology category. This means that any differences between carcinoma-in-situ, 
severe dysplasia, mild and moderate dysplasia could not be detected. Interpretation of the 
histology of small, often crushed biopsies can lead to significant error in the classification of 
biopsies into these categories, and thus the results of previous studies must be interpreted 
with caution. Although the differences between the different histological grades were lost in 
the present study, the accuracy of the histological diagnosis was maintained, improving the 
reliability of the results obtained. 
 
The evolution of pre-invasive lesions 
Progression to invasive carcinoma 
The present study followed lesions using serial biopsy, but the progression suggested by 
previous studies from normal epithelium through pre-invasive lesions of increasing 
histological and cytological abnormality to the development of carcinoma106 was not 
observed. Pre-invasive lesions were noted to progress from low-grade to high-grade 
histology but the number of lesions in which this was observed was relatively low (5/60, 8%). 
New lesions were found the majority of which were high-grade at the point of first detection.  
 
Autofluorescence was the main mode of lesion detection used in the present study. It has 
already been demonstrated that the sensitivity of autofluorescence for low-grade lesions is 
poor, with as many lesions detected using random bronchial biopsy as were identified using 
autofluorescence (see Part 2). It is likely that the low detection rate for low-grade histology 
lesions prior to their development into high-grade lesions is due to the lack of sensitivity of 
autofluorescence for such lesions.  
 
All of the carcinomas developed from HGLs which agrees with the previous studies that 
suggested that HGLs carry the highest risk of malignant transformation (Part 1: pre-invasive 
lesions of the bronchus). Of the 60 pre-invasive lesions under observation, 46 showed high-
grade histology during the course of the study, but carcinoma developed in only eight lesions 
during this period of follow-up. Most of the previous studies classified lesions by their initial 
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histology and consequently may have pre-selected lesions at the highest risk for malignant 
change, which may not be representative of all lesions attaining high-grade histology (see 
Part 1: pre-invasive lesions of the bronchus). In the present study follow-up was longer than 
most of the previous studies but was not of sufficient duration to establish whether all the 
HGLs would progress to malignancy. There were no specific clinical, radiological or 
bronchoscopic features that predicted the risk of progression to malignancy for an individual 
lesion.  
 
HGLs may continue to grow and progress across the epithelium, with the bronchoscopic as 
well as the histological extent of the lesion increasing over time. This is not clearly 
associated with invasion, although it is difficult to determine the presence of invasion within 
such a large area of abnormality (e.g. lesion L3, in whom a small focus of invasion was 
found within a large area of CIS117). At present, even when there is a large HGL in the 
bronchial tree, neither the risk of invasion nor the specific focus of invasion can be 
determined with any reliability. Further studies are required to identify specific bronchoscopic 
or biological features that can determine the presence of invasion within any given lesion.  
 
Regression to normal epithelium 
Regression of lesions to histologically normal epithelium was observed in some lesions. The 
mechanisms by which regression occurs are not known. Pre-invasive lesions are thought to 
accumulate genetic damage during their evolution due to the effects of exposure to 
carcinogen118. It is possible that as a lesion evolves genetic damage, amplification of parts of 
the genome and loss of function of others may lead to gene rearrangements that may be 
lethal, or activate apoptosis, rather than confer a growth advantage. Alternatively, the lesion 
may fail to develop a blood supply through failure of angiogenesis due to a lack of, or an 
inability to produce, appropriate growth factors or signalling mediators and so may not be 
able to grow or develop further, leading to involution of the lesion. Further work is required to 
define the mechanisms by which regression of lesions occurs, using genome and RNA 
analysis techniques, and also examination of the tissue interactions between pre-invasive 
lesions and their local environment. 
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Some observations call into question whether histological regression of pre-invasive lesions 
genuinely occurs. At the bronchoscopic site of lesions of both high and low grade that were 
deemed to have regressed, pre-invasive lesions were found in later biopsies (e.g. L22, L33, 
L54, L57). There is also the finding that serial sampling of a lesion shows biopsy to biopsy 
variation in the histopathological diagnosis. Lesions such as L19, L29 and L30 showed high-
grade histology interposed between normal histology. There may be several explanations for 
this.  
 
1. There may be failure to accurately re-biopsy the lesion. Once biopsied, a bronchoscopic 
location has abnormal autofluorescence for a number of months, making re-biopsy of the 
exact location straightforward26. Careful mapping and recording of the location of 
biopsied abnormalities was undertaken to further minimise this potential source of error.  
 
2. It could be suggested that the technique of biopsy debulks the lesion and that this 
accounts for the histopathological changes observed in pre-invasive lesions26. This 
technique disrupts the lesions, and the effect of this disruption has not been adequately 
studied and may have several consequences. 
 
a. The lesion may take a variable amount of time to regrow depending on the biology of 
the lesion. Furthermore, it is possible that epithelial healing after the trauma of 
biopsy may cover the originally sampled lesion, which takes time to penetrate the 
relatively normal overlying healing epithelium. This theory is less plausible as pre-
invasive lesions usually have a growth advantage over histologically normal adjacent 
epithelium, but support for this idea may be found in lesions L2, L19, L24, L29 and 
L30 where a series of abnormal biopsies is punctuated by histologically normal 
samples.  
b. Disruption of lesions using photodynamic therapy has been shown to affect their 
outcome through an immunological effect119,120, and it is possible that disruption of 
small pre-invasive lesions due to biopsy may have a similar effect and consequently 
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influence their natural history. There are techniques in development that permit 
analysis of lesions in vivo without their physical disruption, including optical 
biopsy121, high-resolution bronchoscopy and confocal microscopy122. When these 
techniques are as reliable, well studied and understood as biopsy and histological 
analysis, studies of the natural history of observed pre-invasive lesions should be 
repeated, using a non-disruptive method of sampling. 
 
c. It has been suggested that biopsy may completely remove the lesion26. When the 
dimensions of the pre-invasive lesions in the study were assessed under 
autofluorescence they were found to be larger than could be removed at biopsy. 
This argues against the total removal of lesions by biopsy as a mechanism for the 
change in the histology at the bronchoscopic locations under observation.  
  
3. The lesion may indeed have regressed and cells from a different lesion or a new clone of 
cells may have grown or migrated into the bronchoscopic epithelial site previously 
occupied by the pre-invasive lesion.  
 
These theories cannot be explored using conventional histopathological techniques, as they 
are of insufficient sensitivity to differentiate between lesions that have the same histological 
grade, but different progenitor cells. There is some evidence to suggest that cells migrate 
along the bronchial epithelium123. This is supported by evidence of similarities between the 
genetic profiles of bronchoscopically remote lesions110,124 but against this is the finding of 
discordant genetic profiles in multiple lesions in remote locations within the bronchial tree 
when sampled at a single time-point110. These data suggest that the currently accepted 
definition of regression, i.e. “the presence of a histologically lower grade of pre-invasive 
lesion than the presenting lesion in two consecutive biopsies”26,27 may not be appropriate 
and that further work in this area is necessary.  
 
The above findings have implications for future research, both in terms of the evaluation of 
the natural history of pre-invasive lesions, but also the outcome of therapies. A series of 
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biopsies, rather than a single set of biopsies taken at a single time-point, are required to fully 
evaluate the long-term behaviour of the bronchial epithelium, or the effect of an intervention 
on the bronchial epithelium. Genetic studies of cells and lesions to determine their clonal 
relationships both across the whole epithelium at a single time-point, and also at a single 
bronchoscopic location over a period of time, are required to clarify these issues. 
 
Deficiencies of the histopathological classification 
The internationally accepted WHO classification of pre-invasive lesions implies that pre-
invasive lesions within each histological grade are identical and consequently there is no 
subdivision or subtyping8. The present data suggests that pre-invasive lesions of the same 
histological grade can have radically different natural histories and outcomes. The study by 
Pasic et al.44 in which resection margin CIS was followed with serial bronchoscopy is of 
particular relevance. They found that CIS could be subdivided depending on the 
histopathological features and identified CIS with extension into submucosal gland acini, CIS 
extending into submucosal gland ducts and CIS involving surface epithelium only. Each of 
these subtypes had different outcomes in terms of progression to malignancy. Keith et al.41 
described the phenomenon of “angiogenic squamous dysplasia”, and showed differences in 
the behaviour of lesions carrying this abnormality compared to standard dysplasia. An older 
Japanese study125 described “nodular” and “superficial spreading” types of CIS, and 
suggested that these histopathological morphologies had different outcomes. These data 
suggest that the current classification of pre-invasive lesions8 may be too crude to 
differentiate lesions that will progress to malignancy from those that will not. Further study of 
high-grade pre-invasive lesions with particular reference to histopathological features 
including cellular and histological ultrastructural features, depth of invasion into glands and 
the size and extent of lesions may be of relevance in the determination and prediction of the 
evolution of a given individual pre-invasive lesion. 
 
Implications for the clinical management of lesions and interpretation of studies of treatment 
Currently the histological diagnosis accorded to an individual pre-invasive lesion when first 
identified is used as the baseline from which the subsequent natural history of the lesion is 
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plotted8. This means that if the lesion is an LGL at diagnosis, and HGL at later biopsy, it 
would be considered to have progressed26,27,39. The variability observed in the histology of 
pre-invasive lesions over time means that the baseline histological diagnosis accorded to an 
individual pre-invasive lesion based on the initial biopsy may not accurately reflect the 
histology of the lesion over the preceding months.  
 
Biopsies at a single time-point are markers along a journey for the individual lesion, which 
can change direction at any point, with some lesions progressing and then regressing, and 
others continuing to progress. The labelling of a lesion based on a single biopsy or 2 
biopsies a few months apart can lead to errors in the prediction of lesion behaviour and 
outcome. For instance, the biopsy taken from lesion L21 at month 10 might suggest a low-
grade lesion that subsequently progressed to a high-grade histology, whereas review of the 
entire sequence of biopsies showed that the lesion was essentially at high-grade with a 
single episode of low-grade histology. Similarly, for lesion L14 the month 8 apparent 
progression from low-grade to high-grade was then followed by histological regression to 
normal epithelium but not for another year. The subsequent evolution and behaviour of any 
lesion and the highest histological grade attained by an individual lesion cannot be predicted 
from a single biopsy, or in many cases two consecutive biopsies a few months apart. This 
has implications for the clinical management of pre-invasive lesions and the interpretation of 
previous shorter-term studies of the natural history of pre-invasive lesions. 
 
The objective of any management strategy is to identify and successfully treat the lesions at 
highest risk of progression to invasive carcinoma. No bronchoscopic, histological or clinical 
factors that predict the outcome of pre-invasive lesions could be identified using the data 
collected. This suggests that the natural history of an individual lesion is unique to the lesion, 
rather than patient-based or dependent on currently identifiable patient factors. Lesions 
attaining high-grade histology are at greater risk of developing malignancy than any other 
histology, but the risk remains relatively low for an individual lesion. During the present 
study, carcinoma developed in 11 of the 26 patients, but in only 8 of the 46 lesions attaining 
high-grade at some point in their observed natural history. The presence of HGLs predicted 
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a higher risk of carcinoma development, not only within the lesion under observation, but 
also at remote locations within the lungs and bronchial tree. 
 
The present study suggests that the outcome of a lesion cannot be predicted by the initial 
histology or from short-term follow-up unless the lesion reaches a critical outcome, i.e. 
progression to fully invasive carcinoma. The development of new lesions at any location in 
the bronchial tree at any time-point suggests that patients harbouring these types of lesion 
require long-term follow-up of the entire visible bronchial tree using autofluorescence 
bronchoscopy, and the non-visible bronchial tree and lung parenchyma using CT scanning. 
High-grade pre-invasive lesions may be a marker for later carcinoma development, the 
location of which cannot be predicted using currently available parameters.  
 
Novel markers that establish the malignant potential of individual manifest lesions are 
needed. These might include molecular biology, immunohistochemical and proteomic 
markers. Although it is possible that a single marker will identify lesions that require 
treatment, it is more likely that a panel of markers will be used to assess the risk of 
malignancy for any given lesion. In parallel, markers to assess the response to treatment, 
and in particular a reduction in the malignant potential of treated lesions, must be developed 
as the natural history of a given lesion is uncertain. Previous studies of endobronchial 
therapies to pre-invasive lesions are difficult to interpret as the untreated natural history and 
the malignant potential of treated lesions were not known (see section 1: pre-invasive 
lesions).  
 
Summary 
The objective of this study was to confirm that squamous cell carcinoma of the bronchus 
develops from carcinogen-exposed bronchial epithelium through a series of pre-invasive 
lesions of increasing histological and cytological abnormality, determine the time-course of 
pre-invasive lesion development and determine whether pre-invasive lesions are committed 
to the development of malignancy. The progression of carcinogen-exposed bronchial 
epithelium to squamous cell carcinoma through a series of pre-invasive lesion was not seen. 
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HGLs were seen to develop into malignancy, but not all lesions were committed to the 
development of carcinoma, with 8 out of 46 lesions exhibiting such progression.  
 
The natural history of pre-invasive lesions is variable with an unpredictable time-course. 
Some lesions progress, some regress and some remain unchanged histologically. Different 
lesions in a single patient may have different natural histories and different outcomes. Short-
term follow-up may misrepresent the long-term evolution of an individual lesion or 
bronchoscopic location. Consequently decisions regarding the clinical management of pre-
invasive lesions cannot be determined solely on the basis of a single biopsy, or a short-term 
period of follow-up. Further work is required to identify novel markers of malignant potential, 
and response to treatment.  
 
The results of the present study are affected by selection bias, as only patients with 
symptoms or clinical suspicion of lung cancer underwent initial evaluation. It is not clear 
whether lesions in these patients are unique, or whether lesions in asymptomatic patients 
behave similarly. The current literature does not provide sufficient information to enable the 
development of effective management guidelines or interpret studies of therapy. Much work 
remains, and given the difficulties in finding lesions for study, multi-centre collaboration may 
be necessary. 
 
The results of genetic studies of biopsies from the present study should determine the clonal 
relationships between the lesions under observation. If the biopsies which are histologically 
more normal show a different genetic profile from the original lesion then this supports the 
theory that another clone of cells grew into the biopsy site and grew over the original lesion, 
which subsequently regrew and became manifest on later biopsies. It is interesting that 
biopsies from some of the bronchoscopic locations in which pre-invasive lesions appeared to 
have regressed showed another abnormality at a later time. The relationship of these lesions 
to the original pre-invasive lesion is not clear, but the mechanism by which a lesion of 
higher-grade histology can evolve into one of a lower grade is not immediately apparent. It is 
more likely that the later lesion originated from a different clone of cells and was therefore 
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unrelated to the original pre-invasive lesion. Comparison of the genetic profiles of the earlier 
and later lesions, should determine their clonal relationships and would provide important 
insights into the natural history of carcinogen-exposed bronchial epithelium, and the 
relationships between manifest lesions. 
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Hypothesis 
The pattern of genetic loss within lesion cells drives the evolution and determines the 
outcome of individual pre-invasive lesions of the bronchus. 
 
Objective 
Investigate the relationship between loss of genetic material at specific chromosomal loci 
and the behaviour and outcome of pre-invasive lesions of the bronchus. Identify consistent 
patterns of genetic loss associated with the behaviour and outcome of lesions. 
 
Method 
The study protocol was approved by the University College London / University College 
London Hospitals committees on the ethics of research on human subjects study no 
01/0148. Written informed consent to enter the study was obtained from each participant 
prior to study entry. 
 
Patient selection 
Patients were selected from those in the “Natural history of pre-invasive lesions of the 
bronchus” study during which biopsies were obtained from lesions followed 
bronchoscopically. In the study, biopsies were collected into formalin for processing into 
blocks for DNA extraction and also fresh frozen into OCT gel and dry ice for later RNA 
extraction. 
Selection criteria for the molecular studies: 
1. Patients with pre-invasive lesions of the bronchus followed within the “natural history 
of pre-invasive lesions of the bronchus” study. 
2. Samples available for DNA extraction for analysis. 
The 5 patients in the study were chosen after analysis of the natural history diagrams in “the 
natural history of pre-invasive lesions of the bronchus” study. All of the patients selected had 
lesions with a clear sequence of changes i.e. lesions that progressed to invasive carcinoma 
or lesions that regressed to normal epithelium, and sufficient samples at each time-point for 
analysis. 
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Patient P6 has one HGL and another HGL that progressed to squamous cell carcinoma. 
Patient P8 had two HGLs that regressed to normal epithelium. 
Patient P12 had a HGL at a bronchial resection margin that progressed to involve an 
extensive area from the left main bronchus to the orifice of the left lower lobe bronchus. 
Patient P4 had a HGL and a LGL that regressed to normal epithelium. 
Patient P11 had a previous carcinoma that was resected, a HGL that developed into 
squamous cell carcinoma and a further synchronous squamous cell carcinoma in the 
contralateral lung. 
 
Sample selection 
The samples for microdissection and DNA extraction were selected by analysis of the results 
of the “Natural history of pre-invasive lesions of the bronchus” study and cross-referencing 
with the database of collected samples. A diagrammatic representation of the bronchial tree 
was used to highlight this (figure 4.1). 
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Figure 4.1: A diagram showing the results of bronchoscopies and their 
relationship to the samples collected and DNA extracted. The numbers e.g. 2003-
63 and R02 028 refer to the blocks containing the bronchial biopsies from the 
bronchoscopic location identified. The bronchoscopic findings are shown on the 
representative bronchial tree diagrams, with the colour indicating the histology at that 
location at that time-point. 
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Biopsy processing for DNA extraction 
1. Formalin-fixed specimens 
Placed onto acetate strips and immediately fixed in at least 10 times the sample volume of 
10% neutral buffered formalin for 4 hours to ensure fixation but minimise exposure of the 
biopsy to formalin. Formalin fixes specimens by producing protein cross-links and excessive 
fixation times have been found to inhibit DNA extraction. The biopsies were processed into 
paraffin wax blocks using a Leica™ TP1050 Vacuum Tissue Processor. This uses an 
overnight cycle involving dehydration of the biopsy in 70%, 90% and 100% ethanol and 
clearing in xylene. The fixed biopsy was then blocked into paraffin wax using the  
Blockmaster™ system supplied by Raymond A. Lamb™ using the manufacturers protocol. 
 
2. Frozen specimens 
The specimen vial containing the biopsy frozen in OCT gel was removed from the –80°C 
freezer and allowed to defrost completely. This was confirmed by the OCT returning to a 
clear gel from an opaque white state when frozen. The biopsy was lifted out of the OCT gel 
with the minimum of trauma using a fine 25G needle and placed directly into at least 10x the 
biopsy volume of 10% neutral buffered formalin. After 4 hours the biopsy was transferred 
into 70% ethanol for transportation to the histopathology department for processing into a 
paraffin wax block using the protocol for formalin-fixed specimens above. 
 
Preparation of sections for Laser Capture Microdissection 
The paraffin was block frozen to -4°C and trimmed so that 4-5 sections in a single ribbon 
could be fitted onto a single microscope slide. Ribbons of 4-5 7µm sections were cut using a 
Shandon AS325 Retraction Rotary Microtome and placed onto the surface of a water bath at 
37°C. The sections were transferred on to standard uncoated glass microscope slides 
without adhesive. The slide and the sections were blotted with filter paper and left to air dry 
at room temperature. This minimised the adhesion of the section to the slide and allowed 
optimal microdissection. The block was cut until a minimum of 10 sections were obtained 
form the centre of the biopsy. 5µm sections were found to provide clear cellular and lesion 
definition when stained for both diagnosis and for laser capture microdissection with the 
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Arcturus Laser Capture Microdissection system. However, the 5µm sections were found to 
be too adherent to the slide for reliable microdissection. 7µm sections were less adherent 
and dissection from the slide was straightforward. At 7µm section thickness the cellular and 
lesion morphology was less well defined, but was sufficient to facilitate microdissection 
(figure 4.2). 
 
Staining for diagnosis and lesion identification 
One slide from near the centre of each biopsy containing 3-5 sections was hand-stained with 
haematoxylin and eosin using a standard protocol. Vectamount™ (Vector™ Laboratories, 
UK) was used to mount the coverslip. A representative haematoxylin and eosin stained 
section was photographed using the Arcturus Laser Capture microdissection microscope 
with the visualiser arm in place. Multiple overlapping photographs through the x10 objective 
were taken and were assembled to give a large high magnification picture using Corel 
Photopaint software on the Macintosh OSX and printed onto Kodak everyday picture paper 
using an Epson Stylus Photo 830 5600dpi colour inkjet printer for maximum resolution 
(figure 4.3). The diagnostic slide was reviewed with a Consultant Histopathologist with a 
special interest in pulmonary malignancy. The epithelial lesion was identified and mapped 
onto the photomicrograph of the section (figure 4.3). 
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Figure 4.2: Photomicrographs of example sections. At 5µm thickness (top sections) 
there is clear lesion and cellular definition. At 7µm (lower sections) the lesion and cellular 
definition is less clear. 
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Figure 4.3: An example section with the abnormalities highlighted. The areas with “SD” 
(severe dysplasia) are shown. 
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Laser Capture Microdissection 
A series of experiments were designed to optimise each part of the laser capture 
microdissection and DNA extraction protocol and are presented in summary form. 
1. The staining method used to define the cells in the section and facilitate 
microdissection. 
2. The power of the laser used for microdissection. 
3. The digestion buffer used for DNA extraction. 
4. The length of time for DNA extraction from the microdissected cells. 
5. Quantification of the extracted DNA. 
6. Dilution of the extracted DNA for LOH analysis. 
 
Laser Capture Microdissection was performed using the Arcturus Laser Capture dissection 
microscope. The lesion of interest was microdissected using the photomicrograph map and 
the Histopathologists directions as a guide. The Laser Capture Microdissection from each 
biopsy was performed using as many slides and sections from the original biopsy as 
necessary to provide at least 50% coverage of the Laser Capture Microdissection cap. For 
carcinoma this could be fulfilled using a single section, but for pre-invasive lesion and normal 
epithelium biopsies, this typically required 10-15 sections. The objective was to provide the 
greatest possible quantity of DNA, and approximately equivalent quantities of DNA from 
each bronchoscopic location. 
 
1. Slide Staining Protocol for laser capture microdissection 
There is evidence that staining with haematoxylin may affect PCR on microdissected DNA. 
Nuclear Fast Red is thought to avoid this issue, but may give less effective definition of the 
lesion cells for microdissection. Haematoxylin using a short (1 second) dip protocol was 
found to give DNA of quality similar to that of Nuclear Fast Red stained specimens when 
compared during microdissection of a single lesion. Consequently a short exposure to 
haematoxylin was used (slide dipped in haematoxylin) to define the lesion of interest prior to 
microdissection. 
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2. Laser Power during microdissection 
It has been suggested that a higher laser power affects a larger area of the cap during 
microdissection, but may cause damage to the specimen, thus reducing DNA yield. The 
yield of DNA using a 50W and 100W laser power was compared. The cap was more 
effectively melted with a 100W laser power; at 50W areas of the glue did not melt adequately 
and specimen was left on the slide in a patchy distribution risking loss of specimen. At 100W 
this was eliminated, with no reduction in DNA quality for PCR.  
 
3. Digestion buffer for DNA extraction from microdissected cells 
Two different buffers were assessed for use in the digestion of microdissected cells. There 
was no difference between the different buffers used. Proteinase K and Tween 20 digestion 
buffer was selected due to familiarity with the buffer within the laboratory. 
 
4. Duration of digestion of the microdissected specimen 
Overnight digestion of the microdissected specimen was found to produce the most reliable 
clearance of the microdissection cap and therefore adequate DNA extraction for PCR 
analysis. 
  
5. Quantification of the Digested DNA product 
It was found that both proteinase K and Tween 20, used in the protocol for digestion of the 
Laser Capture dissected specimens gave a positive result on picogreen assay. This 
invalidated the results, and made quantification of the DNA impossible. Purification of the 
DNA was not attempted as there was very little DNA from each specimen due to the small 
size of the lesions under investigation, and it was decided not to risk loss of DNA in 
processing when the PCR protocols were known to work with unpurified samples.  
 
6. Dilution of the DNA product for LOH analysis by PCR 
A series of dilutions of the template extracted DNA was used to determine the optimum 
dilution for PCR. Dilutions of 1:20, 1:10, 1:5 and no dilution were used. The most consistent 
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and best quality results were obtained with 1:5 dilution. At 1:10 and 1:20 dilutions there were 
some failures of PCR. 1:5 dilution of the DNA product was selected for the studies. 
 
Loss of Heterozygosity analysis 
Selection of method 
Loss of heterozygosity analysis was selected as: 
i. This technique has been used extensively and successfully to detect genetic loss in a wide 
range of carcinomas including lung. 
ii. In a previous pilot study of one patient117, differences in the loss of heterozygosity pattern 
was found between pre-invasive carcinoma-in-situ and the post-invasion squamous cell 
carcinoma that developed in the same anatomic location. 
iii. Detailed allelotyping is possible using this technique with a better resolution for genetic 
loss than is possible with whole genome methods such as comparative genome 
hybridisation. 
iv. The DNA extracted from the bronchial biopsies is optimised for PCR-based analysis. 
v. Loss of heterozygosity has been extensively studied in squamous cell carcinoma of the 
bronchus but there are few data from studies of pre-invasive lesions. However, it is 
suggested that genetic loss occurs in a sequential manner during the progression of pre-
invasive lesions to carcinoma of the bronchus, and therefore studies of genetic loss and 
their relationship to the behaviour of pre-invasive lesions are required. 
 
Selection of chromosomal loci for analysis 
Previous studies of genetic loss in squamous cell carcinoma of the bronchus were found by 
a search of the Pubmed database and reference lists from the papers obtained from 
Pubmed. Chromosomal locations and polymorphic microsatellite markers that showed 
genetic loss and the frequency with which it was found within the specimens analysed was 
recorded where available. The majority of the studies were 5-10 years old and so the 
markers used in the studies were remapped onto the latest draft of the human genome 
(2003, using the NCBI UniSTS and the Genome Database) and plotted onto an ideogram 
(figure 4.4). This approach revealed candidate locations in the genome where genetic loss 
Part 4: The molecular biology of pre-invasive lesions 
Page 95 of 178 
appeared to be a frequent occurrence in squamous cell carcinoma of the bronchus. This 
information was used to determine which chromosomal locations would be analysed in the 
pre-invasive lesions. The chromosomal locations selected were: 3p (3p12, 3p14, 3p21 and 
3p25), 4p16, 5q (5q15 and 5q21), 8p22, 9p16 and 17p13. Some loci, such as 3p, 9p and 
17p had been shown in previous studies to be associated with early stage pre-invasive 
lesions and squamous cell carcinoma of the bronchus. Other loci, such as 5q15 and 5q22 
were chosen as known tumour suppressor genes had been found in the loci, and there had 
been consistent LOH found in previous studies of squamous cell carcinomas (figure 4.4). 
4p16 was selected as previous work in the laboratory had shown an association between 
LOH and the progression of an HGL to squamous cell carcinoma in one patient.  
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Figure 4.4: Ideograms showing genetic loss throughout the genome in squamous cell 
carcinomas. The reference numbers do not correspond to the reference numbers within the 
reference list. The percentage of squamous cell carcinomas showing loss are shown where 
the data were available. 
 
 
Part 4: The molecular biology of pre-invasive lesions 
Page 97 of 178 
Part 4: The molecular biology of pre-invasive lesions 
Page 98 of 178 
Part 4: The molecular biology of pre-invasive lesions 
Page 99 of 178 
Part 4: The molecular biology of pre-invasive lesions 
Page 100 of 178 
Part 4: The molecular biology of pre-invasive lesions 
Page 101 of 178 
Part 4: The molecular biology of pre-invasive lesions 
Page 102 of 178 
Chromosome markers from the candidate chromosomal regions were selected using the 
UniSTS, HGMP and Ensemble databases. The criteria for selection were: 
a. A polymorphic microsatellite di-nucleotide repeat marker. 
b. Location in the chromosomal region of interest. 
c. Size of PCR product  < 200 base pairs. 
d. Heterozygosity frequency in the general population of > 75% quoted on the Human 
Genome Database. 
 
The sequences of the primers for these markers were copied from the Human Genome 
Database (UniSTS and HGMP GDB) and manufactured by Sigma-Genosys™. In each 
patient, DNA was extracted from blood leucocytes as a source of “normal” patient DNA. The 
markers selected were assessed for heterozygosity within the patients “normal” DNA. If the 
marker was homozygous or the 2 alleles were too close together on the gel to facilitate 
accurate reading then another marker from the same chromosomal location was analysed 
until a marker of sufficient quality was found.   
 
Loss of heterozygosity analysis protocol 
20µl PCR reactions were set up using the protocol in box 4.1. The forward primer was 
labelled with 32PdATP using T4 polynucleotide kinase. The PCR reactions were run on a 
thermal cycler with a heated lid for 35 cycles using Amplitaq goldTM DNA polymerase with a 
10 minute 95°C activation/denature step, and a 10 minute 72°C final extension step. 
 
Box 4.1 The PCR protocol for 20µ l reactions 
  
Stock 
concentration 
Concentrations 
in reaction Totals (µl) 
water   9.85 
Labelled primer   2.00 
forward primer (20uM) 20µM 0.35µM 0.35 
reverse primer (20uM) 20µM 0.4µM 0.40 
Reaction buffer (10x) 10x 1x 2.00 
MgCl2 (25 mM) 25mM 1.5mM 1.20 
dNTP (2mM) 2mM 0.2mM 2.00 
template DNA   2.00 
Taq 5U/µl 1 unit 0.20 
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Polyacrylamide gel electrophoresis  
6% denaturing polyacrylamide gels were used to separate the PCR products. A formamide / 
EDTA stop buffer with boiling of the combined PCR product / buffer solution was used to 
maintain the DNA in the denatured state. The gels were dried on a standard gel drier with a 
vacuum pump at 80°C for 1 hour. The gels were then exposed to autoradiograph film for 
varying time-periods judged to provide the optimum definition of the bands on the gel. 
Several exposures were made of each gel. The gels were then read by visual inspection. 
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Patient P6 
Introduction 
This 61 yrs old male was referred after a conventional white light bronchoscopy for recurrent 
pneumonia had shown an abnormality in the lingula. A HGL was found in the biopsies. There 
was a history of smoking 60 cigarettes per day for 47 years, but he had stopped smoking 
one year prior to referral.  
 
At bronchoscopy, two months after the initial bronchoscopy at the referring institution, there 
was a single small abnormality visible under white light and autofluorescence in the lingula. 
This was maintained under observation using white light and autofluorescence 
bronchoscopy (figure 4.5). The bronchoscopic appearance of the lingula did not change, with 
abnormal mucosa seen under white light and autofluorescence. Biopsies from the lingula at 
month 2, month 6 and month 14 showed histologically normal epithelium only. At month14, 
there was abnormal mucosa under white light and autofluorescence in the apical segment of 
the left lower lobe. Biopsies showed a HGL. Two months later, squamous cell carcinoma 
was identified in the apical segment of the left lower lobe both on bronchoscopic biopsy and 
PET scan. This was successfully treated with a left lower lobectomy.  
 
Results of molecular studies 
The results of the LOH analysis are shown as raw data in table 4.1 and figure 4.5 and as a 
schematic diagram in figure 4.6. Specimens from the lingula and the apical segment of the 
LLL were available for analysis. Fifteen markers from ten loci were analysed in all the 
specimens. The PCR failed in all the specimens for the marker on 8p22. 
 
Lingula  
The extent of the LOH in the HGL at month 0 was 4/9 loci. There was LOH at only one of the 
four 3p loci tested (3p21) and 4p16, 5q15 and 9p21. The other loci analysed retained 
heterozygosity (3p12, 3p14, 3p25, 5q22 and 17p13).  
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Table 4.1: Raw data LOH studies of patient P6. The numbers refer to the alleles present 
on the LOH study. A missing number means that there was LOH at that allele. The histology 
numbers of the specimens, their bronchoscopic location and the month into the study when 
they were obtained is shown. 
 
 Specimen no H02 17502 2003 125 2003 126 2003 131 2003 129 2003 162 
  Location Lingula  Lingula Lingula Lingula LLL apical LLL apical 
  Histology HGL NAD NAD NAD CIS CIS/SQC 
Locus Marker 0 2 6 14 14 16 
3p12 D3S 3633 1,2 1,2 1,2 1,2 1,2 1,2 
                
3p14 D3S 2318 1,2 1,2 1,2 1,2 1 1 
  D3S 1228 1,2 1,2 1,2 1,2 1,2   ,2 
                
3p21 D3S 2409   ,2 1,2 1,2 1,2 1 1 
  D3S 1573 1,2 1,2 1,2 1,2   ,2   ,2 
                
3p25 D3S 1293 1,2 1,2 1,2 1,2 1 1 
  D3S 1298 1,2 1,2 1,2 1,2 1,2 1,2 
                
4p16 D4S 2935 1 1,2 1 1,2 1,2 1,2 
  D4S 394 1 1 1 1 1,2 1 
                
5q15 D5S 592 1 1,2 1,2 1,2   ,2   ,2 
  D5S 421 1 1,2 F 1,2 1 1 
                
5q22 D5S 644 1,2 1,2   ,2 1,2 1,2 1,2 
                
8p22               
                
9p21 D9S 171   ,2   ,2 F 1,2   ,2   ,2 
                
17p13 D17S 1574 1,2 1,2   ,2 1,2 1,2 1,2 
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Figure 4.5: Raw data of LOH analysis of patient P6. The data are shown by the 
chromosome marker used, and the histology number of the lesion from which the sample 
analysed was taken. 
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Figure 4.6: Schematic diagram of bronchoscopy findings and LOH findings in patient 
P6. Each oval represents the results of LOH analysis at a single marker, the colour 
represents the locus analysed. The top half absent shows LOH at the upper allele, and the 
lower half absent shows LOH at the lower allele. The arrows show the location in the 
bronchial tree and in the natural history where the samples were taken. 
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Biopsies from the lingula at months 2, 6 and 14 showed histologically normal epithelium 
suggesting regression of the HGL. The extent of the LOH in these specimens was less, at 2-
3/9 loci, than the HGL. There was retention of heterozygosity in markers that had shown 
LOH in the HGL (D3S 2409 at 3p21 and both markers on 5q15) and LOH in markers that 
retained heterozygosity in the HGL (5q22 and 17p13 in the month 6 specimen). At D4S 394 
on 4p16, the same allele was lost in the HGL and in the subsequent biopsies. In the other 
marker on 4p16, D4S 2935, there was LOH in the HGL but retention of heterozygosity in the 
subsequent biopsies except the month 6 specimen, in which there was LOH at the same 
allele as the HGL.  
 
In the lingula samples at months 2, 6 and 14 there was LOH at the same allele at D4S 394 
on 4p16. The rest of the allelotypes show that they did not derive from each other as the 
pattern of LOH is different  in each sample. The month 2 specimen had LOH at 4p16 and 
9p21. The month 6 specimen had LOH at both markers on 4p16, and additionally at 5q22 
and 17p13. The sample from month 14 had LOH at one marker on 4p16 only. This suggests 
that although the cells in the samples may have had a single progenitor, they had developed 
different mutation patterns and were therefore from different clones.  
 
Left lower lobe apical segment  
The extent of the LOH in the HGL at month 14 was 5/9 loci and was comparable with that of 
the HGL in the lingula. There was LOH at three of the four 3p loci analysed (4/7 of the 
markers) and LOH at 5q15 and 9p21. At D3S 2409 on 3p21 the LOH was at allele 1 in the 
lingula, but allele 2 in the LLL apical segment. Allele 2 was lost at D5S 592 on 5q15 in the 
lingula segment HGL, but allele 1 was lost in the LLL apical segment. The same alleles were 
lost in both the lingula HGL and the LLL apical segment HGL at D5S 421 on 5q15 and D9S 
171 on 9p21. There was more extensive 3p LOH in the LLL apical segment HGL, with LOH 
at 3p14, 3p21 (both markers) and D3S 1293 on 3p25. In the specimen from the lingula HGL 
at month 0 both markers showed LOH at 4p16 whereas in the LLL apical segment at month 
14 heterozygosity was retained at that locus.  
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The LLL apical segment HGL progressed histologically to squamous cell carcinoma after 2 
months, and was visible as an area of increased activity on PET scan. The pattern of allele 
loss in the carcinoma was identical to the HGL in all the markers that had shown LOH in the 
HGL (D3S 2318 on 3p14, 3p21 both markers, D3S 1293 on 3p25, 5q15 both markers and 
9p21). There was retention of heterozygosity in both the HGL and the carcinoma at 3p12, 
D3S 1298 on 3p25, D4S 2935 on 4p16, D5S 644 on 5q22 and 17p13. Within the carcinoma 
there was expansion of the 3p LOH to 5/7 markers (although still 3/4 loci) with additional 
LOH at D3S 1228 on 3p14. There was new LOH on 4p16 (D4S 394) in the carcinoma, which 
had not been observed in the preceding HGL. This suggests that the carcinoma developed 
directly from the high-grade lesion at the same bronchoscopic location but in the transition 
from HGL to invasive carcinoma the extent of the 3p LOH had increased, and there was new 
LOH at 4p16. 
 
Discussion 
The allelotypes suggest that the LLL apical segment HGL and the lingula HGL derived from 
different progenitor cells and were not clonally related. The lingula lesion showed relatively 
little 3p LOH, only one marker out of seven showing allele loss, with LOH at 4p16, 5q15 and 
9p21, a pattern associated with regression of the HGL. The LLL apical segment HGL had 
more extensive (5/7 markers) 3p LOH, with 9p21 and 5q15 LOH. This pattern, with the 
acquisition of the 4p16 LOH, appeared to drive the HGL to invasive carcinoma. The most 
striking difference between the lingula HGL that regressed, and the LLL apical HGL that 
progressed to invasive carcinoma was the extent of the 3p LOH. It is possible that extensive 
3p LOH, with 9p LOH and 4p16 LOH is required to generate a fully invasive phenotype and 
avoid regression of the lesion. 
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Patient P8 
Introduction 
This 61 year old male was referred to his local unit with haemoptysis. He had smoked 40 
cigarettes per day for 48 years and there was a history of asbestos exposure. Conventional 
white light bronchoscopy showed abnormal mucosa in the RLL apical segment, biopsies 
from which showed a HGL. One year later in our unit, under white light and 
autofluorescence, there was the previously noted RLL apical segment lesion and an 
abnormality in the RUL. Both were histologically HGL. A CT and PET scan did not 
demonstrate a significant abnormality. Two subsequent bronchoscopies performed at 
months 17 and 24 showed bronchoscopic and histological regression of both abnormalities 
to normal epithelium (figure 4.7). The haemoptysis had resolved soon after the first 
bronchoscopy, and the patient remained asymptomatic throughout.  
 
Results of molecular studies 
The results of the LOH analysis are shown as raw data in table 4.2 and figure 4.8 and as a 
schematic diagram in figure 4.7. Specimens from the RLL apical segment and the RUL were 
available for analysis. Fifteen markers from ten loci were analysed in all the specimens. 
 
Right lower lobe apical segment 
From this location four specimens were analysed, two showing HGL at month 0 and month 
12 and two from subsequent histologically and bronchoscopically normal epithelium at 
month 17 and month 24.  
 
The extent of the LOH was 5/10 loci in the HGL at month 0 and month 12. In the markers 
showing LOH, the same allele was lost in both samples suggesting that they may be from 
the same lesion (D3S 2318 on 3p14, D3S 1573 on 3p21, 9p21 and D17S 1574 on 17p13). 
There was retention of heterozygosity at 3p25, 4p16, 5q22 and 8p22 in both specimens. 
There were differences between the two specimens. The LOH at 5q15 at month 0 was not 
present at month 12, and the extent of the LOH at 17p13 increased from month 0 to 
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month12, with one marker showing LOH at month 0 but both markers involved at month 12. 
The 3p12 marker was not interpretable as the PCR failed in the month 0 sample. 
 
In the two subsequent specimens, both of which showed normal histology, the extent of LOH 
was 2/7 loci at month 17 and 3/10 loci at month 24, which is less than in the preceding HGL. 
The month 17 specimen results are difficult to interpret due to the high number of failed 
PCRs. At month 24 there was LOH at 3p25, 9p21 and 17p13. The allele lost at one of the 
markers on 17p13 was different to that of the preceding HGL, and 3p25 showed LOH which 
was not present in either of the HGL samples. This suggests that the bronchoscopically and 
histologically normal epithelium at month 24 was not clonally related to the previous HGL.  
 
Right upper lobe 
A sample taken at month 17 with histologically normal epithelium that was taken from the 
location of a previous HGL was analysed. Unfortunately, the original HGL specimen had no 
remaining lesion cells, and so DNA was not available for study. Of the informative loci, two 
failed to provide results suitable for analysis (3p12 and 17p13) due to failed PCR.  
 
The extent of the LOH was 3/8 loci (4/12 markers), which is similar to the extent of LOH in 
the RLL apical segment specimens that showed normal histology after histological 
regression of the HGL. There was LOH at 3p21, 3p25 and 4p16, in contrast to the 
histologically normal RLL apical segment specimens (3p25, 9p21 and 17p13), but the same 
allele was lost at 3p25. Heterozygosity was retained at 9p21, 5q15, 5q22 and 8p22. The 
allele lost at 3p21 was the same as the HGL in the RLL apical segment but there was LOH 
at 3p25, 4p16 and the other marker on 3p21(D3S 2409), which was not seen in the HGL.  
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Table 4.2 : Raw data LOH studies of patient P8. The numbers refer to the alleles present 
on the LOH study. A missing number means that there was LOH at that allele. The histology 
numbers of the specimens, their bronchoscopic location and the month into the study when 
they were obtained is shown. 
 
 Specimen no WALES 2003 3 2003 49 2004 12 2003 50 
  Location RLL apical RLL apical RLL apical RLL apical RUL control 
  Histology HGL HGL NAD NAD NAD 
Locus Marker 0 12 17 24 17 
              
3p12 D3S 1254 F   ,2 F 1,2 F 
              
3p14 D3S 2318 1 1 F 1,2 1,2 
  D3S 1228 1,2 1,2 1 1,2 1,2 
              
3p21 D3S 2409   1,2   1,2   ,2 
  D3S 1573 1 1 1 1,2 1,2 
              
3p25 D3S 1293 1,2 1,2 1,2   ,2   ,2 
              
4p16 D4S 2935 1,2 1,2 1,2 1,2 1 
  D4S 394 1,2 1,2 1,2 1,2 1,2 
              
5q15 D5S 592 1 1,2 1,2 1,2 1,2 
              
5q22 D5S 644 1,2 1,2 1,2 1,2 1,2 
              
8p22 D8S 136 1,2 1,2 1,2 1,2 1,2 
  D8S 133 1,2 1,2 F 1,2 1,2 
              
9p21 D9S 162   ,2   ,2 F   ,2 1,2 
              
17p13 D17S 1176 1,2   ,2   1   
  D17S 1574 1 1 F 1 F 
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Figure 4.7: Schematic diagram of bronchoscopic and LOH results from patient P8. 
Each oval represents the results of LOH analysis at a single marker, the colour represents 
the locus analysed. The top half absent shows LOH at the upper allele, and the lower half 
absent shows LOH at the lower allele. The arrows show the location in the bronchial tree 
and in the natural history where the samples were taken. 
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Figure 4.8: Raw data of LOH analysis of patient P8. The data are shown by the 
chromosome marker used, and the histology number of the lesion from which the sample 
analysed was taken. 
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Discussion 
There are differences between the allelotypes of the specimens from the RLL apical HGL. 
The specimen at month 12 had LOH at an additional marker on 17p13 but the LOH at 5q15 
in the month 0 specimen was not present. This suggests that the lesion at month 12 did not 
evolve directly from the month 0 lesion. It is more probable that although both specimens 
had the same cell of origin, there was clonal divergence i.e. the original lesion cells evolved 
into separate clones with different molecular changes (figure 4.7). This implies that there 
may be heterogeneity within the HGL, with clones of cells within the lesion having a single 
common progenitor but subsequently evolving different molecular changes. The concept of 
lesion heterogeneity is discussed in more detail in section 4 of the main discussion. 
 
The sample from the RUL at month 17 was from the location of a previous HGL. It is 
unfortunate that the previous HGL was not available for analysis, as there was no lesion left 
within the remaining specimen block, suggesting that this HGL may have been completely 
resected during biopsy. This is borne out in the LOH analysis, in which the allelotype did not 
resemble that of the HGL in the RLL apical segment or other previously analysed HGLs in 
other patients. This suggests that the bronchoscopically and histologically normal epithelium 
at month 24 may not have been clonally related to the previous HGL.  
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Patient P12 
Introduction 
This 61yr old male was referred to his local unit with haemoptysis. Three years earlier he 
had undergone a LUL lobectomy for squamous cell carcinoma after which there had been 
intermittent haemoptysis. Conventional bronchoscopy one year after the lobectomy had 
shown no abnormality. A further conventional bronchoscopy at the referring institution two 
years later had identified abnormal mucosa at the LUL stump, biopsies from which showed a 
HGL. The patient had stopped smoking at the time of the lobectomy, having smoked 30 
cigarettes per day for 35 years. 
 
Bronchoscopy was performed 5 months later at our unit using white light and 
autofluorescence.  There was abnormal mucosa around the LUL stump visible with both 
imaging modalities, biopsies from which showed a HGL. In subsequent follow-up 
bronchoscopies between months 5 and 33 the area of bronchoscopically abnormal mucosa 
increased in size to extend from the proximal LMB to the orifice of the LLL (figure 4.9). The 
autofluorescence appearance of the mucosa worsened showing increased nodularity. 
Biopsies of the bronchoscopically abnormal mucosa showed HGLs. Histologically, the 
appearance of the HGL at the LUL stump changed over time to show epithelial out-pouching 
into the subepithelial stroma (figure 4.10). This was not seen in the proximal LMB. The LLL 
orifice was bronchoscopically and histologically normal. The bronchoscopic and histologic 
appearance of the LUL stump led to a completion left pneumonectomy at month 54. Within 
the resection specimen a nodule of invasive carcinoma was found at the LUL stump.  
 
Results of molecular studies 
The results of the LOH analysis are shown as raw data in table 4.3 and figure 4.10 and as a 
schematic diagram in figure 4.9. Samples from the  LUL (the original carcinoma), the LUL 
stump, the proximal LMB and the orifice of the LLL were available for analysis with a biopsy 
of histologically and bronchoscopically normal epithelium from the RUL. Eighteen markers 
from ten loci were analysed in all the specimens.  
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Table 4.3 Raw data LOH studies of patient P12. The numbers refer to the alleles present on the LOH study. A missing number means that there was LOH 
at that allele. The histology numbers of the specimens, their bronchoscopic location and the month into the study when they were obtained is shown. 
 
 Specimen no 597.9266 500.6251 R02 019 R02 028 R02 021 2003 44 2003 61 2003 42 2003 40  2003 59 
 Location LUL LUL 
LUL 
stump 
LUL 
stump 
LUL 
stump 
LUL 
stump LLL LLL L main RUL 
  Histology SQC SQC HGL HGL HGL HGL NAD HGL HGL NAD 
Locus Marker     5 9 14 33 0 33 33 0 
3p12 D3S 1284 1,2 1 1 1 1 1,2 1,2 1 1 1,2 
                        
3p14 D3S 1228 1,2 1,2 X X X X X X X X 
  D3S 2318 1,2 1,2 1 1 1 1 1 1,2 1,2 1,2 
  D3S 1233 X X F 1 1 1 1 1,2 1   ,2 
  D3S 1234 X X   ,2   ,2   ,2   ,2   ,2 1,2   ,2 1,2 
                        
3p21 D3S 2409   ,2   ,2 X X X X X X X X 
  D3S 1573 1 1 1,2 1 1 1 1 1 1 1,2 
                        
3p25 D3S 1293 1,2 1,2 1       1 1 1,2 1 1,2 1 1,2 
                        
4p16 D4S 2935 X X 1,2 1,2 1,2 1  1,2 1,2 1   1,2 
                        
5q15 D5S 394 X X F   ,2 1,2   ,2   ,2   ,2   ,2 1,2 
  D5S 592 1 1 1 1 1 1 1 1 1  1,2 
                        
5q22 D5S 644 1 1 1,2 1,2 1,2 1,2 1,2 1,2 1,2 1,2 
  APC     1,2 1,2 1,2 1,2 1,2 1,2 1,2 1,2 
                        
8p22 D8S 133 1,2 1,2 1,2 1,2 1,2 1,2 1,2 1,2  1,2 1,2 
  D8S 136 1,2 1,2   ,2 1,2 1,2 1,2 1,2 1,2 1,2 1,2 
                        
9p21 D9S 162 1 1,2   ,2 1,2 1,2 1,2 1,2 1,2 1,2 1,2 
  D19S 1749        2   ,2   ,2   ,2   ,2   ,2 1,2 1,2 1,2 1,2 
                        
17p13 D17S 1574 x x 1 1,2 1,2 1,2 1,2 1,2 1,2 1,2 
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Figure 4.9: Schematic diagram of bronchoscopic and LOH results from patient P12. 
Each oval represents the results of LOH analysis at a single marker, the colour represents 
the locus analysed. The top half absent shows LOH at the upper allele, and the lower half 
absent shows LOH at the lower allele. The arrows show the location in the bronchial tree and 
in the natural history where the samples were taken. 
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Figure 4.10A: Raw data of LOH analysis of patient P12. The data are shown by the 
chromosome marker used, and the histology number of the lesion from which the sample 
analysed was taken. 
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Figure 4.10B: Raw data of LOH analysis of patient P12. The data are shown by the 
chromosome marker used, and the histology number of the lesion from which the sample 
analysed was taken. 
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Left upper lobe carcinoma (the “original carcinoma”) 
The bronchoscopic biopsy and the resection specimen from the LUL carcinoma were 
analysed. The results are limited by the failure of the PCR for the markers on 4p16 and 
17p13 despite multiple attempts. The extent of the LOH was 5/8 loci (6/12 markers) in the 
biopsy specimen, and 4/5 loci (6/12 markers) in the resection specimen. There was LOH at 
the same alleles in both the biopsy and the resection specimen at 3p21 (both markers), 5q15 
(D5S 592), 5q22 (D5S 644) and 9p21 (D9S 162). In the resection specimen there was more 
extensive 9p21 LOH (involving additionally D9S 1749) but there was retention of 
heterozygosity at 3p12 which had shown LOH in the biopsy specimen.  
 
Left upper lobe stump 
Month 5 biopsy: LOH was found at 7/10 loci (9/14 markers). There was extensive 3p LOH 
(3p12, 3p14 and 3p25) with LOH at 5q15, 8p22 (D8S 136), 9p21 (both markers) and 17p13 
and retention of heterozygosity at 3p21, 4p16, 5q22 and 8p22 (D8S 133).  
Month 9 biopsy: LOH was found at 6/10 loci (9/16 markers). There was retention of 
heterozygosity at loci that had shown LOH at month 5, specifically 8p22 (D8S 136), 9p21 
(D9S 162) and 17p13. There was new LOH at 3p21 and LOH at 5q15 (D5S 394) for which 
the PCR had failed in the month 5 specimen.  
Month 14 biopsy: The LOH pattern seen in the month 9 specimen was maintained in the 
month 14 sample, but with retention of heterozygosity at 5q15 (D5S 394) where previously 
there had been LOH.  
Month 33 biopsy: The allelotype of the month 33 biopsy was similar to the preceding 
samples but showed LOH at fewer loci (5/10 loci, 8/16 markers). There was retention of 
heterozygosity at 3p12 and 3p25, loci that had shown LOH in the preceding specimens. 
There was LOH at 5q15 (D5S 394) similar to the month 9 sample, and LOH at 4p16 that had 
not been present in any of the earlier specimens.  
 
The HGL remained histologically the same diagnosis throughout, although there was 
epithelial out-pouching into the stroma. An invasive carcinoma was found within the LUL 
stump HGL during histological examination of the completion pneumonectomy at month 54. 
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The allelotypes of the LUL squamous cell carcinoma and the subsequent LUL stump HGL 
were compared. This was limited by the failure of PCR of markers at 3p14, 4p16 and 17p13 
within the specimens from the carcinoma. Nevertheless, the extent of the LOH was greater 
in the LUL stump HGL (7/10 loci) than the carcinoma (5/8 loci). This was largely due to 3p; in 
the carcinoma two of the four loci showed LOH compared to all four loci in the stump HGL. 
There was LOH at the same alleles in both the carcinoma and the LUL stump HGL at 3p12, 
3p21 (D3S 1573), 5q15 (D5S 592) and 9p21 (D9S 1749). In the month 5 sample from the 
LUL stump HGL, a different allele was lost at one of the 9p markers (D9S 162) compared to 
the carcinoma. In the subsequent specimens from the LUL stump HGL there was retention 
of heterozygosity at this marker. There was LOH at 5q22 (D5S 644) in the carcinoma that 
was not found in the specimens from the HGL.  
 
Left main bronchus 
The specimen from this location was taken when the LUL stump HGL had extended 
bronchoscopically into the LMB. The extent of the LOH in the LMB was similar to the LUL 
stump specimens (6/10 loci analysed). Comparing the allelotypes of the LMB and LUL stump 
samples, the same allele was lost at 3p12, 3p14 (2 out of 3 markers), 3p21, 3p25, 4p16 and 
5q15. However, there was retention of heterozygosity in the LMB specimen at one of the 
3p14 markers (D3S 2318) and the 9p21 marker (D9S 1749) that had shown LOH in all of the 
LUL stump samples. The LMB HGL had not progressed to squamous cell carcinoma prior to 
the completion pneumonectomy. 
 
Left lower lobe 
Samples from the bronchoscopically and histologically normal mucosa of the LLL taken 33 
months apart were analysed. The extent of the LOH was 4/10 loci in the month 0 specimen 
and 3/10 loci in the month 33 specimen, less than that of the LMB HGL and the LUL stump 
HGL (6-7/10 loci). In those markers showing LOH in the LLL the alleles lost were the same 
as the LMB and LUL stump, 3p12, 3p14, 3p21, 3p25, and 5q15.  
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There were differences in the allelotypes of the LLL specimens. The month 0 specimen 
showed extensive 3p LOH at 3p14 (three markers) and LOH at 3p21 and 3p25. In contrast 
there was LOH at 3p12 and 3p21 but not 3p14 or 3p25 in the month 33 specimen. This 
suggests that although the cells of both specimens had the same progenitor, there were 
different clones of cells in the samples at month 0 and month 33.  
 
Right upper lobe 
This location was bronchoscopically remote from the left bronchial tree abnormalities, was 
bronchoscopically normal under both white light and autofluorescence, and contained 
histologically normal epithelium. There was LOH at one locus (3p14) of ten in the analysis 
and only one marker of the sixteen analysed. At this marker, the LOH was in a different allele 
to the allele lost in the LUL stump, LLL, and LMB specimens. This suggests that the cells 
forming this area of epithelium were not clonally related to the cells of the other 
bronchoscopic locations sampled. 
 
Discussion 
The LUL stump was abnormal with a HGL that extended bronchoscopically to involve the 
LMB but not the LLL over 33 months. The specimens from the LUL stump showed similar 
but not identical patterns of LOH with differences between the allelotypes of each specimen. 
The reasons for this genetic heterogeneity of lesions are not clear, but are discussed in more 
detail in section 4 of the main discussion.  
 
Left upper lobe carcinoma 
The allelotypes of the two specimens from the original LUL carcinoma showed similar LOH 
patterns at 3p21, 5q15 and 5q22 but differences at 3p12 and 9p21. The discrepancy could 
be due to sampling error, as one specimen was a bronchial biopsy and the other a resection 
specimen. The specimens were accurately microdissected, and only tumour cells were used 
in the analysis which should have minimised the risk of contamination of the specimen with 
cells of a clone different to the lesion cells. Only 1 month had elapsed between the 2 
specimens, making it unlikely that the allelotype of the entire tumour had changed. The 
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observed LOH changes suggest that there may have been genetic heterogeneity within the 
carcinoma, with differences in the extent or pattern of the molecular abnormalities in different 
parts of the lesion. This phenomenon has been observed in other lung tumours126 but the 
mechanism by which this may occur is not known but is discussed in part 4 of the main 
discussion. 
 
Left main bronchus 
The bronchoscopic abnormality at the LUL stump appeared to extend to involve the left main 
bronchus (LMB), from which specimens showed a HGL. Intuitively, it would seem that the 
LMB lesion was an extension of the LUL stump lesion. This is not supported by the 
molecular studies. The LMB HGL had LOH at 3p, 4p16 and 5q15 but no LOH at 9p or 3p14 
(D3S 2318). During follow-up carcinoma did not develop in this bronchoscopic location. The 
LUL stump specimens showed LOH at 3p, 9p21 and 5q15 and the acquisition of 4p16 LOH 
at month 33 was associated with progression to invasive carcinoma. These results suggest 
that although the LMB HGL and the LUL stump HGL may have had the same progenitor, the 
LMB HGL did not evolve directly from the LUL stump HGL, but were two different lesions 
formed from different clones of cells with different outcomes. 
 
The lesions may either have grown towards each other along the bronchial epithelium, or the 
LMB lesion may have developed from the original progenitor stem cell of the LUL stump 
HGL, with migration of the cells along the bronchial epithelium. The evolution of this clone 
would generate an allelotype similar to that of the LUL stump HGL, but with significant 
differences as observed in the molecular studies. Further study would be required to 
determine the origin of the LMB lesion. 
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Patient P4 
Introduction 
This 62 year old male presented to his local unit with haemoptysis. There was a past history 
of Chronic Obstructive Pulmonary Disease, Type II Diabetes Mellitus, a high alcohol intake 
and 53 pack-years of smoking. Conventional white light bronchoscopy showed abnormal 
mucosa in the LUL, biopsies from which contained a LGL. At follow-up bronchoscopy 
performed 4 months later there was bleeding at the origin of the LUL biopsies from which 
showed a HGL.  
 
At our institution 6 months later (month 10) the mucosa of the LUL carina was abnormal 
under both white light and autofluorescence, although the abnormality appeared more 
extensive under autofluorescence than white light (figure 4.11). A HGL was found in biopsies 
from this location. A CT scan of the Thorax at this time showed no lesions. There was no 
change in the bronchoscopic and histologic appearance of the LUL at months 16 and 22. At 
month 22 there was abnormal mucosa under autofluorescence but not white light in the LLL. 
Biopsies showed a LGL. The patient stopped smoking at month 25.  
 
Bronchoscopies performed at months 27, 32, 43 and 50 showed progressive resolution of 
the LUL bronchoscopic abnormality. The histology showed a LGL in the LUL at month 27, 
and then normal epithelium from months 32-50. There was regression of the previous LGL to 
normal epithelium in the LLL at months 27-50. At month 27, a CT scan showed a 1 cm 
nodule in the LUL, separate from the bronchoscopically abnormal mucosa. There was no 
change in the size or morphology of the nodule 6 months later. At months 50 & 57, biopsies 
from the orifice of the LUL, which had shown no abnormality under white light or 
autofluorescence, demonstrated histologically normal epithelium.  
 
Results of molecular studies 
The results of the LOH analysis are shown as raw data in table 4.4 and figure 4.12 and as a 
schematic diagram in figure 4.11. Specimens from the LUL taken at months 10, 16, 22, 32, 
43 and 50 were available for analysis. From the LLL there were biopsies from months 22 and 
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43, and from the LUL orifice at months 50 and 57. The specimens were analysed using 12 
markers from 10 chromosomal loci.  
 
Left upper lobe 
The extent of the LOH was 9/10 loci (10/12 markers) in the LUL HGL at month10. The 
results in the month 16 specimen were compromised by failure of the PCR at 3p21 (D3S 
1234) and the month 22 specimen by failed PCRs at 3p14 (D3S 1233), 3p21 (D3S 1234) 
and 4p16. There was LOH at 3p, 4p16, 5q15, 5q22, 9p21 and 17p13. The same alleles were 
lost at all the markers that had shown LOH in the RUL HGL specimens (3p12, 3p14, 3p21, 
3p25, 5q15, 5q22, 9p21 and 17p13).  
 
There was LOH in all the 3 RUL HGL specimens at 3p12, 3p21, 3p25, 4p16, 5q15 and 5q22. 
At 8p22, the initial month 10 specimen was heterozygous, but LOH was detected at month 
16 and subsequently retention of heterozygosity was found at month 22. At 9p21, the month 
10 specimen showed genetic loss, at month 16 there was retention of heterozygosity but at 
month 22 LOH was observed. The marker at 17p13 showed genetic loss at month 10 and 
month 16 but retention of heterozygosity at month 22. At 3p14 (D3S 1228) LOH developed 
between month 10 and 16, and was persistent at month 22.  
 
Bronchoscopically and histologically the LUL HGL appeared to regress to normal epithelium, 
which was sampled at 3 time-points, months 32, 43 and 50. The extent of the LOH in all 
three specimens was less than that of the preceding HGL. In the month 32 specimen there 
was LOH at 6/10 loci (6/12 markers), 2/10 loci (2/12 markers) in the month 43 specimen, and 
1/10 loci (1/12 markers) at month 50. The allelotypes of these samples differed from the prior 
high-grade lesion samples. Different alleles were lost at 3p21 (D3S 1573), 3p25 and 4p16 at 
month 32. At month 43, there was LOH at 3p14 (D3S 1233) and 17p13, although the alleles 
lost at these markers were similar to the previous HGL. The allelotype differed from the 
sample of month 32, as there was retention of heterozygosity at 3p12, 3p21 (D3S 1573), 
3p25, 4p16 and 8p22. The month 50 sample showed allele loss at only one locus, 4p16. At 
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this locus the same allele was lost as the high-grade lesion samples but this was a different 
allele to that lost in the histologically normal sample at month 32. 
 
Left lower lobe 
The left lower lobe was first sampled at month 22 because of a bronchoscopic abnormality 
(histologically LGL) and at month 43 (bronchoscopically and histologically normal). The 
extent of the LOH was 5/10 loci (6/10 markers, as two had failed PCR) in the month 22 LGL 
specimen, and 6/10 loci (7/12 markers) in the month 43 sample. In the month 22 sample 
there was LOH at 3p12, 3p21 (both markers), 3p25, 9p21 and 17p13. In the month 43 
sample, there was LOH at 3p14 (both markers), 3p21 (D3S 1573), 4p16, 5q22, 9p21 and 
17p13. In the month 43 sample compared to the month 22 sample, there was retention of 
heterozygosity where there had previously been LOH at 3p12, 3p21 (D3S 1234) and 3p25. 
Markers that had shown retention of heterozygosity at month 22 showed LOH at month 43, 
i.e. 3p14 (D3S 1228) and 4p16. These data suggest that the normal epithelium found at 
month 34 was not clonally related to the LGL at month 13.  
 
Lingula 
There was no bronchoscopic or histological abnormality in the LLL orifice which was 
sampled as a “control” specimen. There was no LOH detected in the specimen taken at 
month 50. At month 57 LOH was found at 3p12, 3p14 (D3S 1233) and 17p13. No 
bronchoscopic or histological abnormality has been observed in the lingula during the year 
since that sample was obtained.  
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Table 4.4: Raw data LOH studies of patient P4. The numbers refer to the alleles present on the LOH study. A missing number means that there was LOH 
at that allele. The histology numbers of the specimens, their bronchoscopic location and the month into the study when they were obtained is shown. 
 
  
Specimen 
no 
R02 
077 
R02 
067 
R01 
260 
R01 
1625 
2003 
57 
2003 
55 
R01 
190 
2003 
53 
2003 
58 
2003 
46 
  Location LUL LUL LUL LUL LUL LUL LLL LLL Lingula Lingula 
  Histology HGL HGL HGL NAD NAD NAD LGL NAD NAD NAD 
Locus Marker 10 16 22 32 43 50 22 43 50 57 
3p12 D3S 1284 1 1 1 1 1,2 1,2 1 1,2 1,2 1 
                        
3p14 D3S 1228 1,2 1 1 1,2 1,2 1,2 1,2 1 1,2 1,2 
  D3S 1233 1 1 F 1,2 1 1,2 F 1 1,2   ,2 
                        
3p21 D3S 1234   ,2 F F 1,2 1,2 1,2   ,2 1,2 1,2 1,2 
 D3S 1573   ,2   ,2   ,2 1 1,2 1,2 1 1 1,2 1,2 
                        
3p25 D3S1298   ,2   ,2   ,2 1 1,2 1,2   ,2 1,2 1,2 1,2 
                        
4p16 D4S2946   ,2   ,2 F 1 1,2   ,2 1,2   ,2 1,2 1,2 
                        
5q22 DS5592 1 F 1 1,2 1,2 1,2 F 1 1,2 1,2 
                        
5q15 D5S644   ,2   ,2   ,2 1,2 1,2 1,2 1,2 1,2 1,2 1,2 
                        
8p22 D8S136 1,2 1 1,2 1 1,2 1,2 1,2 1,2 1,2 1,2 
  D8S133 1,2 1,2 1,2 1,2 1,2 1,2 1 1,2 1,2 1,2 
                        
9p21 D9S1749   ,2 1,2   ,2   ,2   ,2   ,2 1,2 1,2   ,2 1,2 
                        
17p13 D17S1574 1 1 1,2 1 1 1,2 1 1 1,2 1 
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Figure 4.11: Schematic diagram of bronchoscopic and LOH results from patient P4. 
Each oval represents the results of LOH analysis at a single marker, the colour represents 
the locus analysed. The top half absent shows LOH at the upper allele, and the lower half 
absent shows LOH at the lower allele. The arrows show the location in the bronchial tree and 
in the natural history where the samples were taken. 
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Figure 4.12: Raw data of LOH analysis of patient P4. The data are shown by the 
chromosome marker used, and the histology number of the lesion from which the sample 
analysed was taken. 
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Discussion 
Bronchoscopically and histologically the LUL HGL regressed to histologically normal 
epithelium over 23 months. During this period the patient stopped smoking. The HGL was 
sampled at 3 time-points, months 10, 16 and 22. The pattern and extent of allele loss in the 
samples were similar to that found in squamous cell carcinomas in previous studies. 
Histological and bronchoscopic regression of the high-grade lesion was associated with 
retention of heterozygosity in 2 of the 3 specimens at 8p22 and in 1 specimen at 9p21 and 
17p13. The other chromosomal loci studied, 3p12, 3p14, 3p21, 3p25, 4p16, 5q22 and 5q15 
all showed consistent LOH within the specimens from the high-grade lesion. These findings 
suggest that the retention of genetic material at 8p22, 9p21 and 17p13 may have been 
associated with the regression of the HGL to normal epithelium despite the presence of 
extensive genetic damage elsewhere in the genome. This is supported by the retention of 
heterozygosity at 8p22 and 17p13 in the LLL LGL at month 22 that regressed to 
histologically normal epithelium. The retention of heterozygosity at 9p21 and 17p13 in the 
HGL occurred in only 1 of the 3 specimens. It is possible that the retention of genetic 
material at 8p22, 9p21 or 17p13, or a combination of these loci may influence the regression 
of pre-invasive lesions. It is similarly possible that these changes are markers of and related 
to more important changes elsewhere in the genome that drive the behaviour of pre-invasive 
lesions.  
 
 
Part 4: The molecular biology of pre-invasive lesions 
Page 132 of 178 
Patient P11 
Introduction 
This 75 year old patient presented with haemoptysis. Two years earlier he had undergone a 
LLL lobectomy for squamous cell carcinoma. There was a past history of chronic obstructive 
pulmonary disease (FEV1 1.32L, FVC 2.1L), type II diabetes mellitus, benign prostate 
hypertrophy and diverticular disease. He smoked 40 cigarettes per day for 40 years until the 
lobectomy. Conventional bronchoscopy found irregular mucosa over the lobectomy stump, 
biopsies from which showed a HGL.  
 
Bronchoscopy was performed 4 months later at our unit. There was abnormal mucosa 
adjacent to the lobectomy stump under white light but with autofluorescence the abnormality 
was more extensive and additionally there was abnormal mucosa in the LUL. Biopsies of 
both these areas showed HGLs. CT of the thorax showed irregularity of the posterior wall of 
the left upper lobe bronchus but a PET scan did not demonstrate any increased uptake.  
 
The HGLs were maintained under bronchoscopic follow-up every 4 months (figure 4.13). 
There was indurated mucosa at the left lower lobectomy stump that was visible under white 
light and autofluorescence. The LUL HGL was only visible using autofluorescence; there was 
no discernible abnormality using white light bronchoscopy. The bronchoscopic appearance 
did not change in extent or severity during this period and histologically, both lesions 
remained HGLs. 
 
At month 17, there was microinvasion of the stroma in biopsies from the left lower lobectomy 
stump. A CT-PET scan revealed a synchronous contralateral 2cm diameter lesion in the 
RLL. Both lesions were squamous cell carcinomas. The RLL lesion was removed by wedge 
resection and the LLL stump lesion was treated with radical brachytherapy with curative 
intent. After treatment, bronchoscopic follow-up of the entire visible tracheobronchial tree 
continued every 4-6 months. The LLL stump was complicated by a post-brachytherapy ulcer 
with aspergillus colonisation that was successfully treated with itraconazole. No abnormal 
lesions were found either in the LUL or the LLL stump during the 17 months after completion 
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of the brachytherapy, between months 27 to 41. In month 41, biopsies from the LUL showed 
HGL. A CT scan of the thorax showed no abnormality. At month 45, micro-invasion was 
found within biopsies from the LUL HGL, and this was treated with photodynamic therapy. 
 
Results of molecular studies 
The results of the LOH analysis are shown as raw data in table 4.5 and figure 4.14 and as a 
schematic diagram in figure 4.13. Samples from the LLL carcinoma, the LLL stump HGL and 
the subsequent microinvasive carcinoma were available for analysis, along with the LUL 
HGL at months 0 and 17, and the RLL carcinoma. Fourteen markers from ten loci were 
analysed in all the specimens.  
 
Left lower lobe  
The results were limited by the failure of the PCR at 3p21 in all of the specimens. The extent 
of the LOH was 7/9 loci (10/13 markers) in the LLL carcinoma, 7/9 loci (10/12 markers) in the 
LLL stump HGL and 6/9 loci (10/12 markers) in the LLL stump carcinoma.  
 
In the LLL carcinoma there was LOH at 3p12 (D3S 1284), 3p14, 3p25, 5q15, 5q22, 8p22 
and 9p21. The HGL at the LLL stump had a very similar pattern of LOH to the LLL 
carcinoma. The only difference was at 3p12 (D3S 3633), which had retained heterozygosity 
in the carcinoma but showed LOH in the HGL. At month 17, there was a carcinoma at the 
LLL stump, at the location of the HGL. The allelotype was virtually identical to the HGL but 
with one important difference. There had been LOH at 8p22 in the LLL carcinoma and the 
LLL stump HGL. In the LLL stump carcinoma heterozygosity was retained at this locus.  
 
The LLL stump was sampled at month 27, 7 months after brachytherapy. There was LOH at 
6/9 loci (6/12 markers). The same alleles were lost at 3p12 (D3S 1284), 3p14(D3S 2318) 
and 9p21 (D9S 162) as the LLL carcinoma and the LLL stump carcinoma. Different alleles 
were lost at 3p25, 5q15 (D5S 592) and 5q22.  
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Left upper lobe 
This was sampled at month 0 and month 17, with HGL found in both specimens. At month 0 
the results were compromised by the failure of the PCR at 5q15 (D5S 421) and 9p21 (D9S 
171). The extent of the LOH was 4/9 loci (4/11 markers) at month 0 and 8/9 loci (12/13 
markers) at month 17. 
 
At month 0 there was LOH at 3p12, 3p14 (D3S 2318), 5q15 (D5S592) and 9p21 (D9S162). 
The alleles lost were identical to the LLL carcinoma, and the LLL stump carcinoma except for 
9p21 (D9S162). At this marker a different allele was lost in the LUL HGL compared to both 
the LLL carcinoma and the LLL stump carcinoma. 
 
At month 17 there was LOH at 3p12, 3p14 (D3S1228), 3p25, 4p16, 5q15, 5q22, 8p22 and 
9p21. Detailed analysis of 4p16 showed that the LOH was only at marker D4S2366. The 
alleles lost were identical to the month 0 HGL except for 9p21 at D9S162, at which different 
alleles were lost in the month 0 and month 17 specimens. At 8p22 there was LOH at month 
17 but retained heterozygosity in the month 0 specimen.  
 
The month 17 sample shows a virtually identical LOH pattern to the previous LLL carcinoma. 
The only differences are LOH at 3p12 (D3S3633) and 4p16 (D4S2366) that had retained 
heterozygosity in the LLL carcinoma although there was LOH at D4S 2925 in the LLL 
carcinoma. Compared to the LLL stump carcinoma, the month 17 HGL showed a virtually 
identical LOH profile apart from LOH at 4p16 and 8p22 that was heterozygous in the LLL 
stump carcinoma.  
 
Right lower lobe 
This was removed by wedge resection with clear margins at month 17. There was LOH at 
8/9 loci (11/13 markers), at 3p12, 3p14, 3p25, 4p16, 5q15, 5q22, 8p22 and 9p21 (D9S171), 
and all the markers used to characterise the 4p16 LOH in detail.  
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Compared to the LLL carcinoma, there was a similar LOH profile with the same alleles lost at 
3p12 (D3S 1284), 3p14, 3p25, 5q15 (D5S592), 8p22 and 9p21. There were different alleles 
lost at D4S2925, 5q15 (D5S 421) and 5q22. There was retention of heterozygosity at 4p16 
(D4S 2366), and 8p22 in the LLL carcinoma but LOH in the RLL carcinoma 
 
Compared to the synchronous LLL stump carcinoma, there was a similar LOH profile with 
the same alleles lost at 3p12, 3p14, 3p25, 5q15 (D5S 592) and 9p21 and retention of 
heterozygosity at 17p13. However, in the RLL carcinoma there was LOH at 4p16 and 8p22 
that had shown retention of heterozygosity in the LLL stump carcinoma. Different alleles 
were lost at 5q15 (D5S421) and 5q22 in the RLL carcinoma compared to the LLL stump 
carcinoma. 
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Table 4.5: Raw data LOH studies of patient P11. The numbers refer to the alleles present on the LOH study. A missing number means 
that there was LOH at that allele. The histology numbers of the specimens, their bronchoscopic location and the month into the study when 
they were obtained is shown. 
 
  Specimen no S SQC R02 023 
U02 
18635B 2003 99 U01 9745D U02 18635A 
U03 
4949 
  Location LLL LLL LLL LLL LUL LUL RLL 
  Histology SQC CIS SQC SD CIS CIS SQC 
Locus Marker Previous 0 17 27 0 17 20 
3p12 D3S 1284   ,2   ,2   ,2   ,2   ,2   ,2   ,2 
  D3S 3633 1,2   ,2   ,2 1,2   ,2   ,2   ,2 
                  
3p14 D3S 1228   ,2   ,2   ,2 1,2 1,2   ,2   ,2 
  D3S 2318 1 1 1 1 1 1 1 
                  
3p21 D3S 2409 H H H H H H H 
                  
3p25 D3S 1293   ,2   ,2   ,2 1 1,2   ,2   ,2 
                  
4p16 D4S 2366 1,2 1,2 1,2 1,2 1,2   ,2 1 
                  
5q15 D5S 421 1 F 1, 1,2 F? 1   ,2 
  D5S 592   ,2   ,2   ,2 1   ,2   ,2 1 
                  
5q22 D5S 644   ,2   ,2   ,2 1 1,2   ,2 1 
                  
8p22 D8S 133 1 1 1,2 1,2 1,2 1 1 
                  
9p21 D9S 171   ,2   ,2   ,2 F F   ,2   ,2 
  D9S 162 1 1 1 1   ,2 1 1,2 
                  
17p13 D17S 1749 1,2 1,2 1,2 1,2 1,2 1,2 1,2 
                  
Part 4: The molecular biology of pre-invasive lesions 
Page 137 of 178 
 
 
 
Table 4.5B: Specimens from chromosome 4 
 
 
 
  S SQC 
U02 
18635B 
U02 
18635A 
U03 
4949 
  Previous 17 17 20 
D4S 2366 1,2 1,2   ,2 1, 
D4S 2935 1,2 1,2 1,2 1, 
D4S 3023 H H H H 
D4S 3034 1,2 1,2 1,2   ,2 
D4S 431 1,2 1,2 1,2   ,2 
D4S 2925 1,2 1,2 1,2   ,2 
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Figure 4.13: Schematic diagram of bronchoscopic and LOH results from patient P11. 
Each oval represents the results of LOH analysis at a single marker, the colour represents 
the locus analysed. The top half absent shows LOH at the upper allele, and the lower half 
absent shows LOH at the lower allele. The arrows show the location in the bronchial tree and 
in the natural history where the samples were taken. 
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Figure 4.14: Raw data of LOH analysis of patient P11. The data are shown by the 
chromosome marker used, and the histology number of the lesion from which the sample 
analysed was taken. 
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Discussion 
The clonal origins of the three carcinomas 
The LLL carcinoma and the LLL stump carcinoma 
The LLL stump carcinoma arose at the resection margin of LLL carcinoma forty-seven 
months later and could represent a recurrence of that tumour. The LLL carcinoma and the 
LLL stump carcinoma had very similar patterns of allele loss with ten out of twelve loci 
having lost the same allele. This might suggest that the two carcinomas had the same cells 
of origin.  
 
The LLL carcinoma and the LLL stump carcinoma both showed LOH at D3S1284 whereas 
the LLL stump carcinoma showed additional loss more proximally on chromosome 3 at D3S 
3633. This LOH at D3S 3633 was also seen in the HGL at month 0, that preceded the LLL 
stump carcinoma. The LLL carcinoma and the HGL at the LLL stump had virtually identical 
LOH profiles, suggesting that the HGL was related directly to the LLL carcinoma. 
“Expansion” of the deleted region on chromosome 3 has been observed in association with 
apparent tumour progression38,93,104,105. Thus this pattern of loss is compatible with the LLL 
stump HGL having developed directly from the LLL carcinoma and the LLL stump carcinoma 
having developed from a clone within the LLL carcinoma.  
 
A marker at 8p22 that showed LOH in the LLL carcinoma was heterozygous in the LLL 
stump carcinoma; a configuration that is difficult to explain if the LLL stump carcinoma 
developed directly from the original carcinoma or the LLL stump HGL. The original LLL 
carcinoma had D4S 2925 LOH whereas the later occurring carcinoma at the LLL stump had 
no loss at this locus mirroring the results at 8p22 locus. This suggests that the LLL stump 
carcinoma did not directly evolve from the original LLL carcinoma or the HGL at the LLL 
stump but from an earlier progenitor (figure 4.13). One interpretation of these observations is 
that the origin of these two tumours was essentially clonal but with divergence of related 
clones with loss around D4S2925 as a late event in the LLL stump carcinoma and loss at 
D3S 3633 and D8S 133 occurring as a late event in the LLL carcinoma.  
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The RLL carcinoma 
The allelotype of the RLL carcinoma was essentially identical to that of the LLL carcinoma 
and the LLL stump carcinoma except for the markers on chromosomes 4 and 5. The LOH 
pattern on 4p in the RLL carcinoma was strikingly different from that of the LLL carcinoma 
and the LLL stump carcinoma in that all five informative loci show clear LOH. One 
interpretation is that the RLL carcinoma developed from a clone within the LLL carcinoma or 
the LLL stump carcinoma in which a region on chromosome 4 was lost resulting in the 
acquisition of a migratory phenotype and thus the RLL carcinoma represents a metastatic 
deposit from the LLL carcinoma or the LLL stump carcinoma.  
 
However the clinical observations mitigate against this hypothesis: the RLL carcinoma, is 
believed to have been another primary tumour.  The molecular data support the clinical 
observations. Although loss of 4p alleles in the RLL carcinoma is consistent with its having 
developed from the LLL carcinoma or the LLL stump carcinoma i.e. being a metastatic 
tumour, the actual alleles lost at  D4S2925, D5S421 and D5S644 are not from the same 
homologues in the RLL carcinoma as in the LLL carcinoma or the LLL stump carcinoma 
implying an independent origin. The allelotypes are incompatible with development of the 
RLL carcinoma directly from the LLL carcinoma but compatible with the RLL carcinoma 
having developed from a progenitor lesion that could be the same lesion from which LLL 
carcinoma and LLL stump carcinoma developed (figure 4.13).  
 
The suggestion of a clonal origin for synchronous and metachronous cancer is not new127 
and the possibility of migrating cancer precursor cells has been discussed particularly with 
regard to colon cancer128,129. More recently this has been elaborated to suggest that the 
mobile cells are cancer stem cells130. In the lung, evidence for mobile epithelial cells has 
been provided by observation of host engraftment of the bronchial epithelium following lung 
transplantation123. Thus analysis of these tumours suggests that although they are clonally 
related they may nonetheless represent independent primary tumours. This is an important 
issue as the degree of allelic congruence shared by these tumours could have been take as 
evidence that they all originated from the first tumour in the left lower lobe. The LLL stump 
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carcinoma and the LLL stump carcinoma were treated with curative intent on clinical 
grounds, and this approach has been supported by the molecular data. 
 
The HGL at the site of the LLL stump carcinoma 
The pattern of allelic loss in the HGL that was detected at the site of the LLL stump 
carcinoma following brachytherapy had more loci scored as heterozygous than either the 
LLL carcinoma or the LLL stump carcinoma and where there was LOH, the alleles lost were 
not always the same as those lost in the tumour. Thus this lesion is likely to have arisen from 
a different progenitor although an early common ancestor cannot be ruled out as the allelic 
loss that is common to the post-brachytherapy stump HGL and the other LLL lesions was 
LOH on chromosome 3 and 9, loci where allele loss is predicted to occur as very early 
events in the development of squamous cell carcinoma104,105,109,112. 
 
The LUL HGL 
The LUL HGL was detected by autofluorescence at month 0 and persisted through to month 
17.. When the LLL stump HGL and LUL HGL detected synchronously at month 0 are 
compared by LOH analysis, they share a pattern of common allelic loss having LOH at those 
loci that are most frequently lost in other lesions in this patient e.g. DS31284, D3S2318 but 
the LUL HGL has more loci that retained heterozygosity. Seventeen months later, the LUL 
HGL has additional allele loss with a pattern of loss that is consistent with its having 
developed from the earlier LUL HGL. There was LOH at month 17 that was not present at 
month 0, suggestive of progression of the changes in the month 0 lesion. The LOH at 9p21 
(D9S162) shows different alleles lost at months 0 and 17. This suggests that the LUL HGL at 
month 17 may not have developed directly from the month 0 lesion, but from a common 
early progenitor, or a different clone of cells. The allelotype of the month 17 HGL is similar to 
both the LLL carcinoma and the LLL stump carcinoma, but with a greater extent of LOH 
suggesting that it may have evolved from one of these carcinomas. Over further follow-up, a 
carcinoma was found at the LUL, in the location of the month 17 HGL. In the absence of the 
molecular data from the carcinoma, it may be concluded that the HGL at the LUL did acquire 
the malignant phenotype, with the pattern of LOH demonstrated at month 17. 
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The LLL carcinoma, the RLL carcinoma and the LUL HGL that developed into the LUL 
carcinoma all shared the pattern 3p and 9p LOH with 4p16 LOH developing pre-invasion. 
The LLL stump carcinoma did not have LOH in the markers chosen. This may be due to the 
markers chosen missing the area of LOH in the specimen, or that there was no LOH at 4p16. 
This might refute the suggestion that the 3p-9p-4p16 LOH pattern is important in the 
pathogenesis of squamous cell carcinoma or imply that additional molecular changes over 
and above the 3p-9p-4p16 pattern are required to develop the invasive phenotype. 
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Discussion of molecular studies 
1. Limitations of the techniques used in the molecular studies 
LOH analysis is associated with a number of problems in its execution and interpretation131 
but nevertheless is used extensively for the analysis of small biopsies38,102,103. There are 
several issues associated with this technique that may affect interpretation of the results: 
 
a. DNA quality 
i.   Microdissection 
H&E stained sections from the samples selected for analysis were reviewed with a 
Consultant Histopathologist with a special interest in pulmonary pathology. The section was 
photographed and the lesion of interest highlighted which facilitated accurate 
microdissection. Contamination from normal epithelial cells not part of the lesion of interest 
may have occurred as the boundary of the lesion was not always clearly defined or non-
lesion cells which were poorly adherent to the microscope slide may have bound to the 
Laser Capture Microdissection cap and been removed inadvertently. Although the system is 
theoretically capable of removing single cells this is not always the case, and cells from 
around the area of the microdissection may occasionally be removed. In a few lesions, there 
was intraepithelial invasion by carcinoma-in-situ, producing a heterogeneous lesion which 
could not be accurately microdissected to remove the lesion cells alone. The protocol was 
designed to enable the most accurate microdissection of the lesion of interest possible within 
these limitations. This used conservative microdissections which maintained as clear a 
boundary as possible between the lesion of interest and non-lesion cells. 
 
A number of the biopsies were disrupted during either the biopsy procedure or in processing 
which resulted in fragmentation or folding of the epithelium. Intercellular adhesion is known 
to be reduced in high-grade lesions which increases the risk of loss of the epithelium. In such 
situations, the cells of the lesion of interest were difficult to identify, and consequently 
microdissection was less accurate, and may have been contaminated by unwanted cells. It is 
possible that contamination with non-lesion cells altered the PCR product band pattern and 
thus compromised the results of the LOH analysis. Any contamination by DNA from non-
lesion cells in the PCR reaction would not produce as strong a PCR product band as the 
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DNA from the lesion of interest due partly to differences in the quantity of DNA template at 
the start of the PCR reaction. LOH would still be observed, but with a reduction in the 
intensity of the “lost” PCR product band, rather than a complete absence of the PCR product 
band. This appearance would be impossible to differentiate from genetically heterogeneous 
lesions, in which some of the cells have loss of genetic material from a particular 
chromosomal locus and others do not. Complete loss of an allele at any genetic locus should 
not occur if there is contamination by non-lesion cells. However, it is still theoretically 
possible to have complete loss of an allele if the non-lesion epithelium has genetic loss at 
the same locus. The presence of genetic loss in histologically and bronchoscopically normal 
epithelium in the present and previous studies means that although unlikely, there is a 
possibility that this may have occurred. In a number of samples, complete loss of an allele 
band was seen at some genetic loci with the appearance of reduction in the intensity of one 
allele at others. To compensate for this in the interpretation of the results, LOH was scored 
when there was either complete or partial loss of a band when compared to the normal 
reference DNA. 
 
ii.  DNA extraction 
There is evidence that using standard histological staining protocols in which there is 5 
minute staining with haematoxylin can reduce the yield of DNA from microdissected 
lesions132. This was observed in the pilot stages of the present study (data not presented in 
this document) and therefore a shorter procedure in which the sections were briefly dipped in 
haematoxylin was used. This minimised the effects of haematoxylin on the DNA, whilst 
providing sufficient nuclear staining to enable accurate identification and microdissection of 
the lesion of interest. Nuclear Fast Red, which in previous studies was not found to affect the 
quality or quantity of the DNA extracted from biopsy samples132, was trialled as the stain 
prior to laser capture microdissection. The stain poorly differentiated the lesion of interest 
from the surrounding stroma, which made microdissection more difficult and consequently 
less accurate (data not presented in this document). Pilot studies showed that the method 
using a short exposure to haematoxylin did not adversely affect the quality of the PCR 
product or the results of LOH analysis when compared to Nuclear Fast Red (data not 
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presented in this document). In the absence of an accurate and reliable DNA quantification 
method this was accepted as evidence that the use of a short exposure to haematoxylin to 
stain the sections prior to Laser Capture Microdissection would not compromise the results.  
 
b. Polymerase chain reaction and LOH 
DNA extracted from the patient’s peripheral blood lymphocytes was used as the source of 
“normal” reference DNA for the analysis. Blood was not available for two patients so stromal 
cells and lymphocytes were microdissected from the slides from which lesions of interest had 
previously been microdissected. This particular source of “normal” subject DNA has been 
used in previous studies of LOH in carcinoma of the bronchus108. In the patients in whom this 
source of “normal” DNA was used, only those polymorphic chromosomal markers that were 
heterozygous in the stromal DNA were selected, which eliminated the risk that the LOH 
analysis would be compromised.  
 
The DNA extracted from the lesions of interest was not quantified prior to use in the LOH 
analyses. In experiments using the Picogreen assay, the buffer used for DNA extraction from 
the microdissected biopsies produced a variable false positive signal. Alternative DNA 
extraction buffers were trialled with similar results (data not presented in this document). The 
results of the quantification were therefore unreliable, and could not be used to define the 
amount of DNA used in the PCR reactions during LOH analysis. The bronchial biopsies used 
in the studies were unique, limited in number and small, the median diameter being 
approximately 1mm. The lesion of interest typically formed less than 10% of the total biopsy. 
Consequently the total quantity of sample DNA was severely limited and it was decided not 
to undertake either a purification step or further attempts at DNA quantification, due to the 
risk of DNA loss during such a procedure. As a result, the quantity of DNA in each PCR 
experiment was not controlled and this may have affected the results. Different starting 
quantities of template may alter the dynamics of primer annealing to the sample DNA and 
alter the products from the PCR. The altered products may affect the interpretation of the 
bands during LOH analysis. To minimise this, microdissection was performed such that an 
approximately equal number of cells were obtained from each sample. This could not 
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eliminate variations in the total quantity of DNA extracted from each biopsy, and hence the 
amount of DNA used in each PCR experiment, but the extent of that variation was reduced. 
Furthermore dilution of the DNA further reduced the variation in the quantity of DNA template 
used in the PCR reactions. The effect of the use of an uncontrolled quantity of DNA template 
in the PCR reaction on the LOH analysis is not known, and introduced an unquantifiable 
variable into the experiment. 
 
c. LOH analysis 
A visual scoring method was used for the LOH analysis which can be criticised as open to 
subjective variation in the interpretation of the band patterns. Only those samples in which 
both the alleles were clearly identifiable on the autoradiograph were evaluated within the 
study. Samples in which there was difficulty in interpretation or in which the PCR product 
bands were unclear were excluded from the analysis, or were corroborated using another 
marker from the same chromosomal location. Prior to use in the LOH analysis, each 
chromosomal marker was used to investigate the patient’s own normal DNA and only those 
markers showing clear visible PCR product bands and heterozygosity were selected for the 
analysis of patient samples.  
 
There are systems in which the PCR product bands can be analysed using computer-based 
imaging. The intensity of the PCR product bands on the autoradiograph are quantified giving 
an objective measure of the differences between the PCR product bands. Experience from 
previous studies had shown that computerised analysis provided little additional information, 
as differences in the bands were reliably identified visually. In the present study, where allele 
loss was scored as either present or absent, quantification by computerised image analysis, 
which provides a ratio of the intensities of the 2 PCR product bands, would not alter the 
result. A fully quantitative method using fluorescent-labelled chromosome primers, and 
analysis on a DNA sequencing machine was an alternative option133. However, the 
technique selected for the analysis in the present studies had the advantage of having been 
used successfully for a number of years within the laboratory and a consequent familiarity 
with the problems, pitfalls and issues regarding interpretation.  
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Table 4.6: LOH findings in the lesions analysed. The red bars represent LOH within the given lesion at the locus shown. The white bars represent failure 
of the PCR and therefore no result. The green bars represent retention of heterozygosity at the locus shown. The extent of the LOH is given as a percentage 
of the total number of loci analysed. 
 
Progression 
 
 Extent LOH 3p12 3p14 3p21 3p25 4p16 5q15 5q22 8p22 9p21 17p13 
HGL P6 LLL apical 55           
SQC P6 LLL apical 67           
HGL P12 LUL stump 70           
HGL P11 LUL 90           
SQC P11 LLL 80           
SQC P11 LLL stump 70           
SQC P11 RLL 90           
 
 
Regression 
 
 Extent LOH 3p12 3p14 3p21 3p25 4p16 5q15 5q22 8p22 9p21 17p13 
HGL P8 RLL apical 50           
HGL P6 Lingula 40           
HGL P4 LUL 90           
LGL P4 LLL 50           
 
 
No outcome 
 
 Extent LOH 3p12 3p14 3p21 3p25 4p16 5q15 5q22 8p22 9p21 17p13 
HGL P12 LMB 60           
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Figure 4.15: Schematic diagram of 4p16. On the ideogram of the region, the genes within the minimal region of LOH are shown. The LOH is shown in red, 
and the green areas represent retention of heterozygosity. The lesions with the LOH shown are shown to the left. 
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2. Features associated with the progression of pre-invasive lesions to carcinoma 
Progression of HGL to invasive carcinoma was observed in 2 lesions in 2 patients (P6 and 
P12), and 3 separate carcinomas were studied in 1 patient (P11). Table 4.6 shows the LOH 
findings in the lesions studied.  
 
In the HGLs that progressed to squamous cell carcinoma (P6 HGL LLL apical, P12 LUL 
stump and P11 LUL HGL) there was extensive LOH at 3p (3 out of 4 loci) and LOH at 9p21 
and 5q15. The HGLs at the P12 LUL stump and P11 LUL acquired 4p16 LOH in the sample 
prior to the identification of invasive squamous cell carcinoma. There was retention of 
heterozygosity at 4p16 in the HGL at P6 LLL apical. Two months later the squamous cell 
carcinoma at the same site contained an identical pattern of allele loss to the HGL but with 
acquisition of 4p16 LOH and extension of the LOH at 3p14. The LLL carcinoma and RLL 
carcinoma in patient P11 had LOH at 3p (2/3 markers LLL carcinoma and 3/3 markers RLL 
carcinoma), and LOH at 9p21, 5q15 and 4p16 although there is no sample from a pre-
existing HGL for comparison. There are 2 other patients in whom LOH at 4p16 on a 
background of 3p and 9p LOH has preceded the development of invasive squamous cell 
carcinoma, reported in a previous publication117.  
 
Previous studies have shown that LOH at 3p and 9p occur as early events in the 
development of pre-invasive lesions of the bronchus104,105,109,112. This is supported by the 
finding of 3p and 9p LOH in all but one of the HGL and LGL analysed in the present study. 
The occurrence of 3p and 9p LOH alone may not drive the progression of an individual 
lesion to invasive squamous cell carcinoma, as similar changes are seen in lesions that 
regress to histologically normal epithelium. LOH at 4p16, shown to occur at or around the 
transition from pre-invasive to fully invasive disease may drive the progression to invasion of 
an individual pre-invasive lesion.  
 
The HGLs and carcinomas that showed 4p16 LOH were mapped to determine a common 
minimally deleted region. Figure 4.15 shows that this region lies between marker D4S2925 
and D4S2366, a region of 1.44Mb (4944252-6385660). Table 4.7 lists the genes included in 
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this region and their known functions. Studies in addition to ours have highlighted the 
association of 4p15-16 loss with the progression from primary to metastatic tumour134-136.  
 
The minimal region defined by deletion mapping encompasses seven genes (figure 4.15, 
table 4.7): two are particularly noteworthy with regard to tumour development. PPP2R2C 
codes for a regulatory subunit of PP2A, a serine/threonine specific phosphatase that 
interacts directly with small T antigen to cause cell transformation137. A number of 
independent studies indicate PP2A’s role in tumour suppressor138 including the observation 
that there are inactivating mutations in the gene for another subunit of the PP2A complex, 
PPP2R1B, in lung and colon cancer139. The CRMP1 gene, coding for collapsin response 
mediator protein, also maps within the minimal deleted region and is an even more attractive 
candidate for the gene in this region whose loss drives tumour invasion/progression. It is the 
downstream effector of CTGF (connective tissue growth factor) which has been shown to 
inhibit invasion and metastases in human lung adenocarcinoma140.  
 
The exception to this pattern is the P12 LLL stump samples. The HGL at the LLL stump 
showed LOH at 3p (3/3 loci), 5q15 and 9p21, an allelotype compatible with a spread or 
recurrence of the LLL carcinoma. The marker used at 4p16, D3S2366, retained 
heterozygosity in the LLL carcinoma, which on detailed testing showed LOH at another 
marker, D4S2925. Thus it is possible that there was unrecognized LOH at 4p16 in the HGL 
at the LLL stump at month 0. The LOH pattern of the LLL stump carcinoma suggested that it 
had not developed from the HGL at the same location, but from an earlier progenitor. There 
was no LOH in the 4p16 markers tested in the LLL stump carcinoma. This argues against 
the 3p-9p-4p16 LOH pattern as an important factor in the development of the LLL stump 
squamous cell carcinoma, or may suggest that not enough markers were used to adequately 
exclude LOH at this locus. The weight of evidence from other lesions in the same patient and 
lesions from four other patients suggest that LOH in this region may be involved in the 
progression to invasion of a pre-invasive lesion.  
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Figure 4.16: The progression of genetic damage within pre-invasive lesions. This shows that the progression of pre-invasive lesions from normal 
epithelium may be related to a. progression of genetic damage within a progenitor clone, b. The progression of genetic damage may not be the same in 
different clones from the same progenitor and c. May be unrelated to other progenitor clones within the bronchial tree. Each circle represents a genetic locus, 
loss of the upper half of the circle represents loss of the upper allele and loss of the lower half of the oval represents loss of the lower allele as seen on 
electrophoresis of PCR products for each locus. 
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Table 4.7: Genes within the minimally deleted region on 4p16 and their putative actions. 
 
Gene ID Name Biochemical action Biological function 
CYTL 1 Cytokine-like 1 Cytokine-like secretory protein Extracellular space receptor binding and signal transduction Unknown 
STK32B Serine / Threonine kinase 32B Serine / Threonine protein kinase 
Involved in cell communication and signal 
transduction. Abnormalities implicated in 
malignant transformation. 
EVC2    Ellis van Creveld syndrome 2 (limbin) Action not known 
Implicated in “Ellis-van Creveld” syndrome a 
developmental disorder 
EVC    Ellis van Creveld syndrome Action not known Implicated in “Ellis-van Creveld” syndrome a developmental disorder 
CRMP1 Collapsin response mediator protein Downstream effector of tissue growth factor  
Inhibition of invasion and metastases in lung 
adenocarcinoma  
WFS1    Wolfram syndrome 1 (wolframin) 
Endoglycosidase H-sensitive membrane 
glycoprotein 
Mutations associated with autosomal 
recessive “Wolfram syndrome” possibly with a 
role in diabetes 
PPP2R2C 
   Protein phosphatase 2B 
Regulatory subunit of a Serine / Threonine 
phosphatase 
Part of Protein Phosphatase 2A complex with 
tumour suppressor function 
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Further studies using more closely spaced markers, or an alternative approach such as 
Single Nucleotide Polymorphism analysis would determine whether there was unrecognised 
4p16 LOH in the LLL stump carcinoma and the validity of the relationship between 3p-9p-
4p16 LOH and the development of invasive squamous cell carcinoma.  
 
3. Features associated with the regression of pre-invasive lesions to normal epithelium 
Within the study 4 lesions in 3 patients were found to have regressed to histologically normal 
epithelium. Three were HGLs (P8 RLL apical, P6 lingula and P4 LUL) and the other was an 
LGL (P4 LLL). The extent of the LOH was 4-5/10 loci except for P4 HGL LUL which had 9/10 
loci showing LOH.  
 
There was consistent 3p and 9p LOH in the lesions (table 4.6), confirming that these 
changes occur early in the development of pre-invasive lesions. The HGL at P8 RLL apical 
showed LOH at 3/4 loci on 3p, and LOH at 9p21 and 17p13. There was no 4p16 LOH. The 
HGL at P6 lingula showed LOH at only 1/4 loci on 3p, but also 4p16, 5q15 and 9p21. The 
LGL in P4 had a similar pattern of LOH, with LOH at 3p (3/4 loci), 9p and 17p13 but no 4p16 
LOH. This suggests that the combination of LOH at 3p, 9p and 4p16 might be required for 
lesion progression otherwise the lesion regresses. Alternatively, 3p and 9p LOH may occur 
as early events in the pathogenesis of pre-invasive lesions, with a further switch within the 
genome that was not tested in the present study. The findings in the HGL at P4 LUL are 
more difficult to explain. In this lesion there was LOH at 4/4 loci on 3p, and LOH on 9p21, 
17p13 and 4p16. This is a similar allelotype to the HGLs that progressed to invasive 
squamous cell carcinoma, and supports the theory that changes further to those observed in 
the present study are required to determine the outcome of individual pre-invasive lesions.  
 
The common feature of all of the lesions that regressed was retention of heterozygosity on 
8p22. Within the squamous cell carcinomas and the HGLs that progressed to squamous cell 
carcinoma, there was LOH at 8p22 in the P11 RLL carcinoma, P11 LLL carcinoma and the 
P11 LUL HGL. In patient P6 the PCR at 8p22 failed giving no information. The LUL stump 
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HGL that preceded the squamous cell carcinoma in patient P12 and the squamous cell 
carcinoma at the LLL stump in patient P11 both retained heterozygosity at 8p22. It is unclear 
whether 8p22 retention of heterozygosity is related to the regression of pre-invasive lesions. 
Analysis of more lesions that regressed, with a greater density of markers would be required 
to establish the relationship between 8p22 retention of heterozygosity and lesion regression. 
 
There may have been another molecular change, not within the scope of the present study, 
that led the lesion to regression rather than progression to carcinoma. Such changes may 
include LOH in other areas of the genome not covered in the present study, gene 
amplification or promoter methylation. Overall it is likely that the combination of changes 
within some HGLs led to regression rather than progression to squamous cell carcinoma. 
 
4. Lesion Heterogeneity 
In serial specimens from some lesions e.g. P8 HGL, P12 HGL LLL stump, P4 HGL LUL, 
significant differences in the LOH patterns were found. At some loci, LOH appeared to be 
followed by retention of heterozygosity and then LOH. This could be due to technical 
reasons such as  apparent LOH due to absence of a band on the gel caused by an 
experimental problem with either the PCR or the gel running process. In the present study, 
the important results were reproduced experimentally and confirmed using another 
microsatellite marker from the same chromosomal locus. This minimised the possibility of a 
false result due to a simple technical error. There are several possible explanations for this 
variation in the allelotypes of samples from lesions in the present study: 
 
a. The molecular damage that generated the abnormal genotype may continue to progress 
Cells from a single progenitor within the lesion accumulates molecular damage, the pattern 
of which may not be the same as adjacent cells from the same progenitor (figure 4.16). 
Some of this molecular damage may confer a growth advantage, causing the affected clone 
of cells to populate that part of the evolving lesion, while other changes may lead to 
apoptosis or cell death of a particular clone of cells, leaving areas of the evolving lesion open 
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to population by adjacent cells with a growth advantage. These changes would lead to 
variations in the LOH pattern in different parts of the same lesion.  
 
b. The location of cells within the lesion may influence their development 
The proximity of the cells to their blood supply, or their relationship to the leading growth 
edge of the lesion or adjacent tissue structures may determine the susceptibility of individual 
cells to further molecular damage, and consequently the pattern of molecular changes in 
different parts of the evolving lesion.  
 
c. Biopsy may alter the progress and outcome of the lesion 
Biopsy creates a physical defect in the lesion, which may then be repopulated by cells of a 
different clone, which both restores the integrity of the lesion, but also changes the lesion 
LOH profile. Each biopsy may have sampled cells from different clones, dependent on which 
clone had repopulated the defect from biopsies taken at the previous bronchoscopy.  From 
lesions analysed after photodynamic therapy119,120, there is evidence that the disruption of 
cells induces a local immunological reaction that causes further tissue damage. The physical 
disruption of lesions by biopsy has not been previously studied, but it may be postulated that 
the disruption of cells may cause a similar local immunological reaction that may further 
influence the behaviour and outcome of the lesion or area of bronchial mucosa. 
 
d. Carcinogen-exposed epithelium develops molecular changes that may lead to the 
formation and progression of lesions throughout the bronchial tree 
Carcinogen-exposed epithelium may develop a unique set of molecular abnormalities related 
to specific fragile sites within the individual141,142. This would result in a similar pattern of 
allele loss and mutations in cells throughout the bronchial tree. Each of these carcinogen-
exposed cells has the potential to evolve further mutations, some of which may be lethal, 
some of which may drive malignant transformation, but which may not follow the same 
pattern as adjacent cells (figure 4.16). For example in patient P8 allelotype of the RUL 
sample was different to the histologically normal sample from the RLL apical segment after 
regression of the HGL in that location. In the RLL apical segment sample there was LOH at 
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3p25, 9p21 and 17p13. In the RUL there was LOH at 3p21, 3p25 and 4p16. This is in 
keeping with previous work showing discordant patterns of allele loss in anatomically remote 
areas of the bronchial tree110. This suggests that the molecular damage induced by cigarette 
smoke may produce consistent changes in some parts of the genome, and variable changes 
in others.  
 
e. The complex karyotypes of pre-invasive lesions and squamous cell carcinoma 
Squamous cell carcinomas of the bronchus are known to have complex karyotypes, typically 
polyploid143. LOH analysis does not allow for changes in copy number that accompany 
polyploidy, but show the relationship in terms of PCR product quantity between the 2 alleles 
amplified during the reaction. LOH is defined as the absence or a reduction in the quantity of 
one of the alleles. In a polyploid genome, successive loss of alleles may result in LOH, then 
apparent retention of heterozygosity and then LOH once again.  
 
Carcinogen induces DNA damage at susceptible sites and so chromosomal and DNA 
abnormalities induced by carcinogens (such as those in cigarette smoke) may induce 
abnormal segregation of chromosomes in mitosis90. This can result in a gain of genetic 
material in a daughter cell. Apparent retention of heterozygosity after LOH may be due to 
fortuitous gain of material in this way. In the present study there was more frequently allele 
imbalance rather than complete loss of an allele detected by LOH analysis which may be 
explained by these mechanisms. However, whilst feasible in a single cell, this sequence of 
changes is unlikely to occur in every cell of a lesion. Furthermore, in some samples, 
complete LOH was found which suggests that this model does not explain all the 
observations and that there is LOH in some loci that are diploid. Techniques looking at the 
actual copy number of individual chromosomal loci within lesion cells in the samples under 
study would clarify this issue. 
 
f. Regression of lesions may occur with new lesions populating the resulting defect in the 
bronchial epithelium 
Genetic changes may confer a growth advantage to a clone of cells adjacent to a pre-
invasive lesion. As the pre-invasive lesion undergoes regression this adjacent clone of cells 
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may expand to replace the pre-invasive lesion.  This adjacent clone of cells may carry a 
different set of genetic changes from the preceding pre-invasive lesion, and so not be 
programmed to regress.  
 
An alternative explanation is that the entire bronchial epithelium carries genetic changes 
induced by carcinogen (supported by the finding of genetic loss in histologically normal 
epithelium in both the present and in previous studies)102,103 which were detected in the 
samples after the bronchial epithelium repaired itself following the regression of the pre-
invasive lesion. The absence of genetic loss in some samples from bronchoscopically and 
histologically normal epithelium suggests that the entire epithelium does not always carry 
carcinogen-induced genetic damage, but it is likely that localised areas of genetic loss 
occurs, the detection of which is outside the scope of the present study. It is similarly 
possible that these changes are markers of and related to more important changes 
elsewhere in the genome that drive the behaviour of pre-invasive lesions.  
 
Further work is required to determine which theory is correct. 
 
5. Histologically normal epithelium 
In the location of previous pre-invasive lesions 
Pre-invasive lesions were observed to regress to bronchoscopically and histologically normal 
epithelium in P6 (lingula HGL), P8 (RLL apical HGL) and P4 (LUL HGL and LLL LGL). In P6, 
the three samples showing histologically normal epithelium taken after regression of the 
lingula HGL (months 2, 6 and 14) show that they did not evolve from the HGL and were not 
related to each other. The histologically normal sample at month 24 from the RLL apical 
segment in P8 showed a different allelotype to the preceding HGL from the same 
bronchoscopic location. A different allele was lost at 17p13 (D17S 1176) compared to the 
HGL and there was LOH at 3p25 that had not been present on the HGL. The LOH at 3p14, 
3p21 and 5q15 that had been present in the HGL was not found in the histologically normal 
epithelium. After regression of the HGL, the histologically normal LUL samples from P4 at 
months 32,43 and 50 showed less extensive genetic loss than the preceding HGL. The 
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molecular studies confirm that the histologically normal epithelium was not clonally related to 
the preceding HGL, and the histologically normal samples were not clonally related to each 
other. 
 
These data suggest that after regression, HGLs are replaced by cells of a different clone. 
These may originate from intact bronchial epithelium adjacent to the HGL, or alternatively, 
basal cells from the edges of the area of the previous HGL may have populated the defect in 
the epithelium left by the HGL or perhaps biopsy debulking the HGL. The clone of cells 
repopulating the epithelium may carry molecular abnormalities of differing extent and 
pattern. The extent of these abnormalities are typically less than the preceding HGL but 
greater than histologically normal epithelium from bronchoscopically normal locations in 
which there had not been a previous pre-invasive lesion. The pattern of molecular 
abnormalities in such epithelium may suggest an origin from a common precursor, or be 
unrelated to any previous identified abnormality within the subject. 
 
Histologically normal epithelium with no previous abnormality 
In patient P12 there was no histological evidence of resection margin carcinoma or HGL 
when the original carcinoma was resected. Two years later a HGL was found at the LUL 
stump. The allelotypes of the original carcinoma and the LUL stump HGL were similar, but 
the lack of 5q22 LOH (at D5S 644) in the LUL stump HGL and the different alleles lost at 
9p21 (D9S 162) suggests that the LUL stump HGL was formed from a different clone of cells 
to the original LUL carcinoma although both clones shared a common progenitor cell. The 
LUL stump HGL was not a recurrence or metastasis of the original LUL carcinoma but a new 
abnormality. There are three possible explanations for the finding of a different clone of cells 
to the original carcinoma at the LUL stump:  
a. The progenitor cell for the clone that generated the HGL may have been present at 
the resection margin, but not identifiable using standard histological techniques. This 
may have subsequently evolved to form the HGL clone of cells.  
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b. The LUL stump HGL clone of cells may have been present at the resection margin 
at the time of the resection but had not formed a lesion at that stage. These cells 
may have subsequently proliferated to generate the HGL.  
c. The HGL may have evolved directly from the cigarette-smoke exposed epithelium at 
the resection margin. 
Using current techniques it is not possible to verify which of these theories is correct.  
 
Samples were taken 33 months apart from histologically and bronchoscopically normal 
epithelium of the LLL in P12. The cells within the samples carried molecular abnormalities, 
the allelotypes of which suggested that they had the same progenitor as each other, and 
also the LUL stump HGL and the LMB HGL, but had sufficient differences to be from 
different clones of cells. There are 2 possible explanations:  
a. It is possible that the original clone of cells at the LLL orifice at month 0 regressed 
and a new clone of cells had populated that area of mucosa by month 33.  
b. The process of biopsy may have removed the clone of cells entirely, and a new 
clone of cells had entered that part of the mucosa as part of the healing process.  
 
There was no bronchoscopic or histological abnormality in the lingula in patient P4. No 
genetic loss was detected in the specimen from this location at month 50. At month 57 LOH 
was found at 3p12, 3p14 and 17p. No bronchoscopic or histological abnormality has been 
observed in the lingula during the year since that sample was obtained. New genetic loss 
was found up to 4 years after smoking cessation in this previously bronchoscopically, 
histologically and genetically normal bronchial epithelium. The mechanism by which genetic 
loss occurs after smoking cessation is not known. There may be carcinogen-induced 
susceptibility without actual genetic loss within the bronchial epithelium in which a later event 
may then result in detectable genetic loss in susceptible loci of the genome.  
 
Molecular abnormalities have been found using LOH analysis102,103,108 and CGH71 in the 
bronchial epithelium of smokers without bronchoscopically or histologically visible lesions. It 
is unclear which abnormalities are markers of cigarette smoke exposure and which drive the 
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development of pre-invasive lesions and squamous cell carcinoma. It has been suggested 
that molecular changes within bronchial epithelial cells precede and then drive the 
development of pre-invasive lesions and that over time a HGL or squamous cell carcinoma 
might develop. The timescale over which lesions develop from cigarette smoke exposed 
epithelium is not known, but the data show that cells may carry molecular abnormalities 
without necessarily forming a lesion for at least 4 years and that 4 years after smoking 
cessation, new molecular abnormalities may develop in histologically normal epithelium. 
 
6. Implications for the interpretation of lesion natural history data 
It is currently thought that a pre-invasive lesion at a bronchoscopic location is the same 
lesion when sampled at different time-points. This has informed the conclusions of all the 
clinical studies of the natural history of pre-invasive lesions26,27. The lesions were sampled at 
a number of time-points with intervals ranging from 4 months to a year depending on the 
histopathological features of the lesions under study. The molecular studies presented have 
shown that a lesion of a given histology at a single bronchoscopic location may not be the 
same lesion genetically when sampled serially over a period of months. The evidence 
suggests that the lesion was unlikely to have developed from the previous lesion at that 
location, but from an earlier progenitor cell. This suggests that the original lesion may have 
regressed, and been replaced by cells of a different clone from adjacent epithelium or by 
cells from the original progenitor stem cell direct. This original lesion may have regressed, 
been removed by biopsy, or disrupted by biopsy and subsequently undergone regression.  
 
Due to the low numbers of lesions in the molecular studies, the incidence of this 
phenomenon could not be estimated. If this is a common occurrence, then this would 
confound longitudinal studies of pre-invasive lesions, as the natural history of a given lesion 
cannot be evaluated from clinical observation alone. This highlights the need for combined 
molecular and clinical studies to evaluate in detail individual areas of the bronchial tree, to 
ascertain the true natural history of the lesions under study. Of course, as previously 
described, such studies are inevitably affected by the biopsy and therefore disruption of 
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lesions, but until non-destructive sampling techniques are developed that are as reliable as 
biopsy and histopathology, this will remain the investigative method of choice.  
 
7. Summary and future directions 
Previous studies have noted allele-specific mutations within the genome of bronchial 
epithelial cells in remote parts of the bronchial tree94,109,111. This suggests that in some 
situations, carcinogen causes consistent effects on the genome of bronchial epithelial cells. 
In the present study, lesions in remote parts of the bronchial tree carried similar mutation 
patterns, with the same alleles lost at the majority of the markers used. However, in many of 
the lesions, significant differences in the allelotypes were found. These data are in 
agreement with the findings of Boyle and colleagues110, who found both “concordant” and 
“discordant” mutations when they compared pre-invasive lesions and synchronous 
carcinomas in specimens resected for lung cancer. There were “discordant” patterns of allele 
loss in 2 out of 8 patients in their study, which means that different alleles were lost at some 
chromosomal loci in the pre-invasive lesions and the carcinoma. The remainder of the 
patients showed loss of the same allele at each chromosomal locus that showed genetic 
loss within both the pre-invasive lesions in the bronchial tree and their synchronous 
carcinomas (“concordant” mutations). 
 
These data suggest that on a background of susceptibility of parts of the genome to the 
mutational effects of carcinogen, genetic damage may occur to other parts of the genome 
that is not consistent throughout the airways. This may be the cause of the differences in the 
natural history of individual lesions. Whereas some of the changes, such as 3p LOH and 9p 
LOH are thought to occur early in pre-invasive lesion development, others occur later such 
as 17p13 and 5q22 LOH. The consistent early changes may be a marker of smoking, rather 
than part of the process by which malignant disease develops102. The present study, along 
with previous studies has shown that 3p LOH increases in extent as the lesion progresses 
from normal epithelium to squamous cell carcinoma104,109,111,112. This suggests that the extent 
of LOH on 3p may be related to the development of malignancy within an individual lesion. 
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Some molecular changes are probably markers of smoking-related damage, while others are 
related directly to the development of malignancy, changes that occur at the transition from 
pre-invasive lesion (carcinoma-in-situ) to invasive disease. It is known that this represents a 
significant biological shift in the nature and behaviour of the lesion, as the survival with 
radical treatment falls from 90% at 5 years for carcinoma-in-situ9 to 60% for stage 1 micro-
invasive carcinoma144. This is largely due to distant spread, which suggests that the lesion 
has acquired metastatic potential at the point of invasion. These phenotypic changes are 
underpinned by molecular changes, which are the result of carcinogen exposure.  
 
In the present studies, LOH at the majority of 3p, with LOH at 9p, both changes associated 
with early stages of pre-invasive lesion development, occurred in concert with LOH at 4p16, 
a locus with a number of candidate tumour suppressor genes, and genes potentially 
responsible for the development of invasion. This suggests that studies of lesions at this 
transition point should yield consistent profiles that may define the lesions at highest risk of 
malignant transformation.  
 
Over the past 4-5 years, attention has focused on gene amplification and overexpression of 
oncogenes as a mechanism of lung carcinogenesis. In a study of high-grade pre-invasive 
lesions identified by autofluorescence bronchoscopy, the copy number of TP63, MYC, CEP6 
and CEP3 increased with increasing lesion histological grade145. When 1-2 markers were 
amplified, the risk ratio of lung cancer development was 4.23, but when 3-4 markers were 
amplified the relative risk rose to 11. In particular, overexpression of TP63 (3q28) and MYC 
(8q24) were associated with an increased risk of malignant change in the lesion. From these 
data, attention has focused on 3q amplification as an important driver of squamous cell 
carcinoma development. In a series of studies, McCaughan and colleagues have shown that 
HGLs have amplification of 3q that is not present in LGLs146. In HGLs progressing to 
squamous cell carcinoma there was incremental amplification of 3q, with the oncogene 
SOX2 showing consistent amplification at the transition from carcinoma-in-situ to invasive 
squamous cell carcinoma147.  
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These findings suggest that the molecular basis of carcinogenesis is multifactorial, with 
consistent areas of genetic loss and amplification generating the malignant phenotype. 
Previous studies were limited by the small quantities of genetic material available from each 
lesion for study, but newer techniques have made higher resolution and genome-wide 
studies of these specimens feasible. Further studies would explore and expand these 
findings by obtaining more detailed allelotypes and combine genetic loss with amplification 
and gain of genetic material to generate a fingerprint that might be able to predict the 
transformation of an individual lesion to invasive malignant disease. Treatment at this early 
stage might reduce the mortality from squamous cell carcinoma of the bronchus by allowing 
targeted therapy to the lesions at highest risk. In addition, this would allow the targeting of 
invasive investigations to those patients carrying high risk lesions.  
 
Future directions: 
1. A re-evaluation of the natural history of pre-invasive lesion studies. This would 
involve serial samples of lesions backed up by molecular profiles using a genome-
wide approach such as CGH or SNP analysis. This would determine whether the 
lesion under observation remains the same lesion during follow-up.  
2. The relationship between a lesion and the surrounding bronchial mucosa. It would 
be necessary to establish the bronchoscopic, histologic and molecular extent of 
lesions to determine accuracy of each technique in the evaluation of bronchial pre-
invasive lesions. 
3. The entire molecular set of abnormalities in an individual lesion, including areas of 
gain and loss, coupled with RNA or immunohistochemical techniques to evaluate the 
effect of these changes on the gene products downstream and therefore cell 
physiology. This would include CpG island Methylation status, and be coupled with 
analysis of the histological and bronchoscopic progress of the lesions studied, to 
provide an accurate evaluation of the bronchial mucosa. This would also provide 
detailed analysis of the molecular switches involved in the invasion and metastasis 
of lesions.  
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4. Serial sampling of individual lesions with a non-disruptive technique, maintaining 
lesion integrity and not altering the number of cells. This would allow an unbiased 
evaluation of lesions in vivo. 
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Glossary of Abbreviations 
AFL Autofluorescence bronchoscopy 
ASD Angiogenic squamous dysplasia 
ChT Chemotherapy 
CI Confidence intervals 
CIS Carcinoma-in-situ 
COPD Chronic obstructive pulmonary disease 
CP Chemoprevention 
CRP C-reactive protein 
HGL High-grade lesion 
LGL Low-grade lesion 
LIFE Light-induced fluorescence endoscopy 
LLL Left lower lobe 
LOH Loss of heterozygosity 
LUL Left upper lobe 
MiD Mild dysplasia 
MoD Moderate dysplasia 
MoD+ Moderate dysplasia, severe dysplasia, carcinoma-in-situ and squamous cell carcinoma combined 
MPA Metaplasia 
NAD No abnormality detected 
PDT Photodynamic therapy 
RLL Right lower lobe 
RML Right middle lobe 
RT Radiotherapy 
RUL Right upper lobe 
SCLC Small cell lung cancer 
SD Severe dysplasia 
Sens Sensitivity 
SQC Squamous cell carcinoma 
WLB White-light bronchoscopy 
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